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I. Introduction 
I.1 Human therapeutic proteins 
One of the driving forces behind the biotech industry today is the development of new 
therapeutic drugs for the treatment of numerous life-threatening diseases. Many of these 
complex diseases, such as HIV, asthma and different kinds of cancer cannot be cured with 
conventional, simply structured molecules; here biopharmaceuticals offer the best promise for 
successful future treatment. 
Biopharmaceuticals are essentially all pharmaceutical drugs, which are based on proteins (e.g. 
monoclonal antibodies, toxins, enzymes), recombinant DNA products, vaccine products, 
cultured cell and tissue/blood products (FROST&SULLIVAN(A) 2003). The trend for 
biopharmaceuticals is predicted to increase further as there are currently more than 350 
products under evaluation in clinical trials (FROST&SULLIVAN(A) 2003). Monoclonal 
antibodies (MAbs) represent the fastest growing segment of the biopharmaceutical market. 
Currently there are 18 approved MAbs and eleven waiting to be approved within the next few 
years (GREENER 2005). MAb demand is calculated to rise up to 6000 kg/year by 2006. This 
indicates a trend towards specific antibodies produced in “high-titre” hosts to meet the annual 
product yield requirements at reasonable costs (COCO-MARTIN 2004). 
I.1.1 Monoclonal antibodies for HIV-therapy 
I.1.1.1 General features of viral replication and infection 
Repeating outbreaks of viral infections worldwide such as Severe Acute Respiratory 
Syndrome (SARS), Ebola and Influenza have shown that infectious diseases present a 
continuing threat to the global health (HEYMANN 2005). Although modern advances, such 
as antibiotics and vaccines, have conquered some diseases new ones are constantly emerging. 
A virus is defined as a noncellular genetic element containing either RNA or DNA, which 
replicates in cells but is characterised by having an extracellular state (BROCK et al. 1994). 
Viruses range in size from about 20 to 300 nm in diameter and generally consist of the viral 
genome and a surrounding protein coat (capsid). Some viruses possess an additional envelope 
around the protein coat resulting in a complete infection particle (virion; MODROW et al. 
2003).  
Immunity to viral infection is triggered by specific and nonspecific mechanisms. Early 
nonspecific responses (nonspecific inhibition by e.g. natural killer (NK) cell activity and 
interferon) limit virus multiplication during the acute phase of virus infection. Later specific 
Introduction  2  
immune responses (humoral and cell-mediated) eliminate the virus and subsequently maintain 
specific resistance against reinfection.  
Humoral immunity is induced by stimulated B-lymphocytes to produce antibodies. These 
antibodies can neutralise the virus by blocking viral-host-interactions or by recognising viral 
antigens on virus-infected cells. Antibody-coated viruses are bound by specific receptors on 
phagocytic cells leading to Antibody-Dependent Cell-meditated Cytotoxicity (ADCC) or 
activation of complement-mediated lysis. Cell-mediated immunity involves cytotoxic T (Tc) 
lymphocytes, NK cells and macrophages, which recognise and kill virus-infected cells. 
Cytokines produced by monocytes, T helper (Th) cells, and NK cells play important roles in 
regulating the antiviral immune functions. The target specific immune response starts after 
exposure and results in the production of antiviral antibody and cell-mediated immunity in 3 - 
10 days.  
During evolution many pathogens have evolved strategies to subvert the normal host 
defences. In these cases the virus is not cleared completely but remains in specific cells of the 
infected individual. Persistent infections may involve stages of both silent and productive 
infection without rapidly killing or producing excessive damage of the host cells. Adeno- and 
Herpes viruses for example reduce the number of Major Histocompatibility Complex (MHC) 
class-I molecules on the surface of infected cells. This inefficient presentation of viral 
antigens complicates the recognition by Tc cells. Hepatitis B Virus (HBV) produces large 
amounts of virus surface proteins (HbsAg) into the blood, which neutralise anti-HBV-
antibodies. Human Immunodeficiency Virus (HIV) and Influenza virus constantly change 
sequence and structure of surface-exposed protein regions and therefore escape neutralising 
antibodies (MODROW et al. 2003). 
I.1.1.2 The Human Immunodeficiency Virus (HIV) 
Robert C. Gallo (National Institute of Health in Bethesda) and Luc Montagnier (Institute 
Pasteur in Paris) discovered HIV at the same time in 1981 as causative agent for the Acquired 
Immune Deficiency Syndrome (AIDS). In 1983, the first HIV particle was isolated out of the 
lymphocytes of an AIDS-patient (BARRE-SINOUSSI et al. 1983). Subsequent research 
activity makes HIV one of the best-described viruses in respect to its molecular biology and 
pathogenesis (MODROW et al. 2003).  
Recently, the findings of a 10-year long research study into the origin of HIV concluded that 
wild chimpanzees became infected simultaneously with two Simian Immunodeficiency 
Viruses (SIVs) which formed a third virus capable of infecting humans and causing AIDS 
(BAILES et al. 2003). In January 2000, a computer model study suggested that the first case 
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of HIV-infection occurred around 1930 (with a 20 year error) in West Africa (KORBER et al. 
2000). Since then HIV-infection spread worldwide and more than 20 million people died of 
AIDS. Estimated 38 millions currently live with HIV-infection and in 2003 alone, 3 million 
people became infected in sub-Saharian Africa (UNAIDS 2004).  
The two types of HIV (HIV-1 and HIV-2) are transmitted by sexual contact, through blood 
and from mother to child and cause clinically indistinguishable symptoms. However, it seems 
that HIV-2 is less easily transmitted, and the period between initial infection and illness is 
longer (CLAVEL et al. 1986; NDOUR et al. 2000). Worldwide, the predominant virus is 
HIV-1, whereas the relatively uncommon HIV-2 type is concentrated in West Africa 
(NDOUR et al. 2000).  
There are three branches in the phylogenetic tree of HIV-1 sequences, which comprise of the 
M (main), N (new or non-M and non-O) and the O (outlier) groups. Among these groups, the 
M viruses are the most widespread, being the variants of HIV-1 that are responsible for 99% 
of infections worldwide (MOORE et al. 2001). The M group is further divided into nine 
distinct genetic subtypes (A through K; MODROW et al. 2003).  
HIV is a single-stranded (ss) RNA virus and belongs to the family of retroviruses, which 
depends on a reverse transcriptase to transcribe the viral RNA genome into DNA. The HIV 
genome contains about 9,500 nucleotides with nine genes that are flanked by long terminal 
repeats. As in all retroviruses the genome codes for the three major proteins gag (group 
associated antigen) for the capsid, pol for the enzymes involved in virus replication and 
integration and env for glycoproteins of the viral coat. 
 
Fig.I-1: Schematic presentation of the HIV-particle. The virus particle is composed of a capsid (p24), which 
contains the RNA dimer and the viral proteins (protease, reverse transcriptase and integrase). The capsid is 
surrounded by a lipid bilayer membrane (the viral envelope) with the transmembrane glycoprotein gp160, a 
complex of gp120 and gp41. The inner side of the envelope is coated with matrix protein (p17); derived from 
www.mcld.co.uk/hiv/. 
 
Introduction  4  
The virion (see Fig.I-1) contains two identical copies of the positive sense ss RNA,  the viral 
enzymes (proteins integrase, protease and reverse transcriptase) inside of a conical capsid of 
capsid protein (p24). The virus envelope, a lipid bilayer membrane, derived from the host cell 
plasma membrane during virus budding, surrounds the capsid itself. The inner side of the 
envelope membrane is lined with matrix protein (p17). The envelope contains constituents of 
the host membrane and the viral transmembrane glycoproteins gp120 and gp41, which serve 
as the viral anti-receptor or attachment protein. These transmembrane proteins are named after 
their apparent molecular weight of 120 and 41 kDa. Gp41 traverses the envelope whereas 
gp120 is present on the outer surface and is non covalently attached to gp41. The precursor of 
gp120/41 (gp160) is synthesised in the endoplasmic reticulum and transported via Golgi 
bodies to the cell surface (MODROW et al. 2003).  
By attachment of gp120 to CD4 (cluster of differentiation, cell surface molecule) the virus 
infects exclusively the CD4-expressing T lymphocytes and macrophages (DALGLEISH et al. 
1984). After fusion and penetration of HIV, the viral RNA is transcribed into double-stranded 
DNA by the reverse transcriptase. This proviral DNA travels to the nucleus of the cell, is 
integrated into the infected cell's chromosomal DNA by the integrase and may persist in a 
latent state for many years. Activation of the host cell due to unknown environmental 
influences results in the transcription of viral DNA back into RNA and translation into viral 
proteins. For this, HIV protease is required to process HIV proteins into their functional 
forms. Viral RNA and viral proteins are packaged and complete virions bud from the infected 
T cell (MODROW et al. 2003).  
Three to four weeks following HIV-exposure, a phase of rapid viral replication starts, with 
high levels of virus in the plasma (viremia) and development of a "flue like" illness. Four to 
six weeks after exposure antibodies to HIV core (p24) and envelope (gp160, gp120, gp41) 
proteins appear. Six to eight weeks after exposure acute symptoms disappear and plasma 
viremia subsides (MODROW et al. 2003), while HIV-1 causes a chronic infection meanwhile 
with reservoirs of virus in T-cell-, macrophages and monocyte compartments. Additionally 
the virus diversifies during the infection, with repeated selection of mutants that escape both 
antibody and T-cell immune responses (McMICHAEL and HANKE 2003). Unless the HIV 
lifecycle is interrupted by treatment, the virus infection spreads throughout the body and 
results in the destruction of the body's immune system (BARON et al. 1994). Secondary 
(opportunistic) infections develop and as one characteristic for AIDS, these infections lead to 
the death of the individual in most cases. With current anti-viral medications, such as reverse 
transcriptase inhibitors (AZT, lamivudine, zidovudine, abacavir, 3TC, d4T, zalcitabine, ddC, 
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ddI, tenofovir, didanosine), protease inhibitors (amprenavir, nelfinavir, saquinavir, indinavir, 
ritonavir, lopinavir) and non-nucleoside reverse transcriptase inhibitors (delavirdinee, 
efavirenz and nevirapine) used in combination therapy, HIV-infection can be contained but 
resistance often occur (reviewed in MARCUS et al. 2002). Still no efficient vaccine is 
available on the market nor is anticipated for the near future.  
I.1.1.3 Neutralising antibodies to HIV 
Theoretically all pathogens (virus, bacteria, fungi, parasites) can be recognised by a B cell via 
a specific antibody. This requires a huge variety of different antibody specificities, which 
arises from recombinations of the variable, diversity, and joining genes (V, J and D), by 
junctional diversity and somatic mutations in affinity maturation of B cells (>108). Human 
immunoglobulins (Ig) are composed of two identical light chains (LC, 23kDa) with a length 
of around 220 amino acids and two identical heavy chains (HC, 50-70kDa) with around 440 
amino acids. The light chain, belonging to the kappa or lambda class, consists of one variable 
and one constant region (VL, CL). The heavy chain, belonging to the alpha, gamma, mu, delta 
or epsilon class, contains one variable and three (or four) constant regions (VH, CH1-CH3/4). 
This results in five different antibody classes (IgA, IgG, IgM, IgD and IgE) in combination 
with the L chains. The Ig classes are further divided into subclasses based on small 
differences in the amino acid sequences, e.g. human IgG1, 2, 3 and 4. The variable region of 
VL and VH consists of three hypervariable regions (complementarity determining regions, 
CDRs) separated by four more conserved regions (frameworks; KABAT et al. 1990). CDRs 
of the heavy and light chain build the antigen binding site (paratope), which is stabilised by 
intramolecular disulfid bonds in the V and C region. These disulfide bonds lead to a three-
dimensional folding into globular regions (domains). Igs and proteins with Ig-like domains [T 
cell receptor (TCR), MHC, CD molecules and receptors] are forming the Ig-superfamily of 
related proteins all containing antiparallel β-sheet structure between invariant cystein 
residues. The domains are classified into variable (V) and constant (C)-like sets, with the C-
set being divided into the C1-set (Ig-related molecules: Ig, TCR and MHC) and the C2-set 
(non-Ig related molecules; (SMITH and XUE 1997). Additional intermolecular disulfid bonds 
connect both heavy chains in the flexible region of the antibody (hinge) between CH1 and CH2 
resulting in the typical Y-shape of an antibody molecule.  
Enzymatic cleavage of antibodies by papain results in specific fragments, such as the Fc 
fragment (fragment crystallisable) consisting of the C-terminal halves of the two HCs linked 
to each other by the residual hinge region and the Fab-fragments (fragment with antigen 
binding) consisting of the LC and the N-terminal halve of the HC connected by an interchain 
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disulfide bond. A F(ab)2-fragment, in which the two arms of the antibody molecule remain 
linked, results from pepsin cleavage.  
Pathogens induce antibody generation (antigen) against an epitope, the local portion of an 
antigen recognised by an antibody. Usually viral capsid proteins and bacterial cell wall 
components have multiple epitopes. In relation to its strength to induce antibody production 
(immunogenicity), antibodies are produced to each epitope. The strength of the resulting 
interaction (affinity) increases with repeated exposure to the antigen. The dissociation 
equilibrium constant (KD) describes the ratio between the rate constants for binding (on-rate) 
and dissociation (off-rate) of antibody and antigen. Typical affinities for IgG antibodies are 
105-109 mol/L (JANEWAY et al. 2001). 
At least three immunoglobulin classes have been demonstrated to exert antiviral activity: IgG, 
IgM, and IgA (JANEWAY et al. 2001). This antiviral activity caused by neutralisation of the 
virus can be achieved by different mode of actions. First, antibodies bind to the virus 
extracellular, either neutralising it immediately or blocking its interaction with host cells 
(JANEWAY et al. 2001). Aggregation of antibody-virus-complexes can also be formed, thus 
preventing the adsorption of virus to cells and decreasing the number of virions. Besides 
binding directly to the virus, antibodies may enhance phagocytosis due to three types of 
antibody interactions: direct binding of antibody to the surface of the phagocytic cells, uptake 
of antigen antibody complexes through Fc receptors, and uptake of antigen-antibody-
complement complexes through the C3b receptor activating the complement system (BARON 
et al. 1994). It is suggested that the level of occupancy of binding sites by antibody molecules 
must exceed an antibody density threshold, after which the entire virion is neutralised 
(PARREN and BURTON 2001). 
Neutralising antibodies are produced by the human body four to six weeks after infection. In 
general, these antibodies can clear virus infections in the following weeks. In case of HIV, 
most neutralising antibodies are effectless due to different reasons. Firstly, the main envelope 
glycoprotein complex gp160 has a trimeric structure composed of six individual subunits, 
three gp120s and three gp41s. This complex undergoes different conformational changes 
before the virus-cell membrane fusion occurs (KWONG et al. 2002). The CD4 binding site is 
devoid of asparagine-linked glycosylation acting as a decoy to stimulate largely irrelevant 
antibodies and additionally, the conserved regions are poorly accessible to antibodies 
(McMICHAEL and HANKE 2003). Secondly, the viral reverse transcriptase has no 
proofreading activity and resulting mutations change the HIV sequence and in consequence 
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the shape of proteins. As soon as the immune system produces neutralising antibodies, the 
target proteins have changed sufficiently to avoid antibody binding (MODROW et al. 2003). 
Nevertheless, studies of protecting vaccines against SIV indicate that antibody-mediated 
protection is possible (DESROSIERS et al. 1989). Sera from individuals infected with HIV 
have been analysed extensively for the presence of neutralising antibodies. Five human 
monoclonal antibodies 4E10 (STIEGLER et al. 2001), 1b12 (BURTON et al. 1994), F105 
(POSNER et al. 1991), 2G12 (TRKOLA et al. 1996) and 2F5 (PURTSCHER et al. 1994) 
have been isolated out of the serum of inapparent patients and were found to be capable of 
neutralising a broad range of primary B-clade HIV isolates, however high titre are required 
for this protection (MASCOLA et al. 1997; LI et al. 1998; PARREN et al. 1999). Their 
epitopes include regions on gp41 (2F5 and 4E10), the CD4-binding site of gp120 (1b12) and 
parts of the carbohydrate moiety of gp120 (2G12; reviewed in CALARESE et al. 2003).  
Work in this thesis focused on the neutralising antibodies 2F5 and 2G12, which were 
generated and characterised by a team led by Hermann Katinger (TRKOLA et al. 1996). The 
neutralising antibody 2F5 of the isotype IgG3 was switched to an IgG1 by ligation of the 2F5 
VH to an IgG1 constant region, since this isotype is known for longer half-live in humans 
(KUNERT et al. 2000). Both antibodies are produced by recombinant expression in Chinese 
Hamster Ovary (CHO) cells as IgG1/κ (BUCHACHER et al. 1994; KUNERT et al. 2000). 
These antibodies target neutralising epitopes on the envelope of HIV-1, which are conserved 
among different subtypes (PURTSCHER et al. 1994; TRKOLA et al. 1996). Briefly, the 2F5 
antibody recognises an apparently linear epitope (ELDKWA) near the C-terminal end of gp41 
(MUSTER et al. 1993). 2G12 binds an unusually dense cluster of carbohydrate moieties 
designated as silent face. In general, oligosaccharides shield potential antigenic epitopes and 
oligosaccharides processed by the host are unlikely to be immunogenic. But in case of 2G12 
first binding studies to recombinant gp120 without N-linked carbohydrates in the C2, C3, V4, 
and C4 regions of gp120 resulted in abolished binding (TRKOLA et al. 1996). Mutagenesis 
studies revealed the glycans at positions 295, 332 and 392 as the most critical for 2G12 
binding (SCANLAN et al. 2002). Crystal structures of Fab 2G12 and its complexes with the 
di- resp. oligosaccharide (Manα1-2Man and Man9GlcNAc2) revealed that two Fabs assemble 
into an interlocked VH domain-swapped dimer (CALARESE et al. 2003). Thus the 2G12 
paratopes interact on gp120 with the N-glycans (Man9GlcNAc2) at the position 332 and 392. 
An additional interaction occurs between the unusual VH/VH’-paratope and one N-glycan at 
position 339. The 2G12 anti-HIV antibody is the only known antibody with a VH/VH’-
interface leading to a third antigen-binding site (CALARESE et al. 2003). 
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Both antibodies, 2G12 and 2F5, potently neutralise the majority of HIV-1 primary isolates in 
vitro and protect macaques against intravenous (MASCOLA et al. 1999) and mucosal (BABA 
et al. 2000; MASCOLA et al. 2000) challenge with chimeric simian/human immuno-
deficiency virus. A first phase I open label study on seven patients has shown the safety, non-
toxicity and non-immunogenicity of both antibodies with maximal plasma concentrations of 
374 µg/ml [2F5] and 605 µg/ml [2G12] (ARMBRUSTER et al. 2002). The half-lives of 2F5 
and 2G12 were 8 days and 16 days, respectively. Modest but significant short-term virologic 
and immunologic response was detected after MAb infusion of 2F5 and 2G12. Five months 
after the last antibody infusion, no antibodies were detectable in the circulation (STIEGLER 
et al. 2002). Conclusively, this first clinical trial of passive immunisation showed beneficial 
antiviral activity in humans chronically infected with HIV-1. 
These findings suggest that neutralising antibodies should be further evaluated as an 
alternative therapeutic approach in HIV-1 mediated disease. However, enormous antibody 
concentrations will be needed in the coming years to potentially treat 38 millions of HIV-
infected persons. Appropriate production and downstream processing platforms have to be 
developed and implemented for production of antibodies at clinical grade and considerable 
production costs. 
I.1.2 Cell surface receptor as therapeutic target 
I.1.2.1 FcγR receptors 
Receptors that recognise the Fc portion of antibodies (FcRs) are found on most immune cells. 
FcRs were identified through the analysis of cytophilic antibodies and their mechanism of 
interaction with intact cells (BERKEN and BENACERRAF 1966). In immune regulation, 
FcRs link antibody-mediated immune responses with cellular effector functions. Specific 
FcRs exist for all classes of Igs, including IgA (FcαR), IgD (FcδR), IgE (FcεR), IgG (FcγR), 
IgM (FcμR).  
The FcR for IgG (FcγR) comprises a multigene family (Fig.I-2), divided into three classes: 
FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) based on differences in receptor 
structure, cell distribution and affinity for IgG (VAN DE WINKEL and CAPEL 1993; 
HULETT and HOGARTH 1994).  
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Fig.I-2: The human Fcγ receptor family. FcγRI, FcγRIIa, FcγRIIIa and FcγRIIIb with two or three 
extracellular immunoglobulin-like domains are presented with their corresponding signalling chains (γ, β, or ζ). 
(derived from ROITT et al. 2001) 
 
The basic structure of FcγR consists of a ligand-binding α-chain with an extracellular part 
composed of two or three conserved Ig-like extracellular domains of the C2 class (SMITH 
and XUE 1997), a divergent transmembrane region and a cytoplasmic tail (QIU et al. 1990). 
FcγRI and -III require the association between the ligand-binding α-chain for signal 
transduction, and signalling γ, β, or ζ-chains (LANIER et al. 1989; RA et al. 1989; 
WIRTHMUELLER et al. 1992). These accessory chains contain signalling motifs in their 
cytoplasmic regions, named Immunoreceptor Tyrosine-based Activation Motifs (ITAM), 
which are involved in the recruitment and activation of specific tyrosine kinases upon 
receptor crosslinking (van den HERIK-OUDIJK et al. 1995). Members of the FcγRII class 
such as FcγRIIA and FcγRIIB are monomeric receptors containing either activatory (ITAM) 
or inhibitory (ITIM) signalling motifs within their ligand-binding chains (DAERON 1995).  
The structural heterogeneity of FcγR is reflected in a wide range of biological activities, 
including clearance of antigen/antibody immune complexes, regulation of antibody 
production, enhancement of antigen presentation, ADCC, phagocytosis, degranulation, and 
activation of inflammatory cells. Many of these responses are unique for selected cell types 
based on differences in tissue-specific expression of FcγRs (reviewed in RAVETCH and 
BOLLAND 2001;van der POL and van de WINKEL 1998). Additionally, diversity of 
individual FcγR receptor-mediated functions are related to genetically determined 
polymorphisms (DE HAAS et al. 1995). 
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FcγRs are expressed on monocytes, macrophages, neutrophils, basophils, eosinophils, 
platelets, B and T lymphocytes, NK cells, dendritic cells and Langerhans cells (van de 
WINKEL and CAPEL 1996).  
The crystal structures of the extracellular domains for both FcγRII and FcγRIII have recently 
been solved, either as free molecule or in complex with IgG, contributing greatly to the 
understanding of these receptors’ mode of action (MAXWELL et al. 1999; SONDERMANN 
et al. 1999; SONDERMANN et al. 1999; SONDERMANN et al. 2000; ZHANG et al. 2000). 
Considerable progress has been made since the high-affinity receptor for human IgG1 (FcγRI) 
was discovered, but detailed in vitro analysis failed so far due to lack of soluble FcγRI.  
I.1.2.2 Fc gamma receptor I (FcγRI) 
Human FcγRI (CD64) is a 72-kDa glycoprotein which binds with high affinity (Ka = 108–109 
M–1) to monomeric as well as aggregated IgG, with selectivity for human IgG1 and IgG3. The 
interaction with IgG4 and particularly with IgG2 is much weaker (van der POL and van de 
WINKEL 1998). FcγRI is a multi-subunit receptor consisting of the heavily glycosylated α-
chain and two γ-chain subunits of the FcεRI (ALLEN and SEED 1989; KUSTER et al. 1990). 
The unique property of FcγRI is its high affinity for monomeric IgG, conferred by a third 
extracellular Ig domain not found in FcγRII or III (which only bind complexed IgGs; ALLEN 
and SEED 1989). Domain-swapping experiments involving FcγRI revealed a major site for 
IgG interactions in the second domain, whereas the third domain increases the binding 
specificity and affinity (van de WINKEL and CAPEL 1996). Mutagenesis studies on IgG 
molecules by Duncon et al. (1988) showed that Leu235 is the major determinant in receptor 
binding; additional interaction between the receptor and the region linking the CH2 domain to 
the hinge was only postulated. Later studies showed that the lower hinge region (residues 
234–237) was one interaction site (LUND et al. 1991) but a second region contributing to 
receptor binding was identified in the hinge-proximal bend (Pro331; CANFIELD and 
MORRISON 1991). 
Three genes for human FcγRI have been identified (FcγRIa, FcγRIb and FcγR1c), all located 
on chromosome 1 (1p13 and 1q21; van de WINKEL and CAPEL 1993) encoding four 
transcripts: FcγRIa, FcγRIb1, FcγRIb2 and FcγRIc (van VUGT et al. 1999). The hFcγRIa 
transcript encodes the high-affinity IgG receptor. Transcripts FcγRIb1 and FcγRIc contain 
stop codons in the third extracellular region, and are predicted to generate secreted receptor 
forms (ERNST et al. 1992), although these have yet to be detected. The alternatively spliced 
hFcγRIb2 transcript encodes a product that is retained in the endoplasmic reticulum (van 
VUGT et al. 1999).  
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FcγRI is expressed constitutively on monocytic cells, macrophages and dendritic cells, 
whereas its expression can be induced by various elicitors on neutrophils, eosinophils, 
glomerular mesangial cells and mast cells (RAVETCH and KINET 1991; van de WINKEL 
and CAPEL 1993; HULETT and HOGARTH 1994; UCIECHOWSKI et al. 1998; 
OKAYAMA et al. 2000). Activation of FcγRI on macrophages induces the clearance of 
antigen/antibody complexes by endocytosis or phagocytosis, leading to enhanced antigen 
presentation on MHC I and II molecules (HEIJNEN et al. 1996; LIU et al. 1996; GUYRE et 
al. 2001). This triggers ADCC by Tc cells and superoxide generation, or the activation of Th 
cells (van de WINKEL and CAPEL 1996; van VUGT et al. 1999; GUYRE et al. 2001). 
Inflammatory reactions can be induced by antibody binding to FcγRI on mast cells, leading to 
the secretion of amines, lipid mediator and cytokines (OKAYAMA et al. 2001; 
WOOLHISER et al. 2001). Surprisingly, despite the importance of FcγRI, one study 
identified four apparently healthy individuals within one family lacking phagocytic 
expression of FcγRI (van de WINKEL et al. 1995). Many other studies have linked variations 
in FcγRI activation to different disease patterns, e.g. overactivation of macrophages in acute 
and chronic inflammation (KIEKENS et al. 2000) or the inhibition of phagocytosis of 
monocyte-derived macrophages (MDMs) in HIV-1 infection in vitro (KEDZIERSKA et al. 
2002). The therapeutic value of FcγRI as a target in tumor therapy, allergic reactions and 
leukaemia has been extensively reviewed (CURNOW 1997; RAVETCH and BOLLAND 
2001).  
Since the characterization of the genes for human FcγRI in 1992 (ERNST et al. 1992), all 
attempts to produce a functional, soluble form of the receptor have so far failed (JEFFERIS 
and LUND 2002). Sondermann et al. (SONDERMANN and OOSTHUIZEN 2002), who 
crystallized soluble FcγRIIb and soluble FcγRIII in complexes with human IgG Fc, even 
suggested that the expression of soluble FcγRI is impossible. However, with optimised 
expression vector-host-systems new approaches might be developed to express the FcγRI 
receptor recombinantly. Expression of recombinant soluble FcγRI might allow in detail 
characterisation of the exact binding site for human IgG and potential modulation of this 
region to enhance IgG binding. Additionally, availability of recombinant soluble FcγRI will 
facilitate the investigation of FcγRI’s therapeutic application. 
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I.2 Expression of human therapeutic proteins in heterologous 
expression systems 
During the last years more and more biopharmaceuticals were approved by the regulatory US 
Food and Drug Administration (FDA) for clinical trials and commercial production resulting 
in a present market of about US$30 billion (COCO-MARTIN 2004). Estimated 4,400 biotech 
companies are globally involved, having brought more than 100 different biopharmaceutical 
products on the (U.S.) market (FROST&SULLIVAN(A) 2003). Actual lists are published by 
the Biotechnology Information Institute (http://www.bioinfo.com/).  
Depending on their required characteristics, biopharmaceuticals are produced in different host 
systems. Although transgenic plants and animals are predicted to become commercially 
competitive for manufacturing therapeutic proteins in the future, every biopharmaceutical on 
the market today is produced in either a mammalian or microbial cell line (THIEL 2004). 
Currently the most important expression systems used in industry are the bacteria E.coli, yeast 
Saccharomyces cerevisiae and Pichia pastoris and mammalian CHO cells (DE NORONHA 
PISSARRA 2004). Production of proteins in plant systems will be an additional emerging 
expression system in the next years, but complete regulatory guidelines such as for the 
production in mammalian and bacterial cells, are not fully established (FISCHER et al. 2004; 
STOGER et al. in progress).  
All expression systems offer advantages and disadvantages, thus the proper choice of a host 
organism for the production of a biopharmaceutical has to be made on a case-by-case basis 
and depends upon the protein under consideration. 
 
I.2.1 Bacterial expression 
Expression of recombinant proteins in E.coli has been investigated extensively over the last 
20 years and is one of the most frequently used systems. Clear guidelines by the competent 
authorities (e.g. European Agency for the Evaluation of Medicinal Products (EMEA) and the 
FDA) for the production of recombinant proteins in E.coli have to be complied (DE 
NORONHA PISSARRA 2004). Some of today’s blockbusters such as interferon (IFN-)alpha 
(Infergen by Intermune), recombinant insulin (Humalog by Lilly), recombinant human growth 
factor (Protropin by Genentech) and granulocyte macrophage colony-stimulating factor (GM-
CSF, Neupogen/Neulasta by Amgen) are expressed in E.coli (THIEL 2004).  
E.coli grows on inexpensive carbon sources, offers rapid biomass accumulation and can be 
easily cultivated and scaled-up in high cell-density fermentations yielding protein 
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accumulation levels in the gram per litre scale (ARISTIDOU et al. 1999; BANEYX and 
MUJACIC 2004). An additional benefit is the well-characterised and established rapid 
cloning and expression procedure. Expression vectors containing a multiple cloning site 
downstream of an inducible promoter are developed to reach expression levels in excess of 
50% of total cell protein (MIAO et al. 1995). Small polypeptide tags, including the hexa-
histidine (his-tag), the FLAG or the anti-c-myc tag are added either N or C terminally to the 
protein for detection and purification (NOVAGEN 2002).  
Expression of recombinant proteins can be performed in the cytoplasm or the periplasm of the 
bacterial cell (BANEYX 1999). The cytoplasm is known to yield much higher protein 
concentrations but it is not uncommon that overexpressed protein associates with each other 
and forms insoluble and inactive aggregates (inclusion bodies; SANCHEZ et al. 1999). 
Moreover, time and labour intensive refolding procedures are undertaken resulting in low 
amounts of functional protein.  
Employing leader sequences (e.g. pelB or ompA leader), recombinant proteins are directed 
into the bacterial periplasm, where the oxidising milieu favours the formation of disulfide 
bonds by the disulfid-oxidoreductase (BRADWELL et al. 1991). Another advantage is the 
presence of chaperones leading to stabilisation of the recombinant protein (reviewed in 
WULFING and PLUCKTHUN 1994). Moreover, the periplasm contains less bacterial 
proteins than the cytoplasm and therefore less proteases, which facilitates the protein 
purification with less proteolytic degradation (TALMADGE and GILBERT 1982). The 
efficiency of periplasmic expression can be additionally enhanced by using compatible 
solutes and induction of protein expression through osmotic stress (BARTH et al. 2000).  
Drawbacks and limitations for expression in E.coli include poor post-translational assembly 
(no glycosylation) and the high grade of inactivity of more complex proteins. Overexpressed 
proteins can also fail to fold correctly and undergo proteolytic degradation, and finally 
bacterial endotoxins can contaminate the purified preparations (PLUCKTHUN 1991). 
Consequently, testing of products derived from E.coli for endotoxin removal is mandatory. 
The work described in this thesis focuses on the use of a pET-derived vector (Novagen) for 
expression in E.coli BL21(DE3)star cells. A pelB leader directs the expressed protein into the 
bacterial periplasm. An N-terminal penta-his tag facilitates the purification and detection of 
the expressed recombinant proteins.  
The extracellular part of the human FcγRIIb was successfully expressed in E.coli cells 
(SONDERMANN and JACOB 1999). Activity of the unglycosylated form was proven by 
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binding of immobilized antibody as well as Fc fragment in solution. Thus, primary expression 
experiments of FcγRI would have to be performed in E.coli.  
Generally, E.coli is the system of choice for the production of antibody fragments, such as 
scFvs (artificial construct comprising the VL and VH of an antibody linked by a stretch of 
peptides), Fabs or F(ab)2 (reviewed in PLUCKTHUN et al. 1996). Only one publication 
described the successful expression of an aglycosylated full-size antibody (SIMMONS et al. 
2002). As glycosylation contributes to the effector function of neutralising antibodies, the 
expression of the anti-HIV antibodies 2F5 and 2G12 in E.coli was not considered. 
I.2.2 Mammalian expression 
Since 1986, when Genentech announced the market approval of human tissue plasminogen 
activator (tPA), the first therapeutic protein from recombinant mammalian cells, this market 
has increased potentially to several hundred clinical candidates currently in company 
pipelines. Commercially manufactured products in CHO cells include Genentech’s Herceptin 
(trastuzumab), Genzymes’s Cerezyme (recombinant imiglucerase), Genentech’s Avastin 
(bevacizumab) and Biogen Idec’s Rituxan (rituximab; THIEL 2004). Sixty to seventy percent 
of all recombinant protein pharmaceuticals are produced in mammalian cells, as mammalian 
expression reveals the most authentic glycosylation leading to a high percentage of active 
complex proteins (WURM 2004). Most proteins are produced in CHO cells, but other cell 
lines were also approved by the FDA, like as mouse myeloma (NS0), Baby Hamster Kidney 
(BHK), Human Embryonic Kidney (HEK-293) or human retinal cells (PER-C6; JONES et 
al. 2003). These cell lines can be or already are adapted to serum-free suspension media 
allowing large-scale production in bioreactor systems in well-defined media and at lower 
costs, since the expensive infrastructure as well as the low expression yields were one of the 
former drawbacks of mammalian expression. Additionally the risk of containing human 
pathogens can be reduced by using serum-free media. Extensive studies have yielded 
mammalian cell productivity in bioreactors to the gram per litre range (corresponding to a 
specific productivity of 20 - 90 pg/cell/day), which represents a more than 100-fold yield 
improvement in the last 25 years (WURM 2004). Employing leader sequences (e.g. Ig kappa 
leader), allows expression of the recombinant protein into the culture supernatant facilitating 
the purification procedure. Correct folding and functionality of the recombinantly produced 
proteins is achieved by chaperones and disulfidisomerases located in the ER (reviewed in 
FERRARI and SOLING 1999). 
Drawbacks of mammalian expression include the long development time to reach stable 
expression clones. Initial cloning procedures are usually carried out in bacterial expression 
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vector, but the development of stably expressing eucaryotic clones is very time and labour 
intensive. Additionally, contamination with pathogens must be extensively removed in 
cleaning validation for clinical use of the recombinant proteins (MARTINEZ 2004), but this 
must be performed in bacterial expression as well. 
For the work presented in this thesis the pSecTag-based system (Invitrogen) was used. An Ig-
kappa leader directs the secretion of the recombinant proteins into the culture supernatant of 
transfected HEK 293T cells (STOCKER et al. 2003). The cell line HEK 293T expresses the 
large T-antigen of the SV40-virus enabling a high copy number of the transfected episomal 
plasmid in the transiently transfected cells. Different studies reported successful expression of 
different glycoproteins (MANNA et al. 2002; DU et al. 2003; NING et al. 2003; PATEL et 
al. 2004) as well as recombinant antibody fragments (GRUNBERG et al. 2003) in HEK 293 
cells. For production of full-size antibodies in general hybridoma, NSO and CHO cells are 
used (BARNES et al. 2003) as in case of the human anti-HIV antibodies 2G12 and 2F5 
(BUCHACHER et al. 1994; KUNERT et al. 2000). 
Soluble human FcγRII was successfully produced in insect cells (SONDERMANN et al. 
1999), whereas human FcγRIII is naturally expressed as soluble form in humans. Expression 
of soluble FcγRI will be tested in mammalian HEK 293T cells for productivity and 
functionality in comparison to the bacterial system. 
I.2.3 Plant expression 
Initially the idea to use plants and plant cells for the production of human proteins was 
“greeted with great scepticism” (SCHILLBERG et al. 2003). However, plant expression 
systems have the potential to provide virtually unlimited quantities of proteins for use as tools 
in human health care offering a simple and low-cost alternative to bacterial and mammalian 
systems (STOGER et al. 2002). The costs of producing recombinant proteins in plants might 
be 90-fold lower than the production in other systems (SCHILLBERG et al. 2003). 
Additionally, safe biopharmaceuticals can be produced in plants, since plants do not harvest 
human pathogens compared to mammalian cells (GIDDINGS et al. 2000). Commercial 
production of plant secondary products, such as codeine and morphine from Papaver 
somniferum and digoxin from Digitalis sp. has been used for centuries in human medicine 
(PAIVA 1999). Bioreactivity screens identified new compounds, especially anticancer 
compounds like as vincristine and vinblastine from Catharantus roseus and taxol from Taxus 
sp. Ginseng roots for example are used as whole whereas anthocyanins and flavours have to 
be extracted. Commercial production of shikonin is reported in the 750-L scale (CURTIN 
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1983), but plant cell suspension cells (TBY-2) were successfully grown up to 20,000-L 
cultures (NAGATA et al. 1992). 
In the last 20 years, plants are gaining more and more acceptance as alternative production 
system for production of recombinant proteins in terms of cost, scalability and safety. Two of 
the world’s most expensive drugs, glucocerebrosidase by CropTech Corp. (Blacksburg, USA) 
and GM-CSF by GeneMedix PLC (Newmarket, UK) have been produced in transgenic plants 
(GIDDINGS et al. 2000) and different companies will enter the market with their products in 
the coming years. Biolex (Pittsboro, USA) e.g. used Lemna minor (duckweed) as a system for 
the production of interferon-alpha currently in clinical phase I, Large Scale Biology Corp. 
(Vacaville, USA) completed clinical phase I studies with a Non-Hodgkin lymphoma vaccine 
produced in tobacco. Meristem Therapeutics (Clermont-Ferrand, France) used corn and 
tobacco for the expression of gastric lipase (clinical phase IIa), Plant Biotechnology 
(Hayward, USA) produced CaroRx against tooth decay (clinical phase II) and RhinoRx for 
common cold (preclinic) in tobacco, ProdiGene (College Station, USA) completed clinical 
phase I with an antibody for Traveler’s diarrhea from corn and SemBioSys (Calgary, Canada) 
entered the preclinical phase with human insulin and apolipoprotein from transgenic oilseed 
(THIEL 2004). 
A variety of different plants can be used as expression hosts for biopharmaceuticals. Hiatt et 
al. succeeded in 1989 with the first antibody and antibody fragment expression in transgenic 
tobacco plants (HIATT et al. 1989). Since then, many approaches have shown the expression 
of full-size antibodies (DURING et al. 1990; MA et al. 1994; VERCH et al. 1998), Fab-
fragments (DE NEVE et al. 1993; DE WILDE et al. 1998), scFv-fragments (OWEN et al. 
1992; FIEDLER and CONRAD 1995; FECKER et al. 1996), diabodies (VAQUERO et al. 
2002) and bi-specific scFv fragments (FISCHER(C) et al. 1999) as well as complex proteins 
(CRAMER et al. 1996; TACKABERRY et al. 1999) in different cell compartiments of 
tobacco (SCHILLBERG et al. 1999), Arabidopsis (DE WILDE et al. 1998), rice, wheat 
(STOGER et al. 2000; STOGER et al. 2004) and alfalfa (KHOUDI et al. 1999).  
The choice of the plant production system depends on factors such as intrinsic efficiency, 
suitability for scale-up, storage and downstream processing (STOGER et al. in progress). 
Tobacco for example is long established as a model system and offers advantages such as fast 
generation of large amounts of biomass, simple gene transfer and regenerations procedures as 
well as optimised vector systems. Large-scale purification of e.g. recombinant antibodies out 
of 200 kg batches of Tobacco leaves was already performed (VALDES et al. 2003). 
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As an alternative to whole plant expression, plant cells or organ cultures can be used. 
Compared to the production of recombinant proteins in transgenic plants, the generation and 
initial up-scaling of transgenic suspension cell lines is considerably faster and requires less 
resources (FISCHER(B) et al. 1999). Production of recombinant antibodies in plant cell 
suspensions allows sterile containment in compliance with GMP-conditions (FISCHER(B) et 
al. 1999; SHARP and DORAN 2001; SCHILLBERG et al. 2003; HELLWIG et al. 2004). 
Additionally, the cost of protein production in plant cell culture is still lower than that of 
mammalian cells (FISCHER(E) et al. 1999; STOGER et al. in progress). However, only two 
secondary metabolites, shikonin by Mitsui Petrochemical Company (Japan) and paclitaxel 
(Taxol) by Bristol-Myers Squibb (New York, USA) have been produced on a commercial 
scale in plant suspension cells (HELLWIG et al. 2004).  
Different plant species have been used so far for the generation and propagation of cell-
suspension cultures, such as Arabidopsis thaliana (DESIKAN et al. 1996) and Cataranthus 
roseus (CAREW and BAINBRIDGE 1976), but also important crop plants like rice (CHEN et 
al. 1994), soybean (UPMEIER et al. 1988), alfalfa (DANIELL and EDWARDS 1995), 
tomato (KWON et al. 2003) and tobacco (NAGATA et al. 1992). Over 20 different 
recombinant proteins have been produced in plant cell cultures, such as human lysozyme, 
anti-trypsin, human erythropoietin, bryodin 1, hGM-CSF, cytokines (IL-2, IL-4, IL-12) and 
antibodies/antibody fragments (HELLWIG et al. 2004). Until now only three reports have 
described the production of assembled full-size antibodies in plant suspension cells. An anti-
TMV mouse IgG2b/κ was produced in suspension cells established from transgenic Nicotiana 
tabacum cv. Petit Havana SR-1 plants (FISCHER(B) et al. 1999) reaching an accumulation 
level of 15 mg/kg fresh weight. Guy’s 13, an IgG1/κ recognising a 185 kDa cell-surface 
protein of Streptococcus mutans, was also produced with levels of 7.5 mg/L in a transgenic 
tobacco Nt-1 derived cell line (SHARP and DORAN 2001). The recently published work by 
Yano et al. (YANO et al. 2004) is the first report in which a human IgG1/κ against a HBV 
antigen was expressed in Nicotiana tabacum L. cv. Bright Yellow (BY-2) suspension cells 
and yields of 16.2 mg/L were achieved. In all studies the constitutive enhanced 35S promoter 
was used and the antibodies were targeted to the apoplast.  
The tobacco suspension cell line BY-2 offers the advantage of direct transformation (co-
cultivation with Agrobacterium tumefaciens) allowing detection of the foreign protein in 
transient expression after 2 – 3 days (SCHILLBERG et al. 2003). Recombinant proteins 
expressed in BY-2 cells can be secreted into the culture supernatant or retained within the 
cells. Chaperones responsible for correct folding and assembly are located in the ER of 
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plasma cells (MELNICK et al. 1994) and homologous proteins were also described for plants 
(FONTES et al. 1991; WALTHER-LARSEN et al. 1993). Since disulfide bridges are formed 
by the disulfidisomerases in the ER as well, plant produced recombinant protein should be 
targeted to the ER (DENECKE et al. 1992). Using a KDEL-retention signal can enhance the 
expression rate in the ER with a factor of 10 – 100 compared to secreted variants 
(WANDELT et al. 1992; SCHOUTEN et al. 1996; CONRAD and FIEDLER 1998). 
Due to different glycan-modifying enzymes, plant produced proteins contain a different 
glycosylation pattern compared with mammalian cells, such as a high-mannose type 
consisting of N-Acetylglucosamine (GlcNAc) and mannose residues (CABANES-
MACHETEAU et al. 1999). Carbohydrate moieties unique to plants may induce immune 
responses when regularly administered into humans. It is known for antibodies, that N-
glycans at the Fc part of the IgG molecule contribute to effector functions (LUND et al. 1990; 
WRIGHT and MORRISON 1998; SHINKAWA et al. 2003). However, one plant produced 
anti-Rabies virus antibody with high-mannose type glycan exhibited the same neutralising 
activity compared with the mammalian derived antibody (KO et al. 2003).  
For the work described in this thesis the pPAM-based system for expression in tobacco leaves 
(Nicotiana tabacum L. cv. Petit Havana) and plant suspension cells [Nicotiana tabacum L. cv. 
Bright Yellow (BY-2)] was used containing an IgG–kappa leader and a SEKDEL-tag for 
retention in the ER. Delivery of the vector-construct into the plant cells is mediated by 
Agrobacteria tumefaciens, which efficiently transfers DNA into the plant cell, where the gene 
of interest is transiently expressed (AN 1995; KAPILA et al. 1996).  
The human anti-HIV antibodies should be expressed in BY-2 suspension cells to generate an 
attractive alternative system for the expression of these therapeutic antibodies to the CHO 
expression system at reasonable costs and yield. Human FcγRI should be expressed 
transiently in tobacco leaves to evaluate the potential of plant expression for functional 
production of this human molecule in comparison to the bacterial and mammalian expression 
systems. 
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I.3 Goal of this thesis 
Two different biopharmaceuticals, one therapeutically relevant CD-antigen and one 
monoclonal antibody were selected for expression and functional characterisation in 
heterologous expression systems in this thesis. 
The number of people infected by HIV is growing steadily and effective vaccines might not 
be available in the near future. With the current combination therapy using inhibitors of the 
viral reverse transcriptase and protease, the infection can be controlled but resistance develops 
very fast. Extensive studies resulted in the purification of five promising antibodies out of the 
sera of inapparent patients, which effectively neutralise a broad spectra of HIV primary 
isolates. Two of these antibodies, 2F5 and 2G12, produced in CHO cells (CHO2F5/CHO2G12) 
have been used successfully in clinical phase I studies. In order to satisfy the requirements of 
antibody in HIV therapy, alternative expression systems should be tested for their ability to 
produce clinical proteins in high amounts at reasonable costs. Plants represent an inexpensive, 
efficient and safe system for the production of therapeutic antibodies. Especially, plant 
suspension cells offer the advantages of bioreactor production in defined media under GMP 
compliance. Thus, protocols for the expression of anti-HIV antibodies expressed in plant 
suspension cells, more precisely in tobacco BY-2 suspension culture (BY-2; BY-22F5/BY-
22G12) have to be developed both on a small-scale (1-L) and large-scale (100-L) feasibility. 
Available equipment for continuous downstream processing on industrial scale should be 
analysed and downstream processes to be developed to recover pure protein for biochemical 
and biophysical characterisation. Plant derived antibody preparations should be analysed 
concerning purity, integrity and stability of the anti-HIV antibody as well as antigen-binding 
property. 
The second aim of this thesis was to investigate FcγRI, the high-affinity receptor for 
monomeric IgG, a potential therapeutic target in tumor therapy, allergic reactions and 
leukaemia. To achieve this the extracellular domain of the receptor headed to be amplified 
from peripheral blood, cloned and the most appropriate expression system needs to be 
determined. As a procaryotic expression system E.coli was chosen and for eucaryotic 
expression both HEK 293T cells and N.tabacum should be used. For the system yielding 
highest expression a protocol headed to be established for the expression and purification. 
Integrity and purity, as well as binding properties of the purified protein preparations will be 
tested. 
A schematic overview of the structure of this thesis is presented in Fig.I-4. 
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Fig.I-3:  Schematic outline of the subjects described in this thesis.     = CHO2F5 and CHO2G12 
antibodies were provided by Polymun Scientific GmbH (Wien),      = work performed by M. Bomble (BOMBLE 
2004). 
Generation of the extracellular 
domain of FcγRI (rsCD64) 
Comparison of production yield 
Therapeutic Relevant Proteins 
Human Fc gamma receptor I (FcγRI) Human anti-HIV antibodies (2F5 and 2G12) 
Construction of rsCD64 in 
procaryotic (pMT) and eucaryotic 
(pMS, pTRA) expression vector
Development of Standard 
operation procedures (SOP) for 
one system  
Expression of rsCD64 in 
• E.coli [BL21(DE3)],  
• Plant cells (N.tabacum) 
• Mammalian cells (HEK 293T) 
In vitro characterisation 
• SDS-PAGE 
• Westernblot 
• Mass-spectrometry 
• ELISA 
• IgG sepharose binding  
Construction of 2F5 and 2G12 in plant 
expression vector (pTRA) 
Transient and stable expression of 
N.t.2F5 and N.t.2G12 in N.tabacum  
Generation of recombinant BY-2 cells 
expressing BY-22G12 and BY-22F5  
Product yield 
Small scale (1-L) expression and purification 
In vitro characterisation 
• SDS-PAGE 
• Dot- and Westernblot 
• Mass-spectrometry 
• ELISA 
• EMSA 
• Biacore 
Fermentation (7 – 100-L) and feasibility 
study of downstream processing equipment  
Generation of CHO2F5 and CHO2G12
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II. Material and methods 
II.1 Material 
II.1.1 Chemicals and consumables 
Unless stated otherwise consumables and chemicals were purchased from Abcam 
(Cambridge, UK), Amersham Pharmacia (Freiburg), AP Biotech (Freiburg), BIACORE 
(Freiburg), Becton Dickinson Bioscience (Franklin Lakes, USA), Biochrom (Berlin), BioRad 
(München), Biozym (Oldendorf), CARR Separations Inc. (Franklin, USA), Ciphergen 
(Goettingen), Clontech (Heidelberg) Corning Inc. (Schiphol-Rijk, Niederlande), Cytogen 
(Obermörlen), Dynal (Hamburg), Eppendorf (Hamburg), ICN (Eschwege), Greiner 
(Solingen), Hewlett-Packard (München), Invitrogen (Eggenstein), Kodak (Stuttgart), KMF 
Laborchemie (St. Augustin), Millipore (Eschborn), MWG-Biotech (Ebersberg), NALGENE® 
(Neerijse, Belgium), News Brunswick Scientific (Nürtingen), New England Biolabs (NEB; 
Schwalbach), Nunc (Biebrich), Pall Filtron (Northborough, USA), Perkin-Elmer (Applied 
Biosystems, Foster City, USA), Pierce (Rockford), Promega (Mannheim), Qiagen (Hilden), 
Roche Molecular Biochemicals (Mannheim), Roth (Karlsruhe), Sarstedt (Nümbrecht), Schott-
Glaswerke GmbH (Neufahrn/San Diego), Serva (Heidelberg), Sigma (Deisenhofen), Starlab 
(Ahrensburg), Whatman (Maidstone, England), VWR (Darmstadt), Werner GmbH 
(Leverkusen) and Zeiss (Oberkochen) were of the highest grade available. Culture media and 
additives were purchased from Duchefa (Haarlem, Niederlande), Invitrogen, Sigma and Roth. 
II.1.2 Media, stock solutions and buffers 
Standard media and stock solutions were prepared according to standard procedures 
(SAMBROOK and FRITSCH 1996; AUSUBEL and BRENT 1998; COLIGAN et al. 1998) 
using deionized water. Solutions were sterilised by autoclaving (25 min/ 121 °C/ 2 bar). Heat-
sensitive components, such as antibiotics, were prepared as stock solutions, filter-sterilised 
(0.2 µm) and added to the medium/buffer after cooling to 50 °C.  
II.1.2.1 General solutions 
10x PBS (pH 7.4)     PBST 
NaCl     1.37 M  1x PBS (pH 7.4) 
KCl    27 mM   Tween 20   0.05 % (w/v) 
Na2HPO4 x 12H2O  81 mM     
KH2PO4   15 mM 
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10x TBE Electrophoresis Buffer (pH 8.3)  50x TAE Electrophoresis Buffer (pH 7.5)  
Tris-base   900 mM   Tris-base   2 M  
Boric acid   900 mM   Glacial acetic acid   5.7 % (v/v) 
EDTA    25 mM   EDTA    50 mM 
        
10x DNA Loading Buffer (blue)   5x OrangeG Loading Buffer 
Bromphenolblue  0.1 % (w/v)   OrangeG   0.1 % (w/v) 
Xylencyanol   0.1 % (w/v)   Glycerol   30 % (v/v) 
Glycerol   50 % (v/v)   in TAE or TBE buffer 
in TAE or TBE buffer 
 
5x SDS PAA running buffer    Blotting buffer 
Tris-HCl (pH 8.3)  125 mM   Tris-HCl (pH 8.3)  25 mM 
Glycine   960 mM   Glycine   192 mM 
SDS    0.5 % (w/v)  Methanol   20 % (v/v) 
 
5x Reducing Protein Loading Buffer  5x Non-Reducing Protein Loading Buffer 
Tris-HCl (pH 6.8)  62.5 mM  Tris-HCl (pH 6.8)  62.5 mM 
Glycerol   30 % (v/v)  Glycerol   30 % (v/v) 
SDS    4 % (w/v)  SDS    4 % (w/v) 
Bromphenolblue  0.05 % (w/v)   Bromphenolblue  0.05 % (w/v) 
ß-Mercaptoethanol  10 % (v/v) 
 
Coomassie Staining Solution    Coomassie Destaining Solution 
Coomassie bb. G-250  0.25 % (w/v)  Methanol    10 % (v/v) 
Methanol    50 % (v/v)  Glacial acetic acid  10 % (v/v) 
Glacial acetic acid  9 % (v/v) 
 
NuPAGE® SDS Running buffer   NuPAGE® Sample Preparation 
20x NuPAGE® MES   50 ml   Sample   x µl 
dH2O    950 ml   NuPAGE LDS sample buffer 2.5 µl 
(200 ml + 500 µl Antioxidant)   NuPAGE reducing agent 1 µl 
       dH2O    ad 10 µl 
 
AP Buffer (pH 9.6)      ELISA Coating Buffer (pH 9.6)  
Tris-HCl (pH 9.6)   100 mM   Na2CO3   15 mM 
NaCl     100 mM   NaHCO3   35 mM 
MgCl2    5 mM 
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II.1.2.2 Media for bacterial cultivation 
LB (pH 7.0)       2xTY (pH 7.4) 
NaCl    1.0 % (w/v)    NaCl    0.5 % (w/v) 
Peptone   1.0 % (w/v)    Peptone   1.6 % (w/v)   
Yeast extract   0.5 % (w/v)    Yeast extract   1.0 % (w/v)   
 
TB (pH 7.4)      Media Supplements:  
Peptone   1.3 % (w/v)   Ampicillin   100 µg/ml 
Yeast extract   2.7 % (w/v)   Kanamycin   25 µg/ml 
Glycerol   0.8 % (v/v)  Agar    1.6 % (w/v) 
 
TfB-I (pH 5.8)      TfB-II (pH 5.8) 
Potassium Acetate   30 mM   MOPS    30 mM  
MnCl2    50 mM   CaCl2     75 mM 
CaCL2    10 mM   RbCl     10 mM 
Glycerol    15 % (v/v)   Glycerol    15 % (v/v) 
 
II.1.2.3 Media for the cultivation of mammalian cells 
Complex RPMI-Media [RPMI (C)] 
RPMI-Media 1640 (Cytogen), serumfree media 
Fetal Calf Serum (FCS) 10 % (v/v) 
Penicillin   50 µg/ml 
Streptomycin   50 µg/ml   Media Supplements:  
L-Glutamine   2 mM   Zeocin® (Invitrogen)  100 µg/ml 
 
II.1.2.4 Media for the cultivation of A.tumefaciens and plant cells 
MMA Buffer       BY-2 Media (pH 5.8) 
MS-salts   0.43 % (w/v)   MS-salts   0.43 % (w/v) 
(Murashige & Skoog, basic salt mixture)   Myo-Inosite (SERVA) 0.1 % (w/v) 
MES (pH 5.6)   10 mM   Sucrose   3 % (w/v) 
Sucrose   2 % (w/v)   Thiamin-HCl   0.2 mg/l 
(Acetosyringone  200 µM   2,4-dichloroph. acid   0.2 mg/l 
was added directly before use)   KH2PO4 (pH 5.6)  0.2 % (w/v) 
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Media Supplements      Extraction Buffer (pH 7.4) 
Agar    0.8 % (w/v)   EDTA    5 mM  
Kanamycin   100 mg/l   β-mercaptoethanol  5 mM 
Claforan (cefatoxim)  200 mg/l 
 
YEB Media       Induction Media 
Nutrient Broth  0.5 % (w/v)   YEB media (pH 5.6) 
Yeast extract   0.1 % (w/v)   MES    10 mM 
Peptone   0.5 % (w/v)   (Acetosyringone  20 µM  
Sucrose   0.5 % (w/v)   added directly before use) 
 
Media Supplements      Glycerol Stock Media (GSM) 
MgSO4   2 mM    Glycerol    50 % (v/v) 
Rifampicin (Rif)  50 mg/l  MgSO4    100 mM 
Carbenicillin (Carb)  50 mg/l   Tris (pH 7.4)    25 mM 
Kanamycin (Km)  25 mg/l 
 
II.1.3 Enzymes and reaction kits 
Unless otherwise stated, enzymes were purchased from NEB, Roche Molecular Biochemicals, 
MWG-Biotech and Invitrogen. Taq DNA-polymerase from Roche was used for PCR 
amplification. The following kits were used: 
 
QIAquick Gelextraction Kit Qiagen  
QiaExII Agarose Gel Extraction Kit Qiagen 
QIAprep Spin Miniprep Kit Qiagen 
QIAquick „PCR-Purification“ Kit Qiagen 
Pre Analytix total-RNA Isolation from blood Qiagen 
One-Step-RT-PCR Qiagen 
PreAnalytiX Kit  Qiagen 
PAXgeneTM Blood RNA System  Becton Dickinson 
BCA Protein Assay Pierce 
Amine Coupling Kit Biacore 
Sucrose, D-glucose, D-fructose Enzymekit Roche 
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II.1.4 Antibodies and antigens 
II.1.4.1 Antibodies 
The following monoclonal primary and enzyme-labelled secondary antibodies were used: 
 
Antibody Epitope Characteristics 
mouse-anti-c-myc, [mAk9E10] 
(EVAN et al. 1985) 
C-terminal c-myc-tag monoclonal 
mouse-anti-c-myc                        [α-
cmycHRPO]                      (Abcam, 
England) 
C-terminal c-myc-tag monoclonal, conjugated 
to HRPO („horse radish 
peroxidase“) 
mouse-anti-penta-his                   [α-
pentaHis Ak]                 (Qiagen) 
N- resp. C- terminal his-tag monoclonal 
mouse-anti-CD64 [M22]       (Maine 
Biotechnology, USA) 
human CD64 monoclonal 
humanized-anti-CD64 [H22]  
(T.Thepen, BioVII, RWTH-Aachen) 
human CD64 monoclonal 
mouse-anti-FSH               
   [scFv4813]                     
(S.Hellwig, BioVII, RWTH-Aachen)
Follicle stimulating hormone 
(FSH) 
monoclonal, single 
chain fragment (scFv) 
chimeric mouse/human-anti-β-hCG 
   [cPIPP]                        
(M. Sack, BioVII, RWTH-Aachen) 
β-hCG monoclonal, chimeric 
mouse/human-IgG1 
CHO2F5IgG1-anti-HIV 
(Polymun Scientific GmbH, Wien) 
gp41 of HIV-virus monoclonal 
CHO2G12IgG1–anti-HIV 
(Polymun Scientific GmbH, Wien) 
gp120 of HIV-virus monoclonal 
mouse-anti-CA19.9IgG1 
(kindly provided by H.Abken, Klinik 
I für Innere Medizin, Cologne) 
CA19.9 monoclonal 
goat-anti-human                   
    [GαHAP (α-IgGγ)]               
(Sigma) 
γ-chain of human IgG polyclonal, conjugated 
to alkaline phosphatase 
goat-anti-human                   
[GαHAP (α-IgG kappa)]        
(Sigma) 
κ-chain of human IgG polyclonal, conjugated 
to alkaline phosphatase 
goat-anti-mouse                   
[GαMAP (α-IgG Fc)]            
 (Sigma) 
Fc of mouse IgG polyclonal, conjugated 
to alkaline phosphatase 
goat-anti-mouse                 
[GαMHRPO (α-IgG Fc)]         
(Sigma) 
Fc of mouse IgG polyclonal, conjugated 
to HRPO („horse radish 
peroxidase“) 
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II.1.4.2 Antigens 
Antigen hCG was kindly provided by M. Sack (BioVII, RWTH-Aachen). GαH-Fab serum 
was purchased from Sigma. Antigens for the antibody 2F5 and 2G12 were purchased from 
NIBSC (Centralised Facility for AIDS Reagents).  
II.1.5 Synthetic oligonucleotides 
Oligonucleotides used for DNA-sequencing or PCR were purchased from MWG Biotech: 
Name Sequence 
pMS-5’ 5’– AGC AGA GCT CTC TGG CTA ACT– 3’ 
pMS-3’ 5’– CAT GCC CGC TTT TGA GAG GGA– 3’ 
pMT-5’ 5’– GTC TGC TGC TCC TCG CTG– 3’ 
pMT-3’ 5’– GGA TAT AGT TCC TCC TTT CAG– 3’ 
pS-5’ 5’- GAC CCT TCC TCT ATA TAA GG-3’ 
pS-3’ 5’- AAA GAG GTC TTA TTA CAC AC -3’ 
cd64-5’ 5’- GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCA 
GTG ATC ACT TTG CAG CCT C-3’  
cd64-cmyc-3’rc 5’-TCA GTC GCT CAG CCT ACA GAT CCT CTT CTG AGA TGA 
GTT TTT GTT CGA CAT GAA ACC AGA CAG GAG TTG-3’ 
 
II.1.6 Recipients of recombinant DNA 
II.1.6.1 Bacterial strains 
E.coli strain XL1-blue was used as a host cell for intermediate cloning constructs; BL21 
(λDE3) was used for expression of recombinant proteins. 
Strain Genotyp 
BL21 (λDE3) F- ompT hsdSR (rB- mB- ) dcm- gal lon-(Novagen, Madison, USA)
XL1-blue RecA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’proAB 
lacIq Z∆M15 Tn10 (Tetr)] (Stratagene, La Jolla (USA)) 
DH5α supE44 lacU169 (Φ80dlacZ ΔM15) hsdR17 recA endA1 gyrA96 
thi-1 relA1 (HANAHAN 1983) 
Table II-1 Name, supplier and genotypes of Escherichia coli strains used throughout the work. 
 
II.1.6.2 Mammalian cells 
HEK 293T (ATCC-Nr.:CRL-11268, SENA-ESTEVES et al. 1999), an adherent human, 
embryonic kidney (HEK) cell line, was used for expression of human rsCD64 (II.2.4). These 
cells were cultivated in complex RPMI-media (II.1.2.3) at 37 °C in a 5 % (v/v) CO2 
atmosphere. 
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II.1.6.3 Agrobacteria strain 
Agrobacterium tumefaciens GV3101 [pMP90RK GmR KmR RifR; KONCZ and SCHELL 
1986] was used for Agrobacterium-mediated DNA delivery into the plant cell genome. 
II.1.6.4 Plants and plant cells 
Tobacco plants of the variety Nicotiana tabacum L. cv. Petit Havana resp. Nicotiana tabacum 
L. cv. Petit Havana SR1 were used for transient expression (I.2.3) and tobacco suspension 
cultures of the variety Nicotiana tabacum L. cv. Bright Yellow (BY-2; KATO et al. 1972) 
were used for expression of the human anti-HIV antibody 2F5 and 2G12 (II.2.5).  
II.1.7 Vectors 
II.1.7.1 pMT-M12 
pMT-M12 (M. Tur, Fraunhofer IME, Germany) is a bacterial expression vector, derived from 
pBM1.1 (MATTHEY et al. 1999) containing an N-terminal his10-tag and a recognition site 
for an enterokinase to remove the his-tag was introduced.  
For expression in E.coli (I.2.1) the cd64 gene (II.2.5) was cloned into this vector.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Fig.II-1: Vector map of pMT-cd64. pelB = signal peptide for transport into periplasma; his10/c-myc = 
sequence for detection and purification of the recombinant protein; cd64 = DNA sequence of extracellular 
domain of CD64; F1 ori = origin of replication for the production of single stranded DNA from M13 phage; Kan 
R = gene for kanamycin resistance; ori pBR 322 = origin of replication; lacI = Lac-repressor; T7-Promoter = 
IPTG inducable. 
 
NcoI HindIII  BlpI SfiI 
ATG pelB stop Enterokinase consensus site 
pMT-cd64 
6169 bp 
F1 ori
lacI 
Kan R 
ori pBR 322 
T7 
c-myc 
cd64  
His10 
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II.1.7.2 pMS-ILAng 
pMS-ILAng (M. Stöcker, Fraunhofer IME, Germany) is a mammalian expression vector, 
derived from pSecTag2 (Invitrogen) that contains an Internal Ribosomal Entry Site (IRES) in 
combination with a reporter gene for enhanced Green Fluorescent Protein (eGFP; 
STOCKER et al. 2003). The cytomegalovirus (CMV)-promoter enables constitutive 
expression of the recombinant protein which is secreted into the culture supernatant due to an 
Ig kappa leader sequence. 
This vector was used for expression of rsCD64 (II.2.5) in HEK 293T cells (II.2.4).  
 
   
   
   
   
 
  
 
 
 
 
 
 
 
 
Fig.II-2: Vector map of pMS-cd64. Igκ-leader = murin signal leader sequence for secretion of protein 
into culture supernatant; cd64 = DNA sequence of extracellular domain of CD64; his6/c-myc = sequence for 
detection and purification of the recombinant protein; IVS = synthetic intron for stabilization of mRNA; IRES = 
internal ribosomal entry site; pCMV = cytomegalovirus (CMV)-promoter (constitutiv); eGFP = enhanced Green 
Fluorescent Protein; BGH = Bovine growth hormone polyadenylation signal and transcriptional termination; 
pSV40 = SV40-Promoter, SV40-origin of replication; ZeoR = gene of Zeocin®–resistance for selection of 
transfected cells; ColE1 = ori of replication in prokaryotes; Amp R = gene of ampicillin resistance for selection 
in E. coli; pCMV = constitutive promoter of cytomegalovirus (CMV). 
 
II.1.7.3 pTRAkc-AH 
pTRAkc-AH (Dr. T. Rademacher, BioVII, RWTH-Aachen) is an optimised plant expression 
vector, derived from pPAM (genbank: AY027531) containing a his6-tag for purification and 
detection downstream of the multiple cloning site (MCS). This binary plasmid contains the 
ColE1- and the RK2-origin which enables replication in E.coli and in A. tumefaciens; the vir-
region is separated from the T-DNA on the agrobacterium chromosome (HOEKEMA et al. 
1984; HELLENS et al. 2000). This vector contains the cauliflower mosaic virus (CaMV)-
NheI 
Ig-κ-
leader 
SfiI BlpI EcoRI
eGFP 
PmeI 
BGH 
Zeo R 
pMS-cd64 
7609 bp 
Amp R 
pCMV 
ColE1 
pSV40 
  
cd64 
c-myc    c-myc his6 
stop 
IVS/IRES
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35S-promoter of the vector pRT101 (TOPFER et al. 1988) with a duplicated 35S-enhancer-
region as well as the termination and polyadenylation sequence of CaMV. Two copies of 
scaffold attachment regions (SAR) of the tobacco gene RB7 were introduced to improve 
transcription. 
pTRA-ERH was used for transformation of A.tumefaciens (II.1.6.3) and translocation of the 
expression cassettes into the genome of N.tabacum. The vector was used for expression of 
rsCD64 (II.2.5) into the apoplast of tobacco leaves.  
   
   
   
   
 
 
 
 
 
 
 
 
  
 
 
 
Fig.II-3: Vector map of pTRA-cd64. LPH = codon-optimised murine signal peptide of mAB24; cd64 = 
DNA sequence of extracellular domain of CD64; his6/c-myc = sequence for detection and purification of the 
recombinant protein; 35SS/pA35S = 35S-promoter with doubled enhancer and terminator of the cauliflower 
mosaic virus (CaMV) 35S gene; SAR = scaffold attachment region of N. tabacum; RK2 ori = origin of 
replication for A. tumefaciens; bla = ampicillin resistance E.coli / carbenicillin resistance A.tumefaciens; ColE1 
ori = origin of replication for E.coli; LB und RB = right and left border of the nopalin-Ti-plasmid pTiT37; Pnos 
and pAnos = promoter and terminator of the nopaline synthase gene; nptII = coding sequences of neomycin 
phosphotransferase gene (kanamycin resistance). 
  
II.1.7.4 pTRAkc-ERH 
The pTRAkc-ERH is based on pTRAkc-AH containing an SEKDEL sequence for retention of 
the recombinant protein in the endoplasmatic reticulum (ER). This vector was used for 
expression of rsCD64 (II.2.5) into the ER of tobacco leaves. 
II.1.7.5 pTRAkt-rfp 
The pTRA-rfp vector is based on the pTRAkc-ERH containing additionally an expression 
cassette for DsRed (JACH et al. 2001) fused to a transit peptide (Dr. T. Rademacher, 
LB 
 LPH 
NcoI SacI 
RK2 ori 
pTRAk-cd64 
8516 bp 
bla 
SAR 
  
cd64 
c-myc     his6   
stop 
P35SS 
SAR 
ColE1 ori 
RB 
npt II 
pAnos 
pA35S 
Pnos 
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unpublished results) downstream the expression cassette of the recombinant proteins. This 
vector was used for the expression of the human anti-HIV antibodies 2F5 and 2G12 in BY-2 
cells (I.2.3).  
The cDNAs of the heavy and light-chains of the 2F5 and 2G12 antibody (BUCHACHER et 
al. 1994) were isolated each with their leader sequence out of the eucaryotic expression 
vectors p2F5IgG1and p2F5LC respectively (KUNERT et al. 2000). The sequence coding for 
a C-terminal ER retention signal (SEKDEL) was fused to the 3’ end of both cDNAs by PCR. 
Each seqence was subcloned into an expression cassette consisting of the double enhanced 
CaMV-35S promoter, the TEV 5’-untranslated region and the CaMV-35S transcriptional 
terminator. For co-expression of the heavy and light-chain both cassettes were inserted in 
tandem (head-to-tail) into pTRAk. The expression units were separated by SARs of the 
tobacco RB7 gene (GenBank: U67919).  
 
LB 
SP SP TP
RB npt II HC LC DsRed bla 
pAnos Pnos P TL pA P TL pA P TL pA RK2 ori ColE1 ori
SAR SAR SAR SAR 
 
Fig.II-4  Schematic view of the T-DNA of the plant expression vector pTRAk-2F5ER-Ds. LB and RB = left 
and right border of the T-DNA; Pnos and pAnos = promoter and terminator of the nopaline synthase gene; npt II 
= coding sequence of the neomycin phosphotransferase gene; SAR = scaffold attachment region; P and pA = 
35S-promoter with doubled enhancer and terminator of the cauliflower mosaic virus (CaMV) 35S gene; TL = 5’-
UTR of the tobacco etch virus (TEV); SP = signal peptide; HC and LC = coding sequence of heavy and light-
chain of the 2F5/2G12 antibody with ER retention signal; TP = transit peptide.  
 
II.1.8 Equipment and applications 
• Cameras: E.A.S.Y. 429K camera (Herolab). 
• Centrifuges: AvantiTM J-30, AllegraTM 6KR and MicrofugeR (Beckman), Biofuge 
Pico (Heraeus Instruments), Eppendorf-centrifuge 5415D (Eppendorf), Picofuge 
(Stratagene), Rotilabo centrifuge with Butterfly-Rotor (Roth), centrifuge tubes 
(Beckman), CARR Powerfuge® P6 (CARR Separations Inc.). 
• Chromatography equipment: Ni2+-NTA Agarose (Qiagen), Protein-A Ceramic 
HYPERD F BioSepra (Ciphergen Biosystems), IgG-sepharose (Amersham 
Biosciences), XK26/20 column (Amersham Pharmacia), UFP-500-K-4X2TCA 
Hollow Fiber unit (500cut-off, 400cm2, Amersham Pharmacia). 
• DNA-sequencing machine: ABI Prism 3700 Capillary-Sequencer (Perkin-Elmer). 
• Easypure UV/UF Watersystem (Werner GmbH). 
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• Electroblotting equipment: Mini Protean III gel chamber (BioRad), XCell II Blot 
Module (Invitrogen), Protein Gel-Apparatus and supplies. 
• Electroporation apparatus: Gene Pulser, Pulse Controller Unit (BioRad) and 0.2 cm 
cuvettes (BioRad). 
• FACSCalibur (Becton Dickinson Bioscience). 
• Gel electrophoresis equipment: Mini PROTEAN IITM, Gel Air Dryer (BioRad). 
• Incubators: InnovaTM 4340 incubator shaker (News Brunswick Scientific), 37°C 
Inkubator (Heraeus Instruments), Incubator (Heraeus Instruments). 
• Laminar-Flow: Hera Safe HS12 (Kendro). 
• Microscope: DM R Fluorescence Microscope (Leica), Leica KL 1500 LCD lamp with 
glass fiber optics (Leitz, Wetzlar) with green excitation (BP: 545/30) and color foil No 
182 light red (colorfilter Lee). 
• PCR-Thermocycler: Primus 96 Plus (MWG-Biotech), Programmable Thermal 
Controller PTC-200™ (MJ Research Inc, Watertown, USA). 
• Photometers: Biophotometer (Eppendorf), Multichannel Photometer (SpektraMax 
340, Molecular Devices). 
• Probe Sonicator: UW2070 (Bandelin electronic, Berlin), Microtip Titan MS72, 
Microtip Titan MS73, Microfluidizer M110-L (Microfluidics Corporation, Newton, 
MA). 
• Pumps: Vacuumpump Trivac S4A (Leybold-Heraeus, Osterode), peristaltic pump 
(MBR Bio Reactor AG, Member of the Sulzer Group). 
• Software: Chromas 1.45 (C. McCarthy, Southport, Australia); Origin 5.0 (Microcal 
Software, Inc.); Clone Manager 5 (Sci-Ed Central), GCG (Wisconsin Package Tenetic 
Computer Group), clustalX 1.8 (NCBI), TreeView (Win32) 1.6.5 (Roderic D.M. Page, 
2001), BioXpert 3.0 (Applikon). 
• Surface plasmon resonance: BIACORE® 2000 (BIACORE®, Uppsala, Sweden) with 
software (BIAControl 1.3 and BIAEvaluation 3.0). 
• Vacuum exsiccator (Glaswerk Wertheim). 
• Vortex-Genie 2 (Scientific Industries Inc., Bohemia, USA). 
• Warring Blender (VWR). 
• 3- and 7-litre autoclavable glass bioreactor (BioBundle), 7-litre Steam In Place (SIP) 
stainless steel benchtop bioreactor (Typ BioBench7) and 140-litre bioreactor (Pilot 
System 140l), Bio Controller ADI 1030/1060, Bio Console 1035, Bio Bench ADI 
1065, Control Console Interface 1040/21 (Applikon). 
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II.1.9 Approbation for the conducted work 
The approbation for the conducted work at security level S1 was given by the 
“Landesumweltamt NRW”, number of registration: 64-K-1.19/02. 
II.2 Methods 
II.2.1 Recombinant DNA technologies 
General recombinant DNA techniques including DNA precipitation, restriction enzyme 
digest, DNA ligation and DNA agarose gel electrophoresis were performed according to the 
standard protocols described by Sambrook et al., (SAMBROOK and FRITSCH 1996) or 
according to the manufacturer’s protocol when using a kit. 
II.2.1.1 Isolation of plasmid-DNA from E.coli 
Plasmid DNA was purified using QIAprep® Plasmid Isolation Mini Kit (II.1.3) according to 
the manufacturers’ manual. Quality and quantity of DNA was confirmed by spectro-
photometric analysis (II.2.1.8) or analytical agarose gel electrophoresis (II.2.1.4). Isolated 
DNA samples were stored at –20 °C. 
II.2.1.2 Polymerase-Chain-Reaction  
Polymerase chain reaction (PCR), a procedure for rapid in vitro enzymatic amplification of a 
specific segment of DNA, was used for the amplification of genes of interest (SAIKI and 
GELFAND 1988) as well as for the insertion of restriction sites or short nucleotide sequences 
like purification-tags. The reactions were performed in 0.2 ml PCR tubes (Biozym), using a 
PCR thermocycler (MWG Biotech or MJ Research Inc.). PCR reactions were carried out in a 
total volume of 25 μl as described in the following table: 
Components Volume Final concentration 
Template DNA 0.5-1 μl 1-10 ng 
10x PCR buffer 2.5 μl 1x 
2.5 M Betain 2.5μl 250 mM 
10 mM dNTP mixture 1 μl 0.4 mM each 
100 pmol/μl forward primer 1 μl 10 pmol/μl 
100 pmol/μl backward primer 1 μl 10 pmol/μl 
Taq DNA Polymerase (5 U/μl) 0.25 μl 1.25 units 
Destilled water added to 25 μl  
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Amplifications were carried out as follows: 
 
 95 °C 5 min initial denaturation 
 95 °C 30 sec denaturation 
             25x TP or gradient 30 sec primer annealing 
 72 °C 1 min/1 kb elongation 
 72 °C 7 min final elongation 
 
The optimal annealing temperature (TP) of the primer was experimentally optimised 
(temperature gradient) or calculated by the empirical formula (WU and UGOZZOLI 1991) 
                                                  TP = {22 + 1.046 [2•(G + C) + (A + T)]} 
PCR products were resolved on a 1-1.2 % (w/v) agarose gel (II.2.1.4) with appropriate DNA 
markers to confirm the successful amplification and integrity of the amplified product. 
II.2.1.3 PCR based analysis of recombinant bacterial clones 
Bacterial clones harbouring plasmid DNA containing the gene of interest were identified by 
PCR as described by Jesnowski et al. (1995). Single colonies were picked with sterile 
toothpicks and the bacteria loaden toothpicks were dipped into a PCR tube containing 10 μl 
sterile water. 15 μl of the PCR mix (II.2.1.2, 250 mM DMSO instead of Betain) were added to 
each 10 μl bacterial suspension giving a final volume of 25 μl. Specific primers annealing to 
the vector backbone were used for PCR reaction (II.1.5). Thermocycler conditions were used 
as described in II.2.1.2 but for effective lysis of the bacterial cells the time for initial 
denaturation was increased to 10 min for E.coli. For Agrobacteria 5 min were kept. Ten μl of 
the PCR product were analyzed on a 1.2 % (w/v) agarose gel (II.2.1.4). 
II.2.1.4 Total RNA extraction from whole blood 
For extraction of total RNA the PreAnalytiX Kit (Qiagen) was used according to the 
manufacturers’ protocol after blood collection with the PAXgeneTM Blood RNA System 
(Becton Dickinson). Briefly, 2x 2.5 ml blood were taken with the BD Safety-LokTM Blood 
Collection Set. The tubes were gently inverted 10 times and stored at room temperature (RT) 
overnight (o/n). 
In the first isolation step nucleic acids were pelleted (10 min/ 4000 g/ 4 °C). The pellet was 
washed with 360 µl RNase free water (BR1), resuspended and incubated in 300 µl optimised 
buffer (BR2) with 40 µl Protein-K for 10 min at 55 °C. In an additional centrifugation step 
(3 min/ 16,000 g/ RT) residual cell debris were removed and the supernatant was transferred 
to a fresh 1.5 ml microcentrifuge tube. Ethanol (350 µl) was added to adjust binding 
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conditions and 700 µl lysate was applied to a PAXgene RNA spin column. After a brief 
centrifugation (1 min/ 7500 g/ RT), RNA was selectively bound to the silica-gel-membrane 
while contaminants passed through. Remaining contaminants were removed in three washing 
steps (700 µl buffer BR3, 2x 500 µl BR4) and RNA was then eluted in 40 µl Buffer BR5. 
Concentration of RNA was determined photometrically (II.2.1.8). 
II.2.1.5 Specific RT-PCR for cDNA synthesis 
First-strand cDNA was synthesized using the One-Step RT-PCR Kit (Qiagen) and gene 
specific primers (cd64, II.1.5) according to the manufacturers’ protocol. Qiagen OneStep RT-
PCR enables efficient reverse transcription and specific amplification in one step. RT-PCR 
reactions were carried out in a total volume of 50 μl as described in the following table: 
Components Volume Final concentration 
Template DNA x μl <1 µg 
5x Qiagen RT-PCR buffer 10 μl 1 x 
10 mM dNTP mixture 2 μl 0.4 mM each 
100 pmol/μl cd64-(L)-5’ 3 μl 10 pmol/μl 
100 pmol/μl cd64-(c-myc)-3’rc 3 μl 10 pmol/μl 
Qiagen One Step Enzyme Mix 2 μl  
Rnase inhibitor 0.25 µl 5 U 
Destilled water added to 50 μl  
 
Amplification was carried out under the following conditions: 
 50 °C 30 min reverse transcription 
 95 °C 15 min inital PCR activation 
 95 °C 60 sec denaturation 
             25x 66 °C 60 sec primer annealing 
 72 °C 90 sec elongation 
 72 °C 10 min final elongation 
 
PCR products were resolved on a 1-1.2 % (w/v) agarose gel (II.2.1.4) with appropriate DNA 
markers to confirm the successful amplification and integrity of the amplified product. 
II.2.1.6 DNA sequencing and sequencing analysis 
DNA sequencing reactions were based on the Dideoxy-chain-termination-method depicted by 
Sanger et al. (1977). Fluorescent labelled dideoxynucleotides were used for sequencing of 
genes or DNA fragments of interest. Sequencing analysis was performed by using an “ABI 
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Prism 3700” Capillary-Sequencer (Applied Biosystems) and BigDyeTM cycle sequencing 
terminator chemistry. The extension products were detected by exciting the unique dyes 
attached to each dideoxynucleotide with a laser, followed by a measurement of fluorescent 
emission using a CCD camera.  
pMT-5’ and pMT-3’ primers (II.1.5) were used for sequencing the cd64 gene cloned in the 
pMT vector. pMS-5’ and pMS-3’ primers (II.1.5) were used for sequencing of cd64 in the 
pMS vector.  
Subsequently, the signals were interpreted by the Applied Biosystems Sequencing Analysis 
Program in order to determine the nucleotide sequence of the DNA template. Chromas 
software package (II.1.8) was used for displaying the chromatogram files. For evaluation of 
sequence data the sequences were exported to the GCG software packages. 
II.2.1.7 Agarose gel electrophoresis 
Undigested DNA (II.2.1.1), restriction enzyme digested DNA (II.2.1.9) and PCR fragments 
(II.2.1.2) were electrophoretically separated on 0.8-1.2 % (w/v) analytical agarose gels 
prepared in TBE or TAE buffer (II.1.2.1) containing 0.1 μg/ml ethidium bromide. 
Known amount of DNA molecular marker such as PstI-digested lambda DNA (MBI 
Fermentas) or 1 kb Marker (Invitrogen) were used for evaluation of sample size, integrity and 
determination of DNA concentration. The DNA was visualised on an UV transilluminator at 
302 nm and documented by a black and white E.A.S.Y 429K camera (Herolab). 
Preparative gels were used for isolation of PCR amplified DNA (II.2.1.2) or DNA fragments 
after restriction enzyme digestion (II.2.1.9) prior to cloning in the appropriate vectors. After 
electrophoresis the desired DNA fragments were excised from the gel and purified using the 
“QIAquick Gel Extraction Kit” (Qiagen; II.1.3) according to the manufacturers’ protocol. The 
concentration of the recovered DNA was measured photometrically (II.2.1.8) or determined 
by analytical agarose gel electrophoresis. 
II.2.1.8 Quantification of nucleic acids 
The amount of RNA or DNA in a sample was estimated by measuring the OD260nm. The 
OD260nm of 1 corresponds to ~50 μg/ml of dsDNA or to ~40 μg/ml of ssDNA and RNA. 
Purity of the nucleic acid was ascertained by the OD260nm/OD280nm ratio of the measured 
optical density, which is 1.8 for pure DNA and 2.0 for pure RNA. 
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II.2.1.9 Restriction digest of DNA 
Restriction endonucleases, appropriate buffers and BSA solution were obtained from NEB 
(Schwalbach). Restriction digest and double restriction digest of DNA were performed 
according to the manufacturers’ protocol.  
II.2.1.10 Dephosporylation 
Dephosphorylation of restricted vector-DNA was done with CIP (Calf Intestine Phosphatase, 
NEB) according to the manufacturers’ protocol. 
II.2.1.11 Klenow Fill-in 
For the Fill-in of single-stranded DNA 5’-fragments, the Klenow Fragment of DNA-
polymerase I of E.coli was used (JOYCE and GRINDLEY 1983). The Klenow-Fill-in 
reaction was carried out according to the manufacturers’ protocol. 
II.2.1.12 Ligation of DNA 
Restriction enzyme digested DNA (II.2.1.9) was ligated using 80 U T4 DNA-Ligase or 1 µl 
Quick T4 DNA-Ligase (NEB) in buffer systems recommended in the manufacturers’ protocol 
in a final volume of 20 µl. Sticky-end ligations were carried out at 22 °C for 30 min whereas 
blunt ligations were incubated at 4 °C (o/n). Ligation product was used for transformation of 
E.coli (I.2.1) or A.tumefaciens (II.2.3.2).  
II.2.2 Bacterial expression system (E.coli) 
II.2.2.1 Heat-shock competent E.coli 
E.coli cells for CaCl2-mediated heatshock transformation were prepared as described 
(HANAHAN 1983). Briefly, 5 ml of LB broth were inoculated with a single bacterial colony 
and cultured at 37 °C o/n. 500 μl of the o/n culture was transferred into 50 ml LB broth 
containing 20 mM MgSO4 and 10 mM KCl. Cells were cultured at 37 °C for 3-4 h until the 
OD600nm reached 0.5 and then transferred to an ice-cold tube. After cooling on ice for 10 min, 
the cells were recovered by centrifugation (10 min/ 2000 g/ 4 °C). The pellet was gently 
resuspended in 15 ml ice-cold TfB-I solution (II.1.2.2) and stored on ice for 10 min. The cells 
were sedimented down by centrifugation as described above and resuspended in 2 ml ice-cold 
TfB-II (II.1.2.2). Aliquots of 100 µl suspension were dispensed into prechilled 1.5 ml 
Eppendorf tubes, frozen immediately in liquid nitrogen and stored at –80 °C. 
II.2.2.2 Heat-shock transformation of E.coli 
The ‘competent’ cells (II.2.2.1) were thawed on ice and ice-cold plasmid DNA (~80 ng) or 
ligation product (II.2.1.10) were mixed gently with the competent cells and placed on ice for 
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30 min. A heatshock of 42 °C was given for 90 sec and the sample was cooled on ice for 
10 min. Pre-heated (37 °C, 900 µl) 2xTB media (II.1.2.2) supplemented with 2 % (w/v) 
glucose were added to the sample and cells were incubated for regeneration at 37 °C for 
30 min. Different samples (10 μl and 100 μl) were plated onto LB or 2xTY agar plates 
supplemented with appropriate antibiotics and incubated at 37 °C o/n. 
II.2.2.3 Cultivation of E.coli and long-term storage 
E. coli XL1-Blue bacterial cells (II.1.6.1) were grown at 37 °C o/n either in liquid LB medium 
in a shaker incubator or plated on solidified LB-agar (1.5 % (w/v) agar w/v) plates. E. coli 
BL21(DE3) were grown in 2xTY or 2xTB medium under the same conditions. The media 
was supplemented with appropriate antibiotics [25 µg/ml kanamycin (pMT) or 100 µg/ml 
ampicillin (pMS)] and 1 % (w/v) glucose for the growth of bacteria. The plates were stored at 
4 °C no more than two weeks. For long-term storage of bacterial strains, glycerol was added 
to a final concentration of 15 % (v/v) to the liquid culture and cells were frozen at –80 °C. 
II.2.2.4 Expression of rsCD64 in E.coli 
rsCD64 (I.1.2.2) was expressed in E.coli and purified according to a modified protocol based 
on Bruell (BRUELL 2004). 
Briefly, a freshly transformed single colony of E. coli strain BL21(λDE3; Novagen) was 
inoculated in 5 ml of LB medium supplemented with 1 % (w/v) glucose and 25 µg/ml 
kanamycin (pMT; LB-Km25-Glu1%), and cells were cultivated o/n at 37 °C with vigorous 
shaking (225 rpm). The following day fresh LB-Km25-Glu1% media was inoculated 1:100 with 
o/n culture and grown (30 °C/ 225 rpm) to an OD600nm of 0.6-0.8. After sedimentation of 
bacteria (15 min/ 5000 g/ 4 °C) the pellet was resuspended in the same volume of LB-Km25-
media and incubated (30 min/ 225 rpm/ 37 °C). Expression of recombinant proteins was then 
induced by addition of IPTG to a final concentration of 1 mM. Cells were cultured for 6 h at 
28 °C. The cells were harvested by centrifugation (10 min/ 5000 g/ 4 °C) and the supernatant 
was discarded. The pellet was stored at -20 °C or was immediately resuspended in ice-cold 
PBS (II.1.2.1) supplemented with 1 M NaCl (extraction buffer) and sonicated on ice 3 times 
for 60 sec (50 %, power 9; Bandelin). Cell debris and insoluble components were removed by 
centrifugation (30 min/ 15000 g/ 4 °C). The supernatant (periplasmic fraction) and the filtered 
culture supernatant were subjected to further analysis. 
Expression under osmotic stress and with compatible solutes was performed as described in 
Barth et al. (BARTH et al. 2000). 
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II.2.3 Plant expression system (Nicotiana tabacum) 
To establish transgenic N.tabacum (II.1.6.4) plant cells Agrobacterium-mediated gene transfer 
was performed (II.1.6.3; KAPILA et al. 1996). 
II.2.3.1 Competent Agrobacterium cells 
A single colony of Agrobacterium tumefaciens strain GV3101 grown on YEB-agar plate 
(II.1.2.4) containing 100 µg/ml rifampicin (Rif) and 25 µg/ml kanamycin (Km; YEB-Rif100-
Km25) was inoculated in 5 ml of YEB-Rif100-Km25 medium (II.1.2.4) in a 100 ml Erlenmeyer 
flask and incubated at 28 °C for 48 h with shaking (250 rpm). 100 ml of YEB-Rif100-Km25 
medium were inoculated 1:100 and cultivated at 28 °C for 15-20 h with shaking (250 rpm) 
until the OD600nm reached 1-1.5. The cells were chilled on ice for 15 min and spun down by 
centrifugation (5 min/ 4000 g/ 4 °C). The culture medium was decanted and the cells were 
washed three times with 10 ml of dH2O by centrifugation and resuspended in 500 µl of sterile 
10 % (v/v) glycerol. Aliquots of 45 µl suspension were dispensed into prechilled 
microcentrifugation tubes, frozen immediately in liquid nitrogen and stored at -80 °C. 
II.2.3.2 Transformation of Agrobacterium cells 
Plasmid DNA (0.2-1.0 µg; II.2.1.1) in sterile dH2O was added to a thawed aliquot of 
electrocompetent Agrobacterium cells (II.2.3.1) and incubated on ice for 10 min. The 
cell/DNA mixture was transferred into a prechilled electroporation cuvette (0.2 cm) and 
assembled into a safety chamber. After application of the pulse (25 µF/ 2.5 kV/ 200 Ω), the 
cells were diluted in 1 ml of YEB medium and incubated (1 h/ 250 rpm/ 28 °C). Finally,       
1-5 µl cells were plated on YEB-Rif25-Km25-Carb50 agar (II.1.2.4) and incubated (48-
72 h/ 28 °C).  
II.2.3.3 Cultivation of A.tumefaciens and long-term storage 
Single colonies of A. tumefaciens were examined for the presence of plasmids by control PCR 
(II.2.1.3). Positive colonies were inoculated in 10 ml of YEB-Rif25-Km25-Carb50 medium and 
cultivated (48-72 h/ 250 rpm/ 28 °C). The culture was transferred to Falcon tubes and 
Agrobacteria cells were pelleted by centrifugation (10 min/ 4000 g/ 15 °C). The cells were 
resuspended in a 1:1 volume of YEB-Rif25-Km25-Carb50 medium and glycerol stock media 
(II.1.2.4). The suspension was aliquoted (100 µl) and stored at –80 °C for further experiments. 
II.2.3.4 Transient expression of rsCD64 
Growth of recombinant Agrobacteria (II.2.3.3) and vacuum infiltration of tobacco leaves was 
performed as described by Kapila et al. (1996) and Vaquero et al. (1999). Expression levels 
of rsCD64 (I.1.2.2) were evaluated in transiently expressing N.tabacum leaves. 
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Briefly, 100 ml of YEB-Rif25-Km25-Carb50 medium was inoculated with 100 µl of glycerol 
stock of the selected recombinant Agrobacteria. Agrobacteria culture for vacuum infiltration 
was grown at 28 °C o/n with shaking at 250 rpm after 24 h. The cells were pelleted by 
centrifugation (10 min/ 5000 g/ 15 °C), transferred into 250 ml of induction medium (II.1.2.4) 
and cultivated at 28 °C o/n with shaking at 250 rpm. Agrobacteria cells were centrifuged 
(15 min/ 4000 g/ 15-25 °C) and resuspended in 50 ml of MMA solution (II.1.2.4) and kept at 
RT for 2 h. The OD600nm was measured after 1:10 dilution and the cell suspension was 
adjusted to an OD600nm of 1. Diluted cell suspension (100 ml) was used for vacuum infiltration 
of plant leaves. Young N.tabacum cv. Petite Havana SR1 leaves (3 leaves for each construct) 
were placed in 100 ml of Agrobacteria suspension in a preserving glass and a continuous 
vacuum (60-80 mbar) was applied for 15-20 min. The applied vacuum was released rapidly, 
the leaves were briefly rinsed in tap water and kept on wet Whatman paper no.1 with adaxial 
side upwards. The plastic tray was sealed with saran wrap and placed at 22 °C with a 16 h 
photoperiod for 60 h. Leaves were weighed and stored at -80 °C till analysis.  
For the extraction of transiently expressed proteins in vacuum infiltrated tobacco leaves, 
leaves were mixed with the extraction buffer (II.1.2.4) and homogenised using a motor driven 
stainless steel pistill or a Waring blender (VWR) for larger amounts of plant material. Total 
soluble protein was extracted using 2 volume of extraction buffer per gram leaf material. Cell 
debris were removed by two rounds of centrifugation (30 min/ 16000 g/ 4 °C) and the 
supernatant used for further analysis. 
II.2.3.5 Expression of BY-22F5 and BY-22G12 in transgenic BY-2 cells 
Transgenic BY-2 cells were used for expression of human full-size antibody BY-22F5 and     
BY-22G12 (I.1.1.3). Briefly, a 3-ml aliquot of 3 d-old Nicotiana tabacum L.cv. bright yellow 2 
(BY-2) cells in BY-2 media with 200 µM acetosyringone (II.1.2.4) was inoculated with a 
recombinant Agrobacteria containing the antibody genes of interest to a final OD600 of 0.05 
and incubated for 3 days at 26 °C (AN 1995). Selection of kanamycin-resistant transformants 
was performed on solid BY-2 agar medium supplemented with 100 mg/l kanamycin and 
200 mg/l claforan (cefatoxim) at 26 °C for 4-6 weeks in the dark. Kanamycin-resistant calli 
appeared after 3-4 weeks of incubation and were screened for DsRed fluorescence (II.2.7.7) 
and transferred to plates with 0.8 % (w/v) Agar in BY-2 medium (II.1.2.4). After 3 weeks the 
expanded calli were screened for accumulation of recombinant protein. Expression levels of 
protein extracts were quantitified by SPR (II.2.7.6) and 4 lines were used to establish 
suspension cultures by subculturing the transformed callus in liquid BY-2 medium. The 
suspension cell lines were tested for accumulation of recombinant protein via Dotblot 
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(II.2.7.3) and the line with the highest antibody accumulation in suspension was used for scale 
up production. These genetically modified cells were cultivated in 500 ml Erlenmeyer flasks 
(working solution 300 ml/ 26 °C/ 180 rpm) and subcultured weekly with a 5 % (v/v) inoculum 
of a 7-day-old cell culture.  
Calli were maintained on solid medium (plus 0.8 % (w/v) agar) in the dark at 26 °C and 
transferred as necessary. Long-term storage methods in liquid nitrogen are currently under 
investigation (K. Schmale, BioVII, RWTH-Aachen).  
In order to achieve higher production volumes or product concentrations expressions on the 2-
L, 5-L and 100-L bioreactor scale were carried out (II.2.6).  
Extraction of soluble protein from BY-2 cells was performed essentially as described 
(FISCHER(A) et al. 1998). Briefly, cells were separated from the culture medium by 
paper/vacuum-filtration and stored at -20 °C. The frozen cells were thawed and resuspended 
in 2 volumes extraction buffer (II.1.2.4) and cells were disrupted in a Microfluidizer M110-L 
(Microfluidics Corporation). Insoluble material was removed by centrifugation 
(30 min/ 4000 g/ 4 °C) and the supernatant was adjusted to pH 8, stirred for 2 h at 4 °C and 
centrifuged (30 min/ 30000 g/ 4 °C). The clear supernatant was passed through a paper filter 
and applied to a Protein-A column (II.2.5.2). 
II.2.4 Mammalian expression system (HEK 293T) 
II.2.4.1 Transfection of HEK 293T cells 
Transfected HEK 293T cells were used to evaluate expression levels of the human rsCD64 
(I.1.2.2). 
Transfection of eucaryotic cells was carried out using the synthetic kationic lipid reagent 
TransFast® (Promega) according to the manufacturers’ protocol. The production cell line 
HEK 293T (II.1.6.2) contains the large-T-antigen of the SV40 virus which allows episomal 
replication of the introduced plasmids due to the early SV40-ori leading to high plasmid copy 
numbers over prolonged time periods. 
Briefly, 1x105 cells were seeded in 1 ml RPMI-(C)-media (II.1.2.3) into a 12-well plate and 
incubated o/n at 37 °C and 5 % (v/v) CO2. The following day 1 µg plasmid DNA (II.1.7.2) 
was mixed with 300 µl RPMI-media and 3 µl TransFast® and incubated for 15 min at RT. The 
supernatant in the 12-well-plate was replaced with the 300 µl transfection mix and cells were 
incubated for 1 h at 37 °C and 5 % (v/v) CO2, then 1 ml RPMI-(C)-media was added into each 
well.  
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Efficiency of transfections was controlled by eGFP fluorescence after 2-3 days and 
successfully transfected cells were transferred into cell culture flasks (75 cm2) and cultivated 
under selection pressure (100 µg/ml Zeocin).  
II.2.4.2 Cultivation and long-term storage of transfected HEK 293Tcells 
Selection and proliferation of transfected cells was controlled every 2-3 days with the 
fluorescence microscope. Recombinant protein was constitutively secreted into the media. 
Accumulation levels were tested by Westernblot (II.2.7.2) and medium was changed every 2-
3 days. Cells were subcultured as soon as a complete monolayer was formed in the cell 
culture flask. For Scale-up of production multi-bottom cell culture flasks were used 
(Labomedic) and cells were transferred to serum-free suspension media (CD 293, Invitrogen). 
Supernatant containing recombinant protein was collected, stored at 4 °C and used for further 
analysis by ELISA (II.2.7.4), Westernblot (II.2.7.2) and SPR (II.2.7.6). 
For long-term storage 1x106 cells were centrifuged and resuspended in RPMI supplemented 
with 20 % (v/v) FCS and 5 %(v/v) DMSO. Cells were frozen in a styrofoam box at -20 °C for 
24 h and were then transferred to liquid nitrogen. 
II.2.5 Purification of recombinant proteins 
Recombinant proteins were expressed in E.coli (I.2.1), HEK 293T cells (II.2.4), N.tabacum 
leaves and BY-2 suspension cells, respectively (I.2.3). Expressions were scaled up using 
larger Erlenmeyer flasks (250 ml, 500 ml, 1-L) and multi-bottom cell culture flasks (175 cm2) 
respectively on laboratory scale. In addition, feasibility studies were carried out in 5-L, 7-L 
and 100-L bioreactors (II.2.6). 
Due to different leader peptides recombinant proteins can be directly secreted into the culture 
broth (E.coli; II.2.2, HEK 293T; II.1.7.2). Alternatively, protein is accumulated in specific 
cell compartments (periplasm for E.coli II.1.7.1, ER for BY-2 II.1.7.3). In the later case, cells 
have to be disrupted in order to extract all soluble protein (I.2.1, I.2.3, II.2.3.5). 
Recombinantly expressed rsCD64 containing a his-tag (II.1.7.1; II.1.7.2) was purified using 
the Ni2+NTA matrix (II.2.5.1) which specifically binds to histidine. 
Some proteins can be purified with specific agents binding to parts of the protein. 
Recombinantly expressed BY-22F5 antibody (I.1.1.3) was purified with Protein-A (II.2.5.2) 
which binds to the Fc-part of most antibodies.  
II.2.5.1 Purification via Ni2+NTA 
Immobilized-metal affinity chromatography (IMAC) was first used to purify proteins 
(PORATH et al. 1975) using the chelating ligand iminodiacetic acid (IDA) in 1975. IDA is 
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charged with metal ions (Zn2+, Cu2+, Ni2+), but has only 3 metal-chelating sites and therefore 
cannot tightly bind metal ions. In contrast, nitrilotriacetic acid (NTA) is a tetradentate 
chelating absorbent (JANKNECHT et al. 1991) and occupies four of the six ligand binding 
sites, leaving two sites free for interaction with the his-tag. Ni2+NTA agarose has a binding 
capacity of approximately 5-10 mg of his-tagged protein per millilitre of resin. 
Due to different amounts of contaminating proteins in the supernatant of sonicated E.coli 
(I.2.1) or homogenised N.tabacum leaves (I.2.3) compared to the supernatant of HEK 293T 
cells (II.2.4.2), different purification procedures were established. 
His-tagged recombinant proteins from E.coli and N.tabacum leaves were purified using 
Ni2+NTA affinity chromatography under denaturing conditions according to “The 
Expressionist 07/97” (Qiagen). The clarified supernatant (II.2.2.4) was desalted on PD10 
columns (Amersham Pharmacia), loaded onto Ni2+NTA columns (gravity-flow-type, BioRad) 
pre-equilibrated with extraction buffer (II.1.2.1), and passed through the column. After two 
washing steps with 2 x bed-volume of washing buffer, the bound protein was eluted with 1x 
bed-volume of elution buffer and protein concentration was determined by Bradford 
(II.2.7.1). The protein-containing fractions were pooled, imidazole was removed by passing 
the protein-sample through a PD10-column and purified samples were stored at 4 °C until 
further analysis.  
 
Washing Buffer     Elution Buffer 
PBS (pH 7.4)      PBS (pH 7.4) 
NaCl   1 M    NaCl   1 M 
Imidazole  10 mM – 40 mM  Imidazole  250 mM 
 
His-tagged proteins in cell culture supernatant (HEK 293T cells) were purified according to a 
slightly different protocol. Cell culture supernatant was centrifuged (3 min/ 3000 g/ RT) to 
remove all cells and the clear supernatant was mixed with 3 volumes of 4x incubation buffer. 
The Ni2+NTA column was pre-equilibrated with 1x incubation buffer and the supernatant was 
loaded onto the matrix with 1 ml/min with a peristaltic pump. After two washing steps with 
2x column-volume of 1x incubation buffer, the bound protein was eluted with 1x column-
volume of elution buffer and protein concentration was determined by Bradford (II.2.7.1). 
The protein-containing fractions were pooled, imidazole was removed by passing the sample 
through a PD10-column and the purified protein was stored at 4 °C until further analysis by 
SPR  (II.2.7.6), Westernblot (II.2.7.2) and ELISA (II.2.7.4).  
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4x Incubation Buffer    Elution Buffer (pH 8.0) 
NaH2PO4   200 mM   NaH2PO4   50 mM 
NaCl    1.2 M   NaCl    300 mM 
Imidazole   40 mM  Imidazole   250 mM 
 
II.2.5.2 Purification via Protein-A 
Protein-A, a 43 kDa cell wall protein produced by the bacteria Staphylococcus aureus 
contains four binding sites for the Fc regions of IgG located in the interface between the CH2 
and CH3 domains (WINES et al. 2000) and is commonly used for antibody purification. 
Protein-A was isolated and purified first by Sjoquist in 1972 (SJOQUIST et al. 1972).  
For the purification of BY-22F5 antibody BioSEPRA Protein-A Ceramic HYPERD F 
(Ciphergen) with a binding capacity of 25 mg human IgG per millilitre Protein-A matrix was 
used (II.2.3.5).  
The clear supernatant of homogenised BY-2 culture (II.2.3.5) was applied onto a Protein-A 
column (gravity-flow-type, BioRad) using a flowrate of 1 ml•min-1•ml-1 (matrix). Non-
specifically bound material was removed by extensive washing with PBS containing 5 mM 
EDTA and full-size antibody was eluted with 100 mM glycine (pH 2) containing 10 % (w/v) 
maltose. Elution fractions were immediately adjusted to pH 4.5 with 1 M unbuffered sodium 
acetate. 
Several elutions were tested for reactivity of the binding the peptide ARP 7073 by SPR  
analysis (II.2.7.6). Fractions containing functional protein were pooled and dialysed 
extensively against degased 10 mM sodium acetate (pH 4.5) with 10 % (w/v) Maltose and 
1 mM EDTA. The preparation was centrifuged at 30,000 g to remove residual insoluble 
material and used for further characterisation by ELISA (II.2.7.4), Westernblot (II.2.7.2) and 
EMSA (II.2.7.5). 
II.2.6 Large-scale protein production in 7-L and 140-L bioreactors 
To scale-up the expression of human anti-HIV antibody in BY-2 cells, feasibility studies were 
carried out in 7- and 140-litre stirred tank reactors with a height-to-tank diameter ratio of 2:1 
(Applikon; II.1.8).  
Set points and control circuits for the regulation of pH, temperature, amount of dissolved 
oxygen, foam and stirrer speed were adjusted by the Applikon ADI Bio Control Units 
(1030/1060; 1040/21). The control units are connected to a computer for data logging and 
supervisory control using the BioXpert software (II.1.8). Equipment required to operate the 
bioreactor system is situated in the ADI Bio Console 1035/ Bio Bench 1065. All bioreactors 
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are equipped with sensors for pH, dO2 and temperature at the top or lower sidewalls. Data 
were collected and reported to the computer in specific time intervalls. Except for the 140-L 
Pilot System, for plant-cell-fermentation bioreactors were equipped with one three-bladed 
Marine impeller stirrer (Ø = 60 mm) and baffles were removed to minimize shear stress. The 
medium was aerated by membrane filtered air through a sinter disc at the bottom of the 
bioreactor. The agitation for the 140-L Pilot System was provided by three six-bladed 
Rushton impellers (Ø = 20 cm) and fitted with a sparger tube for aeration from the bottom. 
pH electrodes were calibrated with pH 4.0 and pH 7.0 reference solutions and the working 
volume of BY-2 Media (II.1.2.4) was filled into the fermenter. This is typically 60 - 85 % of 
the fermenter total volume. The 7-L autoclavable glass reactor (Biobundle) was used with 5-L 
cell suspension media. The 7-L stainless steel bioreactor (Biobench 7) was filled with 4.5-L 
and the 140-L Pilot system with 110 L water to solve the solids of the BY-2 media 
components directly in the bioreactor. Glass bioreactors with media were autoclaved in the 
Varioklav (H+P Labortechnik AG), stainless steel reactors containing the media were 
sterilized by steam heated jacket. The antifoam Pluronic®L61 [0.01 % (v/v), BASF] was 
added separately into the bioreactor. pH was adjusted after autoclaving to pH 5.8, but not 
controlled during the fermentation. Temperature was maintained at 26 °C. The stirrer was 
operated at 100 rpm (50 rpm in the 140-L Pilot System). Aeration was constant at 0.1 vvm 
(0.2 vvm for 140-L Pilot System). Dissolved oxygen was controlled not to drop below 20 % 
(v/v) saturation using a DO control loop linked to aeration supply of max. 0.1 vvm. The 
bioreactors were inoculated with 5-10 % (v/v) of 5-7 d-old BY-2 cultures. The 140-L Pilot 
System was inoculated with the 11 d-old fermentation broth of a 7-L bioreactor. For transfer 
of the fermentation broth the 7-L bioreactor and the 140-L reactor were connected via a sterile 
silicon tube (ID 10 mm). Fermentation was performed for 10-17 days and samples were taken 
every 8-24 h.  
II.2.6.1 Off-line data collection 
Determination of fresh/dry weight and solid content were performed from 10 ml BY-2 culture 
in 14 ml polypropylen tubes (10 min/ 3000 g/ 4 °C). The PCV was read at the marking of the 
tube. 1 ml of supernatant was transferred to 1.5 ml Eppendorf tubes and stored at 4 °C until 
SDS-PAGE, Westernblot (II.2.7.2), analysis of glucose, fructose and sucrose (II.2.6.2) or 
determination of phosphate (II.2.6.3). 
The remaining supernatant was resuspended with the cell pellet and vacuum filtrated through 
a 50 mm cellulose filter (Whatman, No 5). The sample was weighed immediately (fresh 
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weight) and after 24 h at 60 °C (dry weight). Samples of 0.5 g of the fresh weight was stored 
at -20 °C for analysis in SDS-PAGE or Westernblot (II.2.7.2). 
II.2.6.2 Determination of substrate concentration 
The substrate level is an important parameter to evaluate the growth behaviour of the cells 
and discover potential growth limitations. 
Determination of glucose, fructose and sucrose in fermentation supernatants was performed 
with the “Sucrose, D-Glucose, D-Fructose” kit (II.1.3) according to the manufacturers’ 
protocol. 
II.2.6.3 Determination of Phosphate 
Phosphate together with carbon and oxygen is an important nutrient for biological systems 
and determination of phosphate level in the supernatant of BY-2 cells reveals growth 
behaviour and growth limitations in fermentation processes. 
The concentration of phosphate was determined by measurement of phosphor-molybdate. 
Hundred µl of supernatant (II.2.6.1) was mixed with 200 µl 10 % (w/v) ascorbic acid, 400 µl 
molybdate solution and filled to 10 ml with dH2O. Reaction was stopped exactly 15 min after 
addition of the molybdate solution and absorbance was measured at A680nm using the 
microplate reader Spectra Max 340 (Molecular Devices). For quantification samples were 
compared with a calibration curve of a dilution series (2.448 – 0.061 g/L) of phosphate. 
Calibration solution was prepared by solving 109.9 mg KH2PO4, dried at 75 °C o/n, in 500 ml 
of acidified dH2O [0.4 % (v/v) of H2SO4 (40 %)]. 
Molybdate solution      
NH4MO7O24· 4 H2O  2.20 mM    
K(SbO)C4H4O6•0.5 H2O 0.21 mM 
Sulphuric acid [40 % (v/v)] 60 % (v/v) 
 
II.2.6.4 Downstream processing of 100-L fermentation 
For the purifcation of BY-22F5 antibody from 100-L fermentation broth, a process involving 
five full time employees (FTE) was implemented. 
Purification of 100-L fermentation broth was carried out in two batches. Five-L samples were 
taken out of the fermenter and BY-2 cells were separated by vacuum filtration with one layer 
of Miracloth membrane 1R (Calbiochem-Novagen, Merck Biosciences). The BY-2 pellet was 
washed once with an equal volume of dH2O and resuspended in 1 - 2 volumes of 200 mM 
borate buffer (pH 8.5) containing 5 mM EDTA and 5 mM β-Mercaptoethanol.  
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Cell disruption was performed in the Microfluidizer M110-L (Microfluidics Corporation) at 
lowest adjustable pressure (150 – 600 bar) and the homogenate was collected in 40-L 
NALGENE® closed dome tanks (Neerijse). Cells debris were removed by passing the 
homogenate through the CARR Powerfuge® P6 (CARR Separations Inc.) with                        
300 - 500 ml/min. The resulting supernatant was additionally clarified in a Hollow Fiber unit 
(UFP-500-K-4X2TCA, Amersham Pharmacia). The preparation was applied onto the 400 cm2 
Hollow Fiber column (500 kDa cut-off) with 30 - 35 ml/min o/n. The concentrated retentate 
was loaded onto a XK 26/20 column (Amersham Pharmacia) packed with 10 ml of Protein-A 
(BioSEPRA Protein-A Ceramic HYPERD F; Ciphergen) with 10-30 ml/min and eluted with 
pH-shift (II.2.5.2). Different elution fractions were tested for the presence of functional 
protein by SPR  analysis (II.2.7.6).  
II.2.7 Protein analysis 
II.2.7.1 Quantification of proteins 
The concentration of purified protein was determined by Bradford (BRADFORD 1976). 
Coomassie brilliant blue G-250, used in Bradford test, exists in three forms: cationic (470 nm 
red), neutral (650 nm green), and anionic (595 nm blue). The binding of the dye to protein 
causes a shift in the absorption maximum of the dye from 470 to 595 nm. The increase in 
absorption at 595 nm was monitored. Concentration measurements were done according to 
the manufacturers’ instructions, using BSA as standard. 
II.2.7.2 SDS-PAGE and Westernblot analysis 
Discontinuous SDS-polyacrylamide gels (LAEMMLI 1970) were used for separation of 
protein samples. 
Purified proteins (50 ng/ml – 1 µg/ml) were separated on 4-12 % (w/v) Bis-Tris NuPAGETM 
gels (Invitrogen; II.1.2.1) under reducing conditions or on home-made 8 % (w/v) SDS-PAGE 
under non-reducing conditions (II.1.2.1). Proteins were visualised by staining with 0.25 % 
(w/v) Coomassie brilliant blue (II.1.2.1). For estimating molecular weights the SeeBlue Plus2 
marker (Invitrogen) for reducing gels, the unstained standard MARK12TM (Invitrogen) and 
the “prestained protein marker broad range“ (NEB) for non-reducing gels was used. 
For Westernblot analysis proteins were electro-transferred to nitrocellulose membranes 
(Amersham Bioscienes). Membranes were blocked for 1 h at RT or at 4 °C o/n with 5 % 
(w/v) skimmed milk dissolved in PBS.  
rsCD64 was detected with either anti-c-myc (1:5000), anti-his (1:5000), M22 (1:500) or H22 
(1:2000) as primary antibody and corresponding anti-human or anti-mouse AP-coupled 
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secondary antibodies (αHAP, αMAP, II.1.4). Both, primary and secondary antibodies, were 
diluted in PBST (II.1.2.1) containing 0.5 % (w/v) skimmed milk. Bound full-size antibody 
2F5 and 2G12 were detected by polyclonal GαHAP-antibodies (heavy and light-chain specific, 
1 h, RT, 1:5000 diluted; Sigma).  
Proteins were visualised by incubation with Nitro Blue Tetrazolium chloride/5-bromo 4-
chloroindol-3-yl phosphate (NBT-BCIP, Pierce). Between the incubation steps membranes 
were washed three times with PBST. 
II.2.7.3 Dot blot analysis 
Twentyfive µl of supernatant containing soluble full-size antibody or 5 µl of homogenised 
BY-2 cells (II.2.3.5) were dotted onto Immobilon-P PVDF membrane using a self-made dot 
blot apparatus (Dr. T. Rademacher, BioVII, RWTH-Aachen). Immobilized antibody was 
detected as described (II.2.7.2). 
II.2.7.4 Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA (ENGVALL and PERLMAN 1971; CLARK and ADAMS 1977) analysis was used 
for quantification of purified rsCD64 and plant-expressed BY-22F5. 
For quantifiaction or rsCD64 Microtitre plates (High-binding; Greiner Bio-One GmbH) were 
coated with approximately 1 µg/ml rsCD64 in 50 mmol/l bicarbonate buffer (pH 9.6) o/n at 
4 °C. The plates were blocked with 5 % (w/v) skimmed milk dissolved in PBS for 1 h. Anti-
HIV hIgG1/κ and mIgG1/κ anti-CA19.9 antibody as well as humanised anti-CD64 IgG1/κ 
(H22) were applied as two-fold serial dilutions starting with 1 µg/ml in PBST. Secondary 
antibodies [GαHAP(γ-chain), Sigma) / GαMAP(Fc), Sigma)] were diluted 1:5000 in PBST. 
Bound antibody was detected by incubation with nitrophenyl phosphate. Between incubation 
steps plates were washed once with PBST and two times with PBS. The OD405 was read using 
a microplate reader Spectra Max 340 (Molecular Devices) and data were evaluated with 
Microcal Origin 5.0.  
For quantification of BY-22F5 plant-derived antibody Microtitre plates (High-binding; Greiner) 
were coated with 400 ng/ml ARP 7073 peptide (II.1.4.2) or GαH-Fab serum (Sigma) diluted 
1:500 per well in coating buffer o/n at 4 °C. Two-fold serial dilutions of CHO2F5 (Polymun, 
Vienna) and BY-22F5 were applied to the coated and blocked wells, starting with 400 ng/ml of 
the CHO2F5. Bound antibodies were detected with polyclonal GαHAP-antibody (heavy-chain 
specific, 1:5000 diluted; Sigma). The ELISA was developed with 1 mg/ml p-nitrophenyl 
phosphate in AP buffer (II.2.7.2). Between incubation steps, plates were washed one time 
with PBS containing 0.05 % (v/v) Tween 20 and two times with PBS. 
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CSample  = concentration of samples 
m(S)  = gradient of regression line of samples 
m(C)  = gradient of regression line of control antibody 
CControl = concentration of control antibody 
V  = used volume 
Resulting absorption was measured at A405nm and evaluated using Microcal Origin 5.0. Data 
were displayed in graphs presenting the dilution/concentration on the x-axis and the 
absorption at 405 nm on the y-axis. The gradient of the linear range of each dilution series is 
proportional to the increase of the dilution of the known sample. Concentrations of assembled 
and functional antibody were calculated with the following formula: 
 
         
( )
( ) VCCm
SmC ControlSample ⋅⋅=
   
 
 
 
II.2.7.5 Electrophoretic mobility shift assay (EMSA) 
The electrophoretic mobility shift assay (ANDREWS 1986) was performed according to 
Coligan et al. (1998). 
The electrophoretic mobility of 1.6 µg of ARP 7073 peptide bound to 1 µg of purified 
antibody (at a ratio of 100:1) was compared with the electrophoretic mobility of purified 
antibody (CHO2F5 and BY-22F5) and ARP 7073 peptide alone. For complex formation ARP 
7073 peptide and antibody were incubated at 28 °C for 30 min. 
The protein samples were diluted in 100 mM phosphate buffer (pH 6.5) containing 5 % (w/v) 
sucrose, loaded on native 10 % PAA gels, prepared with the same buffer and run at 100 V for 
3 h at 4 °C. Proteins were visualised by Coomassie blue staining. 
 
4x Phosphate Gel Buffer (pH 6.5)    PO3 Nondenaturing PAA-Gel (10 %) 
NaH2PO4xH2O  400 mM   PAA    13.3 ml 
       4x phosphate gel buffer 10 ml 
Protein Loading Buffer     H2O    16.48 ml 
Sucrose   5 % (w/v)  10 % (w/v) APS  0.2 ml 
In dH2O      TEMED   0.02 ml 
 
II.2.7.6 Surface plasmon resonance (SPR) analysis  
Binding analysis of BY-22F5 and determination of kinetic constants of 293TrsCD64 were 
calculated with SPR (MALMQVIST 1993) using BIACORE® 2000. This method allows real-
time measurements of molecule interactions. The reaction partner were (covalently or none 
covalently) bound onto the chip-surface. Interaction leads to adsorption at the surface 
changing the fraction index which is displayed as resonance units (RU). Data are presented in 
a sensogram placing the signal over time. 
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All injected samples were diluted in HBS buffer (10 mM HEPES, 150 mM NaCl, 3.4 mM 
EDTA, 0.005 % Surfactant P20) and subjected to centrifugation prior to injection 
(10 min/ 14000 g/ 4 °C) to remove insoluble components.  
For antibody-capturing 100 µg/ml Protein-A was immobilized on a CM5-rg sensorchip 
following the standard EDC/NHS protocol (Biacore; (JOHNSSON et al. 1991)). After 
immobilisation the surface was conditioned with three 15 second pulses of 100 mM HCl. The 
fraction of active binding sites was determined by capturing about 1000 RU of CHO2F5 or    
BY-22F5 followed by injection of 50 µg/ml of peptide ARP-7073 using the kinetic mode. The 
assay was performed at 25 °C using a flowrate of 30 µl/min. The surface was regenerated by a 
15 second injection of 30 mM HCl. 
For detection of 293TrsCD64 first hCG (II.1.4.2) was immobilised on the CM5-rg sensor chip. 
Secondly, cPIPP-IgG1 (kindly provided by M. Sack, BioVII, RWTH-Aachen) was bound to 
the immobilised hCG. In a third step, 293TrsCD64 was injected to determine hte kinetic rate 
constants and active protein concentration. 
The data were analysed using the BIAevaluation (3.0) software. 
II.2.7.7 DsRed fluorescence 
The fluorescence of the reporter gene DsRed (II.1.7.4) was controlled during incubation of 
transient infiltrated tobacco leaves (II.2.3.4) and in transgenic BY-2 (II.2.3.5) with an LCD 
lamp with glass fiber optic (Leika KL1500), an additional excitation filter for green excitation 
(BP545/30) and a colour foil (No. 182, light red). Strongest fluorescing cultures were used for 
scale-up expression and the accumulation of recombinant protein was determined by Dotblot 
(II.2.7.3). 
II.2.7.8 Mass Spectrometry 
SDS-PAGE of the target protein rsCD64 was performed (II.2.7.2). After Coomassie-staining 
(II.2.7.2), the protein band of interest was excised from the gel, the gel slice cut into small 
pieces and transferred to an Eppendorf tube. The in-gel reduction, alkylation and tryptic 
digestion was performed according to an in-gel-digestion protocol of EMBL Analytical 
Research Group (EMBL) and samples were analyzed by liquid chromatography electrospray 
ionization mass spectrometry.  
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III. Results 
In this thesis two complex human proteins were expressed and characterised in heterologous 
expression hosts. 
The first chapter of the result section focuses on human anti-HIV antibodies expressed in 
plant suspension cells. The broadly neutralising human anti-HIV antibodies 2F5 and 2G12 
were already expressed in CHO cells and in clinical phase I, the safety, non-toxicity and non-
immunogenicity of both antibodies was shown (ARMBRUSTER et al. 2002). Previously 
generated tobacco suspension cells BY-2 expressing the anti-HIV antibody BY-22F5 or BY-
22G12 had to be evaluated in small-scale expression and purification. The integrity, stability 
and purity of the antibody preparation was tested and antigen binding activity was 
determined. Initial fermentations with one of the antibodies aimed in a feasibility study of a 
100-L fermentation and establishment of a large-scale downstream processing protocol. 
The second chapter focuses on the establishment of an expression and purification protocol 
for soluble expression of recombinant FcγRI (rsCD64). The therapeutic value of FcγRI as a 
target in tumor therapy, allergic reactions and leukaemia was extensively reviewed in the 
literature, and availability of a recombinant soluble form might allow in detail 
characterisation of the high-affinity receptor for monomeric IgG. As production of 
recombinant soluble FcγRI was postulated to be impossible (SONDERMANN and 
OOSTHUIZEN 2002), the expression of rsCD64 was optimised by investigating E.coli, 
mammalian and plant cells. The rsCD64 gene was amplified, cloned into three different 
expression vectors and expression levels were compared. Production protocols in the most 
suitable system were established and purification of functional protein will be performed to 
determine the stability as well as the IgG binding property. 
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III.1 Expression and characterisation of the BY-22F5 antibody 
One of the human anti-HIV antibodies BY-22G12 and BY-22F5 ought to be expressed on a 100-
L scale as a feasibility study. To initiate this, expression and purification protocols were 
established based on 1-L culture volumes for the BY-22F5. The cloning into the pTRA-rfp 
vector (II.1.7.4) and the generation of a 2F5 producing BY-2 suspension culture (II.2.3.5) was 
done by M. Bomble (BOMBLE 2004). Accumulation of BY22F5 peaked at 30 % (v/v) PCV 
reaching 2.9 mg/kg fresh weight. No antibody was detectable in the culture supernatant, 
confirming the efficiency of SEKDEL mediated ER-retrieval (BOMBLE 2004). 
III.1.1 Small scale (1.2-L) expression and purification  
Small-scale expression was performed in 3x 400 ml culture contained in 1-L baffled shake 
flasks. Cells (340g) were harvested 8 days after “sub”-culturing and stored at –20°C. For 
purification purposes the cell pellet was thawn, homogenised in extraction buffer and cell 
debris were removed by centrifugation (II.2.3.5). SPR (II.2.7.6) was used to monitor the 
successive purification of BY-22F5 on-line during all steps on a Protein-A ligand (data not 
shown). The purification process was also followed by SDS-PAGE in a 10 % (w/v) gel 
(Fig.III-1).  
No significant amounts of antibody were detected in the flow-through or the washing 
fractions. The affinity-purified antibody preparation displayed two distinct major bands of 
approximately 49 and 28 kDa corresponding to the BY-22F5 heavy and light-chain. 
 
Fig.III-1: Monitoring of the purification process of BY-22F5 by SDS-PAGE. Transfected BY-2 cells 
were cultured and harvested (II.2.3.5). Cell pellet was thawn for purification, resuspended in extraction buffer 
(II.1.2.4) and homogenised (II.1.8)]. Cell debris were centrifuged (30 min / 4000 g / 4 °C) and clear supernatant 
was purified via Protein-A (II.2.5.2). Successive samples during purification were applied onto 10 % (w/v) SDS-
PAGE and stained with Coomassie (II.2.7.2). Lanes: 1 = Protein-A load, clear supernatant of homogenised BY-2 
cells; 2 = flow through of non-bound material through Protein-A column; 3 = washing fraction with PBS 
containing 5 mM EDTA; 4 = unstained protein standard marker (Mark12TM, Invitrogen); 5-9 = subsequent 
elution fractions with 100 mM glycine and 10 % (w/v) maltose; 10 = 11 µg of CHO2F5; HC = heavy-chain of 
CHO2F5; LC = light-chain of CHO2F5. 
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BY22F5 was enriched more than 500-fold and 1.1 mg were retrieved from 340 g (wet-weight) 
of BY-2 cells giving a yield of 3.2 mg/kg or 0.92 mg/L suspension culture. The purified 
antibody was intact and contained only minor amounts of impurities. After extensive dialysis 
and subsequent centrifugation the degree of purity increased further probably due to 
precipitation of contaminants (Fig.III-2). 
 
Fig.III-2: Reduced SDS-PAGE of dialysed BY-22F5 versus CHO2F5. Preparation of Protein-A purified 
BY-22F5 was subsequently dialysed and centrifuged (30 min / 30,000 g / 4 °C) to remove precipitates of 
contaminants. Integrity and purity of BY-22F5 was compared with the control antibody CHO2F5 on a 4-12 % (w/v) 
Bis-Tris NuPAGETM gel stained with Coomassie (II.2.7.2). Lanes: 1, 4 = prestained protein marker (SeeBlue 
Plus2, Invitrogen); 2 = 1 µg of Protein-A purified and dialysed BY-22F5; 3 = 1 µg of CHO2F5; HC = heavy-chain 
of 2F5; LC = light-chain of 2F5. 
 
Degradation pattern can be revealed by specific detection of the BY-22F5 preparation in light-
(κ)- and heavy-(γ)-chain Westernblots. Neither the γ-chain nor the κ -chain showed any 
protein degradations (Fig.III-3). 
 
Fig.III-3: Reduced κ-chain and γ-chain Westernblot of BY-22F5 versus CHO2F5. BY-22F5 preparation 
purified with Protein-A and dialysis was checked for degradation in a reduced Westernblot analysis (II.2.7.2) 
versus the control antibody CHO2F5. 50 ng of each antibody were applied onto 4-12 % (w/v) Bis-Tris NuPAGETM 
gels and blotted onto nitrocellulose membrane (II.2.7.2). The Westernblots were detected with GαHAP antibodies 
[1:5000; γ- and κ-chain specific; (II.1.4)]. Lanes: 1, 6 = prestained protein marker (SeeBlue Plus2, Invitrogen); 2 
= 50 ng of BY-22F5 detected with GαHAP (κ-chain specific); 3 = 50 ng of CHO2F5 detected with GαHAP (κ-chain 
specific); 4 = 50 ng of BY-22F5 detected with GαHAP (γ-chain specific); 5 = 50 ng of CHO2F5 detected with GαHAP 
(γ-chain specific); HC = heavy-chain of 2F5; LC = light-chain of 2F5. 
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The electrophoretic mobility of the BY22F5 LC is slightly lower than that of the CHO2F5 
because of the C-terminal addition of the SEKDEL sequence. The electrophoretic mobilities 
of the HC do not show significant differences probably due to the smaller relative size 
difference or the different N-glycans. While the ER-retained BY22F5 harbours high-mannose 
type N-glycans, the secreted CHO2F5 contains mammalian complex-type N-glycans. Non-
reducing denaturing SDS-PAGE and Westernblot was performed to investigate the state of 
assembly of plant and mammalian produced 2F5 (Fig.III-4). 
 
                                                  A                                                     B 
Fig.III-4: Non-reduced SDS-PAGE (A) and non-reduced heavy and light-chain Westernblot of BY-
22F5 versus CHO2F5 (B). Protein-A purified BY-22F5 and control antibody CHO2F5 were checked for state of 
assembly in non-reduced SDS-PAGE and Westernblot analysis (II.2.7.2). For each antibody 1 µg was applied 
onto a 4-12 % (w/v) Bis-Tris NuPAGETM gels and stained with Coomassie. For each antibody 50 ng were 
applied onto 4-12 % (w/v) Bis-Tris NuPAGETM gels and blotted onto nitrocellulose membrane (II.2.7.2). 
Detection was carried out with GαHAP antibodies [1:5000; γ- and κ-chain specific; (II.1.4)]. Lanes: 1, 4, 5, 8 = 
prestained protein marker (SeeBlue Plus2, Invitrogen); 2 = 1 µg of BY-22F5; 3 = 1 µg of CHO2F5; 6 = 50 ng of BY-
22F5 detected with GαHAP (κ-chain specific); 7 = 50 ng of CHO2F5 detected with GαHAP (κ-chain specific); 9 = 
50 ng of BY-22F5 detected with GαHAP (γ-chain specific); 10 = 50 ng of CHO2F5 detected with GαHAP (γ-chain 
specific). 
 
No differences were found, showing that the antibody was efficiently assembled within the 
ER of BY2 cells. The GαHAP (κ-chain specific) antibody detected the same three-band pattern 
(weakly visible in the Westernblot, Fig.III-4B). 
III.1.2 Large Scale (7-L - 100-L) expression and purification 
In order to express and purify one of the clinical relevant anti-HIV antibodies 2G12 or 2F5 in 
a 100-L feasibility study, protocols for expression and purification established in shake flasks 
cultures were first transferred to a 7-L fermentation. 
III.1.2.1 7-L fermentation 
One fermentation was carried out with BY-2 cells expressing BY-22G12 (II.1.2.4). Cloning of 
the 2G12 full-size antibody into the pTRAkc vector was done by M. Bomble (BOMBLE 
2004). The final construct (pTRAkc-GD) contained the heavy- and light-chain of the human 
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antibody 2G12 and the DsRed gene and transient expression in N.tabacum yielded 
77.8 mg/kg (BOMBLE 2004).  
The BY-22G12 producing BY-2 suspension culture was developed by Dr. T. Rademacher 
(BioVII, RWTH-Aachen, II.2.3.5). Cultivation of BY-2 cells and supply of 500 ml 7-d-old 
BY-2 culture was performed by Dr. F. Schuster (BioVII, RWTH-Aachen) to inoculate the 7-L 
bioreactor.  
The bioreactor was equipped as described (II.2.6) and data collection was started after 
inoculation with 5 % (v/v) BY-2 suspension culture. This initial fermentation was carried out 
without antifoam for maximal cell growth of BY-2 cells. Time flow of the fermentation 
included collected on-line and evaluated off-line data is presented in Fig.III-5. 
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Fig.III-5: Batch fermentation of human anti-HIV antibody BY-22G12 in 7-L glass reactor. BY-2 cells 
expressing the anti-HIV antibody BY-22G12 were cultured in suspension in a 7-L glass reactor. Data for dissolved 
oxygen, control of oxygen and pH were collected on-line. Samples of supernatants and cell pellets were taken 
every 8-24 h (II.2.6.1) to determine off-line data such as packed cell volume, dry weight, fresh weight, substrate 
and phosphate concentration, expression yield of BY-22G12 and total protein concentration. On-line data: dO2 = 
level of dissolved oxygen; ctrldO2 = control of dO2; pH = pH value in the media; Off-line data (II.2.6.1): PCV = 
packed cell volume; DW = dry weight; FW = fresh weight; Sucrose, Glucose, Fructose = sugar consumption in 
fermentation (II.2.6.2); PO4 = Phosphate consumption (II.2.6.3); [2G12]/kg cells = concentration of human anti-
HIV BY-22G12 antibody per kilogram cells; [total protein] = concentration of total protein in the BY-2 pellet 
determined by Bradford (II.2.7.1). 
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pH was not controlled during the fermentation and showed a typical time course (Fig III-19D, 
black line). During the first 24 h the pH dropped more than one unit from 5.8 to 4.5 and 
increased steadily to pH 6 over the next 150 h due to release of stored ions and uptake of 
nutrients such as ammonium (PAIVA 1999). With a maximal air input of 0.1 vvm of air 
(FigIII-19D, magenta line) the amount of dissolved oxygen was maintained at 20 % (v/v) for 
the lag- and the initial log-phase of the BY-2 culture but decreased to 1.5 % (v/v) during 
exponential growth of the cells (Fig-III-19D, blue line). The increase of biomass was 
illustrated by determining the packed cell volume (C, red line and squares), fresh cell weight 
(C, green line and squares) and dry cell weight (C, orange line and squares; II.2.6.1). After an 
initial lag-phase of approximately 24 h, constant cell growth was observed for 200 h. With a 
5 % (v/v) inoculum, fermentation of 300 h resulted in a yield of 350 g fresh cell weight per 
litre reactor volume and an exceptional PCV of 80 % (v/v).  
Phosphate- and sugar levels in the culture supernatant were determined to document the 
course of fermentation (II.2.6.2; II.2.6.3). Both nutrients were depleted after 90 h (FigIII-19B, 
blue down triangles; grey line and squares). The sucrose in the media was hydrolysed by BY-
2 cells into the monosaccharides glucose and fructose (PAIVA 1999). Therefore levels of 
glucose (B, olive line and circles) and fructose (B, wine line and up triangle) increased in the 
early log-phase of the fermentation, whereas sucrose levels decreased.  
Recombinant human BY-22G12 was constitutively expressed during the first 120 h of 
fermentation and detected during the whole fermentation process, as shown in Fig.III-5A (red 
line and squares) and in Westernblot analysis (Fig.III-6). Antibody expression level per 
kilogram cells was determined by ELISA (II.2.7.4; II.1.4). For Westernblot analysis and 
ELISA frozen pellet samples (II.2.6.1) were thawn and homogenised (II.2.3.5). Clarified 
supernatant was analysed first in Dotblots [(II.2.7.3); data not shown] to preselect samples 
containing protein for the Westernblot (II.1.4). BY-22G12 accumulated in the first 120 h of the 
fermentation to a maximum concentration of 7 mg/kg cells (FigIII-19A, red line and squares) 
and decreased slowly until the end of the fermentation to 2 mg/kg cells. For a maximum of 
antibody (7 mg/kg), the fermentation should have been terminated after 120 h. The 
Westernblot revealed a decrease in the amount of heavy-chain (Fig.III-6A), whereas the 
amount of the light-chain accumulated over the whole fermentation process (Fig.III-6B). The 
total protein concentration (Fig.III-5A, violet line and diamonds), determined by Bradford 
analysis (II.2.7.1) of the homogenised pellet samples (II.2.3.5) increased to 4 g/L in the first 
70 h indicating the start of cell activity. 
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Fig.III-6: Westernblot of BY-22G12 expression in a 7-L fermentation. Samples of BY-2 cells were 
taken every 8-24 h and stored at -20 °C (II.2.6.1). For analysis cell pellet was thawn, resuspended in extraction 
buffer (II.1.2.4) and sonicated (II.1.8). Cell debris were centrifuged (30 min / 4000 g / 4 °C) and clear 
supernatant was applied onto 12 % (w/v) reducing SDS-PAGE and blotted onto nitrocellulose membrane 
(II.2.7.2). A: Detection with γ-chain specific GαHAP antibody (1:5000); B: Detection via κ-chain GαHAP 
antibody (1:5000; II.2.6.2). Lanes: 1 = 38 hours post inoculation (hpi); 2 = 63 hpi; 3 = 89 hpi; 4 = 110 hpi; 5 = 
prestained protein marker broad range (NEB) with 100 ng CHO2G12; 6 = 134 hpi; 7 = 158 hpi; 8 = 184 hpi; 9 = 
207 hpi; 10 = 231 hpi. 
 
Human full-size anti-HIV antibody BY-22G12 was expressed in a 7-L bioreactor. Expression 
level peaked at 7 mg/kg cells in the early growth phase. Light- and heavy-chain of the 
antibody showed minor degradations during the whole fermentation process.  
Cells started to grow on nearly all surfaces in the bioreactor and cumulated on the media 
surface. The fermentation was repeated in the presence of 0.01% (v/v) Pluronic (data not 
shown) to achieve more homogeneous cell growth. Except for overall reduction of cell growth 
no differences were seen in comparison to the previous fermentation. Cells were more 
homogeneous building micro-aggregates of 2-4 cells even to a PCV of 80 % (v/v) with 
comparable antibody production rate (data not shown).  
Proof of functional expression of BY-22G12 (binding to gp120) failed both in SPR  and ELISA 
(data no shown). Thus a new cloning strategy was necessary to exchange an amino acid in the 
light chain of the 2G12 antibody sequence, which was different from the original sequence 
(BUCHACHER et al. 1994) and might have caused the non-functionality. 
III.1.2.2 100-L fermentation 
Results from the small-scale expression of BY-22F5 (3.2 mg/kg or 0.92 mg/L) and initial 
fermentations yielding in stable BY-22G12, prompted the feasibility study of a 100-L 
fermentation. For inoculation of the 140-L reactor the complete fermentation broth of a 
preceding fermentation in a 7-L reactor was used. This fermentation was carried out in a 
stainless-steel reactor to enable a transoculation into the 140-L reactor and based on the 
experience of the previous fermentations Pluronic®L61 anti-foam was added into the 
fermentation media. The time course of the 100-L fermentation including on-line and 
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evaluated off-line data is presented in Fig.III-7. The pH was adjusted to 5.8 before inoculation 
and the temperature was lowered to 28 °C after 3 days at 37 °C as sterile control. The 
bioreactor was equipped with three six-bladed Rushton impeller and stirrer was operated at 
50 rpm to reduce shear forces. To ensure sufficient oxygen transfer the aeration was adjusted 
from 0.1 vvm after 48 h to 0.2 vvm (Fig.III-7D, blue line). The dO2 was controlled to keep 
20 % (v/v) with 0.2 vvm aeration. 
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Fig.III-7: Batch fermentation of human anti-HIV antibody BY-22F5 in 140-L stainless steel reactor 
(Pilot System). BY-2 cells expressing the anti-HIV antibody BY-22F5 were cultured in suspension in a 140-L 
stainless steel reactor. Data for level of dissolved oxygen, control of oxygen and pH value were collected on-
line. Samples of supernatant and cell pellet were taken every 8-24 h (II.2.6.1) to determine off-line data as PCV, 
DW, FW, substrate and concentration, expression yield of BY-22F5, and total protein concentration. On-line data: 
dO2 = level of dissolved oxygen; ctrldO2 = control of dO2; pH = pH value in the media; Off-line data (II.2.6): 
PCV = packed cell volume; DW = dry weight; FW = fresh weight; Sucrose, Glucose, Fructose = sugar 
consumption in fermentation (II.2.6.2); [2F5]/kg cells = concentration of human anti-HIV BY-22F5 antibody per 
kilogram cells; [total protein] = concentration of total protein in the BY-2 pellet determined by Bradford 
(II.2.7.1). 
 
Cell growth (Fig.III-7C) and demand of oxygen, measured in supply of oxygen (Fig.III-7D, 
magenta line), increased in the first 100 h and concentration of oxygen (Fig.III-7D, blue line) 
declined in early growth phase to 0 % (v/v) after 180 h. Cell growth was not affected by this 
oxygen limitation (Fig.III-7C). Sugar was consumed completely after 240h (Fig.III-7B). 
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Expression of BY-22F5 antibody in the cells decreased slowly over the fermentation process 
from 1.8 mg/kg to 1.3 mg/kg cells (Fig.III-7A, red line and squares). 
The integrity and stability of the expressed BY-22F5 antibody in BY-2 cells during the 
fermentation process was checked in Westernblot analysis (Fig.III-8; III.1.2.1).  
   
                                      A                                                                           B 
Fig.III-8: Reduced Westernblot of BY-22F5 expression in a 100-L fermentation. Samples of BY-2 
cells were taken every 8-24 h and stored at -20 °C (II.2.6.1). For analysis cell pellet was thawn, resuspended in 
extraction buffer (II.1.2.4) and sonicated (II.1.8). Cell debris were centrifuged (30 min / 4000 g / 4 °C) and clear 
supernatant was applied onto 12 % (w/v) SDS-PAGE and blotted onto nitrocellulose membrane (II.2.7.2). A: 
Detection with γ-chain specific GαHAP antibody (1:5000); B: Detection via κ-chain GαHAP antibody (1:5000; 
II.2.6.2). Lanes: 1 = 1 hpi; 2 = 23 hpi; 3 = 41 hpi; 4 = 68 hpi; 5 = 93 hpi; 6 = 118 hpi; 7 = 143 hpi; 8 = prestained 
protein marker broad range (NEB) containing 100 ng CHO2G12; 9 = 162 hpi; 10 = 188 hpi; 11 = 212 hpi; 12 = 
240 hpi; 13 = 262 hpi; 14 = 286 hpi; 15 = 327 hpi. 
 
Full-size heavy and light-chain were detected in the 100-L fermentation over the entire 
fermentation process (Fig.III-8). A double-band pattern was detected for the light chain until 
the end of the fermentation (Fig.III-8B). The amount of intact heavy-chain decreased over the 
fermentation process dramatically as cells grow under oxygen limitation and degradation 
accumulated (Fig.III-8A). At the time of harvest almost no intact heavy-chain was detected in 
the BY-2 cells. Nevertheless, a downstream processing was established.  
III.1.2.3 Large-scale purification 
The fermentation broth was processed stepwise in two batches starting after 340 h of 
fermentation. Successive purification of BY-22F5 was followed on-line during all steps by SPR 
(II.2.7.6) on a Protein-A surface and is illustrated in Fig.III-9.  
The first 40-L batch for downstream purification was taken in 5-L samples out of the 
fermenter and cells were harvested by vacuum filtration. Resuspension of the BY-2 pellet was 
initially performed in one volume borate buffer and later in two volumes due to recurring 
plugging of the French Press. For the same reason the pressure in the French Press was 
adjusted from 150 bar to 600 bar. Thus, cells were disrupted into fines as observed in previous 
experiments (data not shown). Fibers and cell wall substances were solubilised and created a 
viscous homogenate.  
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Fig.III-9: Flowchart for large-scale downstream processing. The flowchart illustrates the different 
steps in the downstream processing of a 40-L batch from the 100-L fermentation (III.1.2.2). 5-L samples were 
taken out of the fermenter (I) and cells were separated by vacuum filtration with Miracloth membrane (Merck 
Biosciences). The BY-2 pellet was washed with one volume of dH2O and resuspended in 200 mM borate buffer. 
The suspension was disrupted in the Microfluidizer (II). Cell debris were separated in the CARR Powerfuge (III) 
and the supernatant (containing the antibody) was filtered using a Hollow Fiber Unit (IV). BY-22F5 antibody was 
purified on a Protein-A column using the retentate (V).  
 
A 2-L sample was taken for small-scale purification following the established protocol 
(III.1.1) and the obtained data are summarised in Table.III-2 and Fig.III-10. 
The large-scale batch was passed through the CARR Powerfuge and cloudy supernatant was 
subsequently clarified in a UFP-500-K-4X2TCA Hollow Fiber Unit. Despite the 500 kDa cut-
off the antibody was detected in the retentate by SPR (II.2.7.6, data not shown). Hence, 
retentate was concentrated to 2-L total volume and centrifuged in two steps (1. 
V. Purification 
IV. Filtration 
III. Centrifugation 
II. Cell disruption 
I. Sample Preparation 
Sampling (5-L) 
Cell harvest (vacuum filtration) 
Washing with dH2O 
Resuspension in borate buffer 
Cell disruption (French Press) 
Removal of cell debris (CARR Powerfuge)
Clarification (Hollow fibre Unit) 
Supernatant 
BY-2 cells
Cell debris 
Supernatant containing BY-22F5
Clear supernatant
Retentate containing  BY-22F5
Purification (Protein-A)   
small-scale 
purification (2-L) 
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        Large-Scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Small-Scale 
60 min/ 30,000 g/ 4 °C; 2. 30 min/ 100,000 g/ RT). Supernatant stored at 4 °C solidified after 
the first centrifugation. Thus, further purification steps including the ultracentrifugation were 
performed at RT. The clear supernatant was applied in 4 h (flow rate: 10 ml/min) onto a 
XK26/20 column packed with 10 ml Protein-A. Flow and elution fraction were tested via SPR 
(II.2.7.6 (see Table.III-2 and Fig.III-10).  
sample volume [L] mAB [mg] mAB [mg/L] yield [%]
FrenchPress Homogenate 25,000 38,250 1,53 100
CARR Supernatant 23,000 36,133 1,57 94
Hollow Fibre Filtrat 17,000 3,438 0,20 9
Hollow Fibre Retentat 2,750 32,184 11,70 84
Protein-A Feed 2,000 33,497 16,75 88
Protein-A Flow through 2,000 0,111 0,06 0,3
Eluate 3 0,005 3,350 670,00 9
Eluate 4 0,017 9,181 540,06 24
Eluate 5 0,023 4,268 185,57 11
Eluate 6 0,030 0,348 11,60 1
Eluate total 0,460 17,150 37,28 45
sample volume [L] mAB [mg] mAB [mg/L] yield [%]
FrenchPress Homogenate 1,750 2,677 1,53 100
Supernatant after Centrifugation 1,750 2,320 1,33 87
Protein-A Feed 1,750 2,320 1,33 87
Protein-A Flow through 1,750 0,055 0,03 2
Protein-A Wash 0,300 0,005 0,02 0,2
Eluate 1 0,001 0,006 9,69 0,2
Eluate 2 0,001 2,239 1565,73 84
Eluate 3 0,001 0,008 14,21 0,3
Eluate 4 0,001 0,000 0,33 0,0
Eluate 5 0,001 0,000 0,02 0,0
Eluate total 0,002 2,252 1348,50 84  
Table III-2: Comparison of antibody yield in small-scale and large-scale downstream processing. The 
table summarises the concentration of BY-22F5 antibody detected by SPR (II.2.7.6) after the different purification 
and concentration steps during purification and compared the yield of the 23-L large-scale purification with the 
2-L small-scale processing. Downstream processing steps include French Press (Microfluidizer), CARR 
Powerfuge, Hollow Fiber Unit and Protein-A column for large-scale purification (II.2.6.4). Small-scale 
purification was separated after French Press and centrifugation and small-scale Protein-A purification was 
performed (III.1.1). 
 
The antibody yield in the different purification and concentration steps is summarised in 
Table.III-2 and illustrated as yield in percent in Fig.III-10. The first antibody concentration 
measured after homogenisation in the French Press was taken as 100 %. During separation of 
cell debris in the CARR Powerfuge 6 % of antibody was lost. In the Hollow Fiber filtration 
step 9 % was detected in the filtrate and 84 % in the retentate. Thus, the retentate was purified 
further, the filtrate was discarded. Almost 50 % of antibody could not be rediscovered after 
the Protein-A purification step.  
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Fig.III-10:  BY-22F5 yield in percent during large- und small scale purification. Antibody yield was 
determined by SPR (II.2.7.6, data not shown). For large-scale samples of the French Press (FP) homogenate, the 
CARR supernatant (CARR), the Hollow fiber retentate (HF retenate) and the Protein-A (Load, Flow and Elution 
fractions) are visualised (II.2.6.4). For the small-scale purification, samples of the French Press (FP), the CARR 
supernatant (CARR), the supernatant after centrifugation (S Centrifuge) and the Protein-A column (load, flow 
through, washing and elution fractions) are presented (III.1.1). 
 
The small-scale purification was separately purified on a laboratory scale after removal of cell 
debris in the CARR Powerfuge. Centrifugation of the small-scale sample caused 7 % 
reduction of antibody yield. During Protein-A purification 84 % were recovered from the 
column. 
Conclusively, an antibody yield of 45 % was achieved in the large-scale purification and 84 % 
in the small-scale sample. The critical step during large-scale downstream processing was the 
Protein-A purification as almost 50 % of the antibody disappeared. Only minor amounts of 
antibody were detected in the other washing fractions (not shown in Table.III-2). Thus, 
antibody was not completely eluted or denatured during the elution with pH 2.  
The second batch was used to test some conditions and possible alternatives in purifying plant 
derived antibodies. Precipitation of fibers and plant polysaccharides with magnesium sulphate 
(200 mM MgSO4) was successfully tested in small scale by M. Sack (BioVII, RWTH-
Aachen). Magnesium sulphate was added to the fermentation broth at two different steps in 
the purification process. First BY-2 cells were resuspended with borate-buffer containing 
200 mM MgSO4 and homogenised in the Microfluidizer (II in Fig.III-9). Homogenate was 
centrifuged (30 min / 30000 g/ 4 °C) and stored at RT o/n. The clear supernatant after 
centrifugation changed colours to deep green but remained clear. BY-2 homogenate contained 
0,954 mg BY-22F5/L without magnesium sulphate. After precipitation with magnesium 
sulphate 90 % corresponding to 0.86 mg/L were detected in the supernatant.  
In the second approach plant fibers were precipitated after one CARR centrifugation step (III 
in Fig.III-9) by addition of 200 mM MgSO4. The supernatant after a second CARR separation 
was less turbid but changed colour to dark green and precipitate became visible o/n. 91 % of 
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antibody were detected in the supernatant. Thus, MgSO4 precipitation reveals a feasible 
method to specifically remove plant fibers without loosing antibody. 
Additionally the capacity of the STREAMLINETM (expanded bed chromatography by 
Amersham Pharmacia) was tested to directly purify recombinant antibodies out of crude 
extracts. The STREAMLINETM column was loaded with 10-L of homogenised BY-2 
suspension, but the expanded bed was slugged out at the end (data not shown).  
III.1.3 Antigen binding activity of BY-22F5  
Besides establishment of expression and purification protocols for the human anti-HIV 
antibody 2F5, the characterisation of the binding activity and comparison with  CHO 
produced 2F5 was essential as well. Different types of experiments were performed to 
compare the antigen binding of BY-22F5 and CHO2F5 in detail. In theory all antibody binding 
sites in the preparation should be able to bind the antigen. Differences of functionality of BY-
22F5 versus CHO2F5 indicates qualitative varieties in both preparations. For all these assays the 
peptide ARP7073 containing the epitope ELDKWAS recognised by the 2F5 antibody 
(II.1.4.2) was used. 
 
Fig.III-11: Electrophoretic mobility shift assay to determine antigen binding activity of BY-22F5 and 
CHO2F5. BY-22F5 antibody was purified as described (III.1.1). 1 µg of purified BY-22F5 antibody and CHO2F5 
control antibody were applied as free antibody and complexed with 3.24 µg of ARP7073 peptide onto the native 
gels (II.2.7.5). 1 µg of CHO2G12 was used for negative control as free antibody and mixed with 3.24 µg ARP7073 
peptide. Lanes: 1 = 1 µg BY22F5; 2 = 1 µg BY22F5 in complex with 3.24 µg ARP7073 peptide; 3 = 1 µg CHO2F5; 4 
= 1 µg CHO2F5 in complex with 3.24 µg ARP7073 peptide; 5 = 1 µg CHO2G12; 6 = 1 µg CHO2G12 mixed with 
3.24 µg ARP7073 peptide; 7 = 3.24 µg ARP7073 peptide. 
 
An 100 M excess of the peptide ARP7073 was added to the antibody preparations in EMSA 
assays to reliably saturate all functional binding sites (Fig.III-11). The change in 
electrophoretic mobility is mainly due to a change of charge in the case of 2F5 (theoretical pI 
of 9.35) and ARP7073 (theoretical pI of 3,97). The difference in size of free (molecular 
weight without glycosylation: 149.85 kDa) and complexed (152,28 kDa or 154,71 kDa) 
antibody is neglectable. The EMSA was performed using PBS buffer at pH 6.5 in order to 
have near-physiological conditions. Under these conditions 2F5 migrated only a short 
distance into the gel. Nevertheless, small differences in the electrophoretic mobility of free 
BY22F5 and CHO2F5 were observed (Fig.III-13, lane 1 and 3). The human anti-HIV antibody 
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CHO2G12 recognising the antigen gp120 (II.1.4) but not the ARP7073 peptide in gp41 was 
used as negative control.  
When excess of ARP7073 is present (Fig.III-11, lane 2 and 4) a clear shift was seen and no 
bands remained at the position of free antibody. Therefore both antibody preparations 
contained no detectable inactive molecules. No differences of free CHO2G12 and CHO2G12 
mixed with the ARP7073 peptide were observed (Lane 5 and 6, Fig.III-11). 
The sensitivity of the assay is however not good enough to reveal a small fraction of inactive 
or partially inactive molecules, i.e. antibodies with only one active binding site and therefore 
provides only qualitative or semi-quantitative information. 
A quantitative comparison of the antigen binding activities of the plant and mammalian 
derived antibody preparations was done by ELISA. To achieve this, total and percentage of 
active antibody concentration was determined on the same plate. Total antibody concentration 
was determined by using GαH-Fab serum (II.1.4) as capture reagent (anti-Fab-ELISA) and 
antibody molecules with at least one active binding site were captured to coated ARP7073 
(400 ng/ml, antigen-ELISA). This enables the use of GαH-IgG (Fc-specific) secondary 
antibody for both set-ups, minimizing possible error-sources and allowing the most direct 
comparison of the two antibody samples.  
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Fig.III-12: Reactivities of CHO2F5 and BY-22F5 determined in an anti-Fab- and antigen-ELISA.       BY-
22F5 was purified as described (III.1.1). GαH-Fab and ARP7073 antigen were used as capture reagent for 
CHO2F5 and BY-22F5 applied in two-fold serial dilutions (II.2.7.4). Detection was performed with GαHAP (γ-chain 
specific) antibody (1:5000). The gradient of the linear range of every dilution series is displayed as reactivity of 
BY-22F5 in anti-Fab-ELISA (orange), CHO2F5 in anti-Fab-ELISA (red), BY-22F5 in antigen-ELISA (green) and 
CHO2F5 in antigen-ELISA (blue). Data column 1-6 represent different positions on the Microtitre plate. 
 
ELISA reactivities obtained for CHO2F5 and BY-22F5 showed no significant differences while 
variation was observed between experiments (Fig.III-12). The relative antigen binding 
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activity of BY-22F5 can be derived by first dividing the peptide binding reactivity by the total 
antibody binding reactivity and then normalising it to the ratio obtained for CHO2F5. The mean 
relative activity of BY-22F5 was 108 % (+/- 20 % SD) of CHO2F5 and thus identical within 
experimental limits.  
A Biosensor was developed by M. Sack (BioVII, RWTH-Aachen) to directly determine the 
percentage of active paratopes. The assay is based on first capturing 2F5 to a Protein-A 
surface followed by injection of the peptide ARP7073 using a peptide concentration high 
enough to achieve total saturation. The amount of antibody captured to the chip and the 
amount of peptide can be directly derived from the sensorgram. Moreover the maximal 
binding capacity is given by the molecular masses of the interacting molecules and the 
stoichiometry of the interaction. Finally, the sensitivity of the Biacore2000 instrument and the 
robustness of the assay is high enough to allow precise and accurate determination.  
 
 
Fig.III-13: SPR assay of CHO2F5 and BY-22F5 for determination of active paratopes in the antibody 
preparations (II.2.7.6). BY-22F5 was purified as described before (III.1.1). In the first step 2F5 was bound to 
immobilised Protein-A. ARP7073 was subsequently injected for analysis. Five repetitive measurements were 
performed with CHO2F5 and BY-22F5 and displayed as overlayed sensorgrams over time. RU = resonance units, 
changes in fraction index due to binding of substances. A = overlay of 5 measurements of binding of CHO2F5 and 
BY-22F5; B = overlayed sensorgrams of 5 measurements of dissociation of CHO2F5 and BY-22F5 (Illustration and 
image editing provided by M. Sack, BioVII, RWTH-Aachen.). 
 
For both antibody preparations 5 repetitive measurements were performed (Fig.III-13A), the 
amount of captured antibody and subsequently bound peptide were determined from the 
sensorgrams and the fraction of active binding sites was calculated (Fig.III-13B). The activity 
of 2F5 was 97 % (+/- 2 % SD) for the CHO and 88 % (+/- 5 % SD) for the BY2 derived 
product. Thus the activity of BY22F5 was only slightly reduced.  
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III.2 Construction, expression and characterisation of rsCD64 
Recent publications (SONDERMANN et al. 1999) describe the expression of the extracellular 
domain of FcγRII as soluble protein. Therefore, the published cd64 sequence (ALLEN and 
SEED 1988) was used as template to identify the extracellular domain of cd64 and synthetic 
oligonucleotides were designed to amplify this. To enable detection of the expressed protein, 
an anti-c-myc-tag sequence was added to the 3’-end by primer sequence (N- or C-terminal 
his-tag sequences are present in each of the expression vectors). Figure III-1 illustrates the 
origin of cd64 and subsequent cloning and expression into E.coli, HEK 293T cells and 
N.tabacum leaves. 
 
 
 
 
Fig.III-14: Schematic presentation of the cloning and expression of rsCD64 in different expression 
systems. Total RNA was isolated from human blood (II.2.1.4) and transcribed by RT-PCR (II.2.1.5) with cd64-
specific primers (II.1.5) into cDNA. cDNA of cd64 was cloned into three different vectors enabling expression 
in E.coli, HEK 293T cells and N.tabacum (II.1.7). pMT = vector for bacterial expression in the bacterial 
periplasm, derived from pET27b (II.1.7.1); BL21(DE3) = E.coli strain for expression of rsCD64 (II.1.6.1); pMS 
= vector for mammalian expression into the culture supernatant, derived from pSecTag2 (II.1.7.2); HEK 293T = 
eucaryotic cell line for expression of rsCD64 (II.2.4); pTRA = plant expression vector derived from pBAM 
(II.1.7.3); A.tumefaciens = soil bacterium used for gene transfer into N.tabacum (I.2.3); cd64 = DNA sequence of 
extracellular domain of CD64; rsCD64 = protein of recombinant soluble CD64. 
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III.2.4 Total RNA extraction from whole blood and cd64-specific RT-PCR 
Total RNA was isolated from 2 x 2.5 ml blood (II.2.1.4) and used for reverse transcription 
and amplification of cd64 (II.2.1.5). Primer pairs annealing at the 5’ and 3’ end of the 
extracellular domain [cd64-5’; cd64-cmyc-3’, (II.1.5)] were designed and used. 
Resulting PCR-products were electrophoretically separated on a 1.2 % (w/v) agarose gel 
shown in Fig.III-15. The PCR product of cd64 in lane 3 shows the expected size of 865 bp. 
The cd64 β-form was amplified as well, resulting in a PCR-product of 569 bp. Successive 
cloning was performed only with the FcγRI α-isoform (Lane 3, I.1.2.2).  
 
Fig.III-15: Agarose electrophoresis of RT-PCR product of amplified cd64. RT-PCR was performed 
with total RNA (II.2.1.5). 2 µl of the 50 µl PCR-reaction were applied onto a 1.2 % (w/v) TBE agarose gel 
(II.2.1.7). Lanes: 1 = λ-PstI Marker (500 ng); 2 = negative control; 3 = PCR-product of cd64 (α- and β-form).  
III.2.5 Bacterial expression system [BL21(DE3) E.coli] 
First expression approaches were carried out in E.coli to prove whether the efficient and cost 
effective bacterial system is applicable for expression of the human rsCD64 protein.  
III.2.5.1 Construction of pMT-cd64 
The extracellular domain of the human receptor CD64 was cloned into the pMT-M12 vector 
for expression in E.coli. An overview of the stepwise construction of pMT-cd64 is presented 
in Fig.III-16.  
Briefly, the cDNA fragment of 865 bp (III.2.4) was excised from the gel (Fig.III-15) and 
subcloned via SfiI and BlpI into pMT (II.1.7.1; Fig.III-16). The construct was transformed by 
heat-shock into E.coli XL1-Blue (II.1.6.1) and checked for presence of the insert in a 
restriction digest with EcoRI/BlpI. Subsequent sequencing analysis of three clones with the 
primer pMT-5’/pMT-3’ (II.1.5) discovered one base pair replacement (T into G) at position 
83 resulting in an aminoacid change from leucine to arginine. Until now no polymorphism 
with this exchange was described in the literature, therefore a transcription error of the 
polymerase in the PCR (II.2.1.2) was suspected (for final sequence see Appendix VII). E.coli 
cd64 (α-isoform) 
 
cd64 (β-form) 
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BL21(DE3) were transformed (II.1.6.1) with this pMT-cd64 construct for periplasmic 
bacterial expression (II.2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
Fig. III-16:  Schematic overview of cloning procedure of cd64 into pMT. pMT = bacterial expression 
vector derived from pET27b (II.1.7.1); his10 = coding sequence of polyhistidine-tag for detection and 
purification of the recombinant protein; pelB = signal peptide for transport into periplasm; c-myc = coding 
sequence of c-myc-tag for detection of recombinant protein; M12 = anti-MUC-1 scFv; cd64 = DNA sequence of 
CD64 extracellular domain.  
 
III.2.5.2 Efficiency of rsCD64 expression in bacteria 
Different IPTG concentrations (0.1 mM – 2 mM) and different induction time periods (6 h – 
24 h) were tested, as well as expression with osmotic stress and compatible solutes. Soluble 
rCD64 could neither be detected in the supernatant of the culture nor in the disrupted E.coli 
cells. As control for IPTG induction scFv expression in BL21(DE3) E.coli was successfully 
performed in parallel (results not shown). Ni2+NTA purification of the protein was carried out 
to concentrate the protein (II.2.5.1). Monitoring of the purification was performed in SDS-
PAGE (results not shown), but a rsCD64 specific band could not be detected. Only 
corresponding Westernblots revealed a protein band at the expected size (Fig.III-17). 
Two very faint bands of approximately 30 kDa and 35 kDa were visualised in the last 
washing and elution fraction. The theoretical molecular weight of bacterial expressed rsCD64 
is 35.4 kDa, corresponding to the larger one of the detected bands. The other band probably 
represents a degradation fragment. Approximately 40 ng rsCD64 were purified per gram 
bacterial pellet (1.7 µg per litre bacterial culture respectively).  
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Fig.III-17: Westernblot illustrating the purification of rsCD64 via Ni2+NTA out of E.coli BL21(DE3). 
E.coli cells were induced with 1 mM IPTG for 6 h to express rsCD64 in the periplasm. After expression cells 
were disrupted by sonication on ice and cell debris were removed by centrifugation (30 min / 15000 g/ 4 °C). 
Clear supernatant was desalted and purified via Ni2+NTA column (II.2.5.1). Samples were applied onto 12 % 
(w/v) SDS-PAGE and blotted onto nitrocellulose membrane. Detection was carried out with α-his antibody 
(1:5000) followed by secondary GαMAP antibody (1:5000; II.1.4). Lane: 1 = flow through of non-bound material 
through Ni2+NTA column; 2 = washing fraction with PBS; 3 = washing fraction with PBS containing 10 mM 
imidazole; 4 = washing fraction with PBS containing 40 mM imidazole; 5 = 250 ng scFv4813 control for 
detection via anti-his and GαMAP antibody; 6 = prestained protein marker broad range (NEB); 7 = elution 
fraction with PBS containing 500 mM imidazole. 
 
III.2.6 Mammalian expression system (HEK 293T cells) 
The feasibility of the HEK 293T mammalian expression system was evaluated for expression 
of human rsCD64. 
III.2.6.1 Construction of pMS-cd64 
The extracellular domain of the human receptor CD64 was cloned into the pMS vector for 
secretion into the culture supernatant of mammalian HEK 293T cells. The cloning strategy of 
pMS-cd64 is presented in Fig.III-18. Briefly, the cDNA fragment of 865 bp (III.2.4) was 
excised from the gel (Fig.III-15) and subcloned via SfiI and BlpI into the pMS vector (II.1.7.2; 
Fig.III-18). The construct was transformed by heat-shock into E.coli XL1-Blue (II.2.2.2). 
The resulting construct pMS-cd64, was checked for presence of the insert in a restriction 
digest with EcoRI. Subsequent sequencing analysis of one clone with the primer pMS-
5’/pMS-3’ (II.1.5) revealed the same one base replacement (T into G) at position 83 as 
discovered in pMT-cd64 (III.2.5.1). Sequencing additionally revealed a loss of 60 bp at the C-
terminal end of the pMS-cd64 construct. Thus one c-myc-sequence and the BlpI restriction 
site could not be detected. Restriction digest confirmed the loss of the BlpI restriction site (for 
final sequence see Appendix VII). HEK 293T cells were transfected with this pMS-cd64 
construct for expression into the culture supernatant (II.2.4.2). 
 
rsCD64 
degradation of rsCD64 
 
scFv 4813 
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Fig.III-18:  Schematic overview of cloning procedure of cd64 into pMS. pMS = mammalian expression 
vector derived from pSecTag2 (II.1.7.2); his6 = coding sequence of polyhistidine-tag for detection and 
purification of the recombinant protein; c-myc = coding sequence of c-myc-tag for detection of recombinant 
protein; eGFP = enhanced Green Fluorescent Protein; Igκ-leader = murine signal leader sequence for secretion 
of protein into culture supernatant; IRES = internal ribosomal entry site; IVS = synthetic intron for stabilization 
of mRNA; IL4-Ang = sequence of interleukine 4-Angeogenin; cd64 = DNA sequence of extracellular domain of 
CD64.  
 
III.2.6.2 Efficiency of rsCD64 expression in mammalian cells 
HEK 293T cells transfected with pMS-cd64 were cultured and production of recombinant 
protein was monitored by green fluorescence under the microscope. Culture supernatant was 
collected and 20 ml were purified via Ni2+NTA (II.2.5.1). Efficiency of rsCD64 expression 
was analysed by Westernblot analysis (Fig.III-19). 
 
Fig.III-19: Reduced Westernblot of purified rsCD64 from cell culture supernatant of transfected 
HEK 293T. Supernatant (20 ml) of transfected HEK 293T cells was purified with Ni2+NTA (II.2.5.1). Eluted 
rsCD64 was applied onto 12 % (w/v) SDS-PAGE and blotted onto nitrocellulose membrane. Detection was 
carried out with α-his antibody (1:5000) followed by secondary GαMAP antibody (1:5000; II.1.4) and subsequent 
chemiluminescence reaction. Lanes: 1 = prestained protein marker broad range (NEB); 2 = elution fraction with 
250 mM imidazole (II.2.5.1). 
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The Westernblot demonstrates clearly that rsCD64 can be expressed in mammalian cells. 
Approximately 20 µg rsCD64 were purified from 20 ml cell culture supernatant (Bradford 
result not shown), corresponding to ~1 mg/L. This translates in a productivity of 3 –15 
pg/cell/day using a overall cell number of 5•106 - 107 cells per culture flask in 50 ml media. 
III.2.7 Plant expression system (Nicotiana tabacum) 
Transient expression in N.tabacum leaves was performed to evaluate whether the plant 
expression system is feasible for the expression of human rsCD64. 
III.2.7.1 Construction of pTRA-cd64 
Expression in N.tabacum plant leaves was performed by cloning the extracellular domain of 
human CD64 into the pTRAkc vector. A schematic overview of the cloning steps is presented 
in Fig.III-20.  
Briefly, the vector pMS-cd64 was restricted with Sau3AI leading to 21 fragments of different 
sizes including one with the cd64 sequence (data not shown). The target fragment with the 
expected size of 835 bp was excised from the gel and purified (II.2.1.7). In parallel, the vector 
pTRA-ERH was digested with NotI and BstEII (II.2.1.9). For the fill-in of 5’ overhangs, the 
Klenow fragment was used (II.2.1.11) resulting in blunt ends of the insert and the digested 
vector.  
After dephosphorylation of the vector (II.2.1.10) and blunt-end ligation of vector and insert at 
the ratio of 1:8 (II.2.1.12), the ligation product was transformed into E.coli DH5α by heat-
shock (II.2.2.2). The resulting construct, termed pTRA-cd64fi (for fill-in), was checked for 
correct insertion in a restriction digest with PstI. The 5’ end of the insert contained the amino 
acids MVTITL instead of the original MAVITL due to the fill-in reaction.  
Additional subcloning was performed to obtain the 3’ end of the cd64 sequence in frame with 
the his-tag. pTRA-cd64fi was digested with EagI and AscI, the vector pTRAkc-ERH and 
pTRAkc-AH with the enzymes NotI and AscI. Restricted insert and vector DNA was purified 
(II.2.1.7), 5’ overhangs were filled-in with the Klenow fragment (II.2.1.11) and handled as 
described above. This cloning procedure resulted in the 3’ end EQKLISEEDRPAAHHHHH. 
Positive clones were detected in a control restriction with AscI and FseI and three clones per 
construct were additionally checked by sequencing. Complete DNA- and aminoacid-
sequences, respectively, are shown in the appendix (VII).  
pTRA-cd64(AH) and pTRA-cd64(ERH) were transformed into Agrobacteria by 
electroporation (II.2.3.2). Three recombinant colonies were screened for the presence of the 
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cDNA insert by PCR (II.2.1.3). A recombinant Agrobacteria culture was prepared from a 
single colony (II.2.3.3) and used for transient expression of N.tabacum leaves (II.2.3.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.III-20: Schematic overview for cloning cd64 into pTRA-ERH and pTRA-AH. pMS = mammalian 
expression vector derived from pSecTag2 (II.1.7.2); Igκ-leader = murin signal leader sequence for secretion of 
protein into culture supernatant; IRES = internal ribosomal entry site; IVS = synthetic intron for stabilization of 
mRNA; his6/c-myc = sequence for detection and purification of the recombinant protein; eGFP = enhanced 
Green Fluorescent Protein; pTRAkc-ERH/AH = plant expression vector derived from pPAM (II.1.7.3); LPH = 
codon optimised murine signal peptide of mAB24; MCS = multiple cloning site; SEKDL = ER retention signal; 
cd64 = DNA sequence of extracellular domain of CD64.  
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III.2.7.2 Efficiency of transient rsCD64 expression in N.tabacum 
Three N.tabacum leaves were transformed with pTRA-cd64(ERH) and pTRA-cd64(AH) by 
vacuum infiltration (II.2.3.4). Leave samples from each leave (Ø = 2 cm) were taken 3, 6 and 
9 days post infiltration (dpi), homogenised (II.2.3.4) and analysed by SDS-PAGE und 
Westernblot (data not shown). 
Highest rsCD64 expression was detected by Westernblot in 3 dpi leaves (data not shown), but 
the corresponding rsCD64 band was partially hidden by high amounts of ribulose-1,5-
biphosphatcarboxylase/oxygenase. Thus purification via Ni2+NTA was performed from 80g 
infiltrated leave material 3 dpi (II.2.5.1)] and purified rsCD64 was detected in Westernblots 
using anti-c-myc and anti-his (II.1.4) antibodies. Comparable expression level of rsCD64 
were determined in the apoplast and the ER of N.tabacum leaves (results not shown), one 
Westernblot of purified rsCD64 out of the ER [pTRA-cd64(ERH)] is presented as example in 
Fig.III-21. Secondary GαMAP antibody was used as a control (Fig.III-21, lane 2). 
                           
Fig.III-21: Westernblot of purified rsCD64 from 80 g homogenised N.tabacum leaves. Transformed 
N.tabacum leaves were homogenised 3 dpi (II.2.3.4) and cell debris were removed by centrifugation 
(30 min / 16000 g / 4 °C). Clear supernatant was purified via Ni2+NTA (II.2.5.1) and rsCD64 preparations were 
applied onto an 12 % (w/v) SDS-PAGE and blotted onto nitrocellulose membrane (II.2.7.2). RsCD64 
preparations were detected by α-his (1:5000) and α-c-myc (1:5000) antibody followed by secondary GαMAP 
antibody (1:5000; II.1.4). Lane 1, 3, 5 = prestained protein marker broad range (NEB) containing 0.2 µg of 
scFv4813 (28 kDa); 2 = elution fraction with 250 mM imidazole detected by GαMAP antibody; 4 = elution 
fraction with 250 mM imidazole detected by α-c-myc and GαMAP antibody; 6 = elution fraction with 250 mM 
imidazole detected by α-his and GαMAP antibody. 
 
The Westernblot (Fig. III-21) revealed an unspecific 30 kDa band which appeared after 
incubation with the secondary GαMAP antibody and a protein band of approximately 47 kDa 
that is specifically detected by anti-his and to a lesser degree with anti-c-myc antibody. 1 µg 
rsCD64 was recovered per gram leaf material from N.tabacum. 
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III.2.8 Summary of expression of rsCD64 in different expression systems 
Three different expression systems (bacterial: E.coli and eucaryotic: HEK 293T mammalian 
cells and N.tabacum plant leaves) were tested for their feasibility to produce the extracellular 
domain of the human high-affinity receptor FcγRI. The expression yield in [mg/kg] 
cells/leave material and [mg/L] culture is summarized in table III-1. 
construct host cell expression yield [mg/kg] expression yield [mg/L]
pMT-cd64 E.coli BL21(DE3)  0.04 0.0017 
pMS-cd64 HEK 293T - 1 
pTRA-cd64 N.tabacum leaves 1 - 
Table.III-1: Summary of expression yield of different expression systems 
 
Bacterial expression yielded lowest expression levels. Due to this, experiments of rsCD64 in 
E.coli were terminated.  
Comparing plant and mammalian expression, 1-L cell culture supernatant is easier to produce 
and handle than 1 kg plant material. Thus, the mammalian expression was scaled-up in order 
to purify sufficient rsCD64 for proof of IgG binding property. 
III.2.9 Initial characterisation of rsCD64 produced in HEK 293T cells 
One litre cell culture supernatant of HEK 293T cells was collected and purified. Progress of 
the Ni2+NTA purification of rsCD64 was monitored via SDS-PAGE (Fig.III-22A) and 
Westernblot (Fig.III-22B). 
  
                                    A                                                                          B 
Fig.III-22: SDS-PAGE (A) and reduced Westernblot (B) monitoring the Ni2+NTA purification of 
rsCD64 from 1-L culture supernatant of transfected HEK 293T (II.2.5.1). A = Coomassie stained 
NuPAGETM 4-12% (w/v) Tris-Bis gel. B = Westernblot using α-his mAb/GαMAP for detection. Lanes: 1 = cell 
culture supernatant, column load; 2 = flow through of non-bound material through Ni2+NTA column; 3 = 
washing fraction with 1x incubation buffer (II.2.5.1); 4 = prestained protein marker (SeeBlue Plus2, Invitrogen); 
5 – 10 = successive elution fraction with 250 mM imidazole (II.2.5.1). 
 
One mg rsCD64 was purified from 1 litre cell culture supernatant. Additional purification was 
carried out with IgG sepharose. The high affinity IgG sepharose 6 (FF) from Amersham 
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Biosciences contains coupled human IgG in random orientation and functional rsCD64 can 
bind to free Fc-parts. Batch purification (Fig.III-23) showed binding of Ni2+NTA eluates to 
the IgG-sepharose as the supernatant contained only marginal amounts of protein (Lane 3).  
                                         
Fig.III-23: SDS-PAGE monitoring the purification and concentration of rsCD64 by IgG sepharose. 
rsCD64 preparation after Ni2+NTA was subsequently purified via IgG sepharose (II.1.8) and concentrated in an 
ultrafiltration (10 kDa MWCO; PALL Filtron). Samples were applied on 4-12 % (w/v) Bis-Tris NuPAGETM gels 
and stained with Coomassie (II.2.7.2). Lanes: 1 = prestained protein marker (SeeBlue Plus2, Invitrogen); 2 = 
pooled and dialysed Ni2+NTA eluates; 3 = flow through of non-bound material through IgG sepharose column; 4 
= concentrated eluate from IgG sepharose. 
 
SPR (II.2.7.6) analysis revealed that all IgG binding activity was removed from the 
supernatant (data not shown). Concentrated functional rsCD64 was eluted from the matrix 
(Lane 4). However, purity of the rsCD64 did not increase significantly as shown by the 
presence of the same contaminating band at around 30 kDa in the elution (Lane 2 and 4). It 
can be speculated that the preparation contained contaminating human IgG due to leaking 
from the IgG sepharose and the initial Ni2+NTA elution may have contained bovine IgG from 
FCS, which was co-purified. Westernblots were performed to detect rsCD64 and to identify 
the contaminating proteins (Fig.III-24).  
9E10 (Lane 2), M22 (Lane 4) and Penta-his (Lane 6) antibodies were used to specifically 
detect rsCD64. Identification of the contaminating proteins was performed by using GαHAP 
specific for κ -chain and γ -chain in reducing (Lane 8 and 10) and non-reducing Westernblot 
(Lane 12 and 14).  
The Westernblot analysis revealed that the affinity-purified rsCD64 is intact and stable. In 
addition the major contaminants are identified to be human IgG/κ from the IgG sepharose, 
which assembled to fully human antibody of approximately 150 kDa as detected in the non-
reduced Westernblot.  
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Fig.III-24: Reduced (A) and non-reduced (B) Westernblot analysis of purified rsCD64 secreted into 
the supernatant of HEK 293T cells. rsCD64 was purified via Ni2+NTA, IgG-sepharose and subsequently 
concentrated by ultrafiltration with a 10kDa cut-off. Samples were applied onto an 4-12 % (w/v) Bis-Tris 
NuPAGETM gels and blotted onto nitrocellulose membrane (II.2.7.2). The rsCD64 was visualised by α-his 
(1:5000), α-c-myc (1:5000) or M22 (α-CD64; 1:500) primary antibodies and detected with GαMAP secondary 
antibodies (1:5000). To identify contaminating proteins detection with GαHAP secondary antibodies (γ- or κ-
chain specific; 1:5000) alone under reducing (A) and non-reducing conditions (B) was performed (II.1.4). Lanes: 
1, 3, 5, 7, 9, 11 and 13 = prestained protein marker (SeeBlue Plus2, Invitrogen); 2 = rsCD64 detected via α-c-
myc-antibody and GαMAP; 4 = rsCD64 detected via M22 (α-CD64) antibody and GαMAP; 6 = rsCD64 detected 
via α-his antibody and GαMAP; 8 = rsCD64 purification incubated with GaHAP (κ-chain specific) antibody; 10 = 
rsCD64 purification incubated with GaHAP (γ-chain specific) antibody; 12 = rsCD64 purification incubated with 
GaHAP (κ-chain specific) antibody; 14 = rsCD64 purification incubated with GaHAP (γ-chain specific) antibody. 
III.2.9.1 Binding activity of rsCD64 
Binding activity of purified rsCD64 to hIgG1/κ (CHO2F5), mIgG1/κ (anti-CA19.9) and 
humanised anti-CD64 IgG1/κ (H22) was determined by a direct ELISA (see Fig.III-25; 
II.1.4.1).  
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Fig.III-25: ELISA for determination of binding of different full-size antibodies to serially diluted 
coupled rsCD64. All samples were applied in duplicates (A+B).      = humanised anti-CD64 hIgG1/κ (H22); 
     = human hIgG1/κ (BY-22F5),      = murine IgG1 (anti-CA19.9). 
 
HIgG1/κ was specifically bound by coated rsCD64 whereas mIgG1/κ was not bound at all. 
H22 showed highest binding activity offering two binding sites to the coated rsCD64: the 
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paratope binding and the human Fc part. Data of binding activity was confirmed by SPR 
(II.2.7.6) analysis. The SPR assay was designed to monitor the direct interaction of rsCD64 
with human IgG1/κ cPIPP (Fig.III-26, done by M. Sack, BioVII, RWTH-Aachen). 
 
 
 
 
 
 
 
 
 
 
 
 
(*) Derived from the sensorgram using the equation MWrsCD64 = MWcPIPP * Rmax / RcPIPP 
 
Fig.III-26: Preliminary SPR (II.2.7.6) analysis of cPIPP-IgG1 and rsCD64 interaction. The anti-hCG 
mouse/human chimeric antibody cPIPP (IgG1/κ) was bound to immobilised hCG. Purified rsCD64 was injected 
for 4 minutes at a flow rate of 30 µl/min and dissociation was followed for 10 minutes. The binding curve was 
fitted using the Langmuir model for a simple monovalent interaction. kon = binding constant of rsCD64 binding 
to cPIPP-IgG1; koff = dissociation constant of releasing rsCD64 from cPIPP-IgG1; KD = relative binding affinity, 
equilibrium dissociation constant between rsCD64 and cPIPP-IgG1; RcPIPP = change of fraction index caused by 
binding of cPIPP-IgG1 onto previously coupled hCG onto the Biacore chip; Rmax = maximal change of fraction 
index caused by binding of rsCD64; MWcPIPP = Molecular weight of cPIPP-IgG1 antibody; MWCD64 = calculated 
molecular weight of rsCD64; cCD64 = estimated concentration of rsCD64 in the preparation; χ2 = quality 
parameter (Measurement and calculations made by M. Sack, BioVII, RWTH-Aachen.). 
 
First, anti-hCG cPIPP-IgG1 was bound to the immobilised hCG (II.1.4). RsCD64 was 
injected for analysis, i.e. to determine the active concentration and kinetic rate constants. 
Binding of rsCD64 to cPIPP was clearly demonstrated. Additionally affinity capture of 
cPIPP-IgG1 was stable and allows multiple analysis of rsCD64 binding, since rsCD64 was 
selectively eluted from the sensor surface without eluting cPIPP-IgG1.  
The on- and off-rate (Koff/Kon) of the binding and dissociation of rsCD64 was determined and 
the KD was calculated to be 2 nM. The RU-values of the IgG-cPIPP and rsCD64 and the 
known molecular weight of cPIPP were used to determine the molecular weight of 
glycosylated rsCD64 to be 45 kDa. Kinetic studies and the determination of parameters was 
performed by M. Sack (BioVII, RWTH-Aachen). 
III.2.9.2 Initial MS analysis of trypsin digested rsCD64 
MS analysis of the rsCD64 preparation was performed to get initial information about the 
glycosylation status. The rsCD64 preparation (III.2.6.2) was separated on an SDS-PAGE 
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(II.2.7.2) from visible contaminants (i.e. human κ-chain) and the protein band at 
approximately 50 kDa, containing rsCD64 and human heavy-chain, was digested with trypsin 
(II.2.7.8) and analysed in MS by M. Küpper (BioVII, RWTH Aachen; Fig: III-14).  
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Fig.III-27: Initial MS analysis of the heavy-chain of human anti-HIV antibody BY-22F5 (A) and 
rsCD64 preparation (B). RsCD64 was purified via Ni2+NTA, IgG-sepharose, concentrated by ultrafiltration 
with a 10 kDa cut-off and separated by SDS-PAGE (II.2.7.2). A 50 kDa protein band was excised and digested 
with trypsin prior to MS analysis (II.2.7.8). A = visualises the peak pattern of peptide fragments detected in the 
control samples containing human anti-HIV antibody BY-22F5; B = pattern of peptide fragments detected in the 
MS analysis of rsCD64 preparation. 
 
In the upper MS graph (Fig.III-27A) the peak pattern of the heavy-chain of hIgG                
(BY-22F5) is shown. The lower MS graph (Fig.III-27B) illustrates the distribution of different 
peptide fragments in the preparation of rsCD64. Several prominent peaks (labeled with blue 
asterisk) corresponding to human IgG1 heavy-chain can be seen, showing that bleeding of 
IgG1 from the sepharose matrix is a serious problem during the purification procedure of 
rsCD64. 
Additionally, MS/MS analysis was performed to verify the presence of rsCD64 in the 
preparation and the status of the N-glycosylation sites (data not shown). Five tryptic 
fragments of rsCD64 [T6 (GWLLLQVSSR), T7 (VFTEGEPLALR), T10 (LVYNVLYYR), 
T16 (YTSAGISVTVK) and T21 (NTSSEYQILTAR)] were unambiguously identified by 
MS/MS. One peptide containing an N-glycosylation motif (T21) was found without 
glycosylation. This demonstrates that this site is either not used at all or not always used for 
glycosylation. No other peptide containing an N-glycosylation motif has been found 
indicating that the other sites are utilised. 
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IV. Discussion 
Two human biopharmaceuticals were expressed in heterologous host systems and 
characterised in this thesis. 
Neutralising antibodies have shown therapeutic value in treatment of HIV infection 
(DESROSIERS et al. 1989). The human anti-HIV antibodies 2F5 and 2G12 produced in CHO 
cells were already tested in clinical phase I studies for mode of action (ARMBRUSTER et al. 
2002). However, large quantities are needed and plant produced antibodies have already been 
proven to be useful for production at reasonable costs (FISCHER(B) et al. 1999; STOGER et 
al. 2002; SCHILLBERG et al. 2003). Plant suspension cells offer additional advantages since 
suspension cells can be contained under GMP compliance and might be approved by the FDA 
(HELLWIG et al. 2004). Therefore, the capacity of the tobacco suspension cell line BY-2 was 
evaluated for production of human anti-HIV antibodies 2F5 and 2G12 in high amounts. The 
BY-22F5 antibody was purified out of 340 g BY-2 cell material at a concentration of 
3.2 mg/kg. Purity, integrity and assembly were proven and antigen binding property was 
comparable to the CHO produced control antibody. Established protocols from small-scale 
expression approaches were transferred to initial fermentation studies with the BY-22G12 
antibody. During  the fermentation process of 14 days intact and stable antibody was 
expressed. Subsequently a feasibility study with the BY-22F5 antibody in the 100-L scale was 
performed and available equipment was tested for application at industrial scale. Based on 
these results, a theoretical process was developed for the downstream processing of a 100-L 
fermentation broth of BY-2 derived anti-HIV antibody 2F5 in two days. 
The high affinity receptor for monomeric IgG, FcγRI, was extensively investigated for its 
potential as therapeutic target in tumor therapy such as acute leukaemia and its role in allergic 
reactions such as rheumatoid arthritis (van de WINKEL and CAPEL 1996). The 
understanding of the interaction of IgG and FcγRI is crucial for the treatment of Fc-mediated 
diseases and this understanding will be enhanced with the availability of soluble FcγRI for 
biochemical studies. For detailed characterisation of the IgG binding and biochemical 
properties in future experiments, the receptor was expressed in recombinant, soluble form. 
The feasibility of three well established expression systems was evaluated for the expression 
of rsCD64. Bacterial expression yielded lowest expression (40 ng/kg), transient expression in 
N.tabacum leaves resulted in 1 mg/kg rsCD64 and mammalian expression was the system of 
choice with 1 mg/L of rsCD64 which was purified in one-step from the culture supernatant. 
Thus, mammalian expression was scaled-up to yield sufficient purified protein for 
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characterisation studies of the protein. Initial kinetic analysis determined the dissociation 
equilibrium constant of rsCD64 (2 * 109M-1) to be in the same range as the KD value 
described in the literature (van de WINKEL and CAPEL 1996). This clearly demonstrates the 
functionality and binding activity of rsCD64.  
IV.1 Generation of the expression constructs 
IV.1.1 Anti-HIV antibody 2F5 
Cloning of the cDNAs of the heavy and light-chain genes in tandem into the binary vector 
pTRA for Agrobacterium mediated transformation was performed by M. Bomble (BOMBLE 
2004). 
IV.1.2 rsCD64 
The easiest way to obtain the cDNA of a human protein, is the isolation of the corresponding 
mRNA out of cells expressing the protein such as body fluids. The mRNA of FcγRI was 
successfully isolated from blood cells (III.2.4). Primer were designed according to the 
published sequence (ALLEN and SEED 1988, II.1.5) and protein specific RT-PCR was 
performed resulting in cDNA of the extracellular domain of FcγRI (I.1.2.2; III.2.4). Cloning 
was performed into the bacterial (pMT) and mammalian expression (pMS) vector (III.2.5) and 
the cd64 gene was verified by sequencing (VII), resulting in two different discoveries. Firstly, 
sequencing revealed a one nucleotide mutation resulting in an aminoacid change from leucine 
into arginine at position 83 in all constructs. As no polymorphism is described in the 
literature, allelic variation can only be speculated. Otherwise this exchange might be 
explained by a PCR error introduced by the Taq DNA-polymerase (Roche), which has a 
mutation rate of 1.3•10-5 (Roche, Technical information). Thus, subsequent PCR will be 
performed with a proof-reading polymerase to avoid this potential problem as it could lead to 
non-functional protein.  
Secondly, in the pMS-construct 3’ of the cd64 sequence 60 bp were missing (VII). This 
unexpected deletion of one c-myc-tag as well as the BlpI restriction site resulted in a pMS 
construct with c-myc and his-tag. This can only be explained as a result of homologous 
recombination by RecA (KO et al. 2002) in BL21(DE3) E.coli, the only E.coli strain 
containing the RecA protein. In spite of this deletion the sequence of cd64 with one c-myc-tag 
was still in frame downstream with the his-tag. Thus, this construct was used for further 
experiments. 
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For expression of rsCD64 in plant cells cd64 was subcloned into the plant expression vector 
(pTRA; III.2.6) by use of the restriction enzyme Sau3AI to avoid further PCR. Due to this 
restriction two amino acids at the 5’ of the cd64-sequence were lost (III.2.7.2).  
Expression of rsCD64 was tested in bacteria [BL21(DE3) E.coli], mammalian cells 
(HEK 293T cells) and N.tabacum. Evaluation of the expression yields in the different 
expression systems can only be an indication as the rsCD64 proteins are similiar but not 
identical. First the rsCD64 out of E.coli carries a N-terminal his10-tag and a C-terminal c-
myc, whereas rsCD64 from mammalian cells and plants contain the c-myc- and his6-tag at 
the C-terminus. The different leader sequences (pelB for E.coli and IgG kappa for 
mammalian and plant expression) are cleaved at different recognition sites resulting in 
different aminoacid overhangs. The probability of cleavage sites can be predicted using 
SignalIP V2.0 available on the Internet (http://www.cbs.dtu.dk). The pelB leader is most 
probably cleaved two amino acids upstream of the histidine-tag resulting in a 32-aminoacid 
overhang at the N-terminus. The Ig kappa leader in the pMS construct is cleaved seven amino 
acids upstream of the protein start codon. Only the plant expression vector pTRA was 
constructed in such a way that cleavage of the Ig kappa leader results in expression of the 
protein alone. 
Finally, at the C-terminal, the pMT-construct is terminated downstream the last amino acid of 
the myc-tag, the pMS-construct contains C-terminal five additional amino acids and the his6-
tag. The pTRA-construct contains four additional amino acids, the his6-tag and the SEKDEL-
tag. Therefore cd64 cDNA constructs yielding recombinant protein with different 
composition and molecular weights [E.colirsCD64 (942 bp = 35.6 kDa), 293TrsCD64 (899 bp = 
31.8 kDa) and NtrsCD64 (894 bp = 33.8 kDa)] were expressed. As an alternative for 
procaryotic expression the pET-26b(+) vector can be used as it contains a C-terminal his6-tag. 
Moreover, only completely translated recombinant proteins will be purified by Ni2+NTA. For 
mammalian expression, the expression cassette of the pTRA vector should be subcloned into 
the pMS plasmid, as all mammalian expression vectors commercially available and 
comparable with our system contain the same sequence downstream of the Ig kappa leader. 
As the aim of this thesis was to compare functional expression of rsCD64 in different 
established expression systems, the available systems were used.  
IV.2 Expression system E.coli 
Expression of problematic proteins in the presence of compatible solutes under osmotic stress 
was successfully performed in our institute (BARTH et al. 2000; TUR et al. 2003).  
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IV.2.1 Anti-HIV antibody 2F5 
Expression of aglycosylated full-size antibodies in E.coli was only described in one 
publication so far (SIMMONS et al. 2002). As the neutralising anti-HIV antibody 2F5 will be 
used in therapeutic approaches in the future and glycosylation contributes to the effector 
function of antibodies, expression in E.coli was not considered.  
IV.2.2 rsCD64 
Bacterial expression of rsCD64 was investigated under standard and osmotic stress conditions 
but both expression approaches resulted in minor amounts of recombinant protein. 
Approximately 40 ng rsCD64 were purified per gram bacterial pellet, corresponding to 1.7 µg 
per litre bacterial culture.  
This low expression yield can be caused by problems in protein translation in E.coli as the 
sequence of the human proteins contain codons that are infrequently used by bacteria. High-
level expression of a human gene causes depletion of the internal tRNA pool resulting in low 
or no expression. Certain codons for arginine, proline, isoleucine and leucine (SHARP and LI 
1987) are known to be problematic. In case of rsCD64, 31 amino acids are coded by rare 
codons. Especially, at position 227-231 an accumulation of rare codons for leucine and 
arginine can be found in the cd64 sequence. It can be speculated that truncation in the protein 
translation occurred and resulted in an rsCD64- with a size of approximately 28 kDa. 
Truncated proteins are purified as well by Ni2+NTA purification using the N-terminal his-tag 
and this can explain the second band on the Westernblot (III.2.5.2) below 30 kDa. 
To circumvent this, strains of E.coli, such as BL21-CodonPlus® (Stratagene), are available for 
AT- and GC-rich genomes which carry additional plasmids that encode and express these rare 
codons. Increase in production level of up to 100 times has been reported using these strains 
(KLEBER-JANKE and BECKER 2000).  
Another possibility is a codon optimisation of the gene of interest. A complete compilation of 
the codon usage for different organisms can be found in the GenBank database at 
http://www.kazusa.or.jp/codon/, where e.g. the probability of specific codons used by E.coli 
and human is calculated. All rare codons will be exchanged by more frequent ones and oligo 
nucleotides covering the whole gene are joined to a new optimised gene in a number of splice 
overlap extension (SOE) PCRs. However, the time- and labour-consuming procedure does 
not guarantee a better expression yield, as experiments with a human scFv have shown (own 
data, not shown). On  the other hand, in the literature some authors claim an increase of 
expression level up to 20 % (EJDEBACK et al. 1997) and 136-fold (TALARICO et al. 2001).  
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Even if rsCD64 is expressed, inclusion bodies can be formed or the protein itself is insoluble. 
In this case, the introduction of fusion tags can facilitate production of soluble proteins 
(NOVAGEN 2004) through the fusion partner who stabilises the protein and encourages the 
folding. Finally, expression can be enhanced by changing growth conditions, reduction of the 
temperature from 37 °C to 28 °C, feeding of complex media supplements to facilitate cell 
growth, and sufficient oxygen supply in order to avoid accumulation of stress signals to the 
cells.  
Conclusively, many improvements and optimisation procedures can be employed to enhance 
the accumulation level of recombinant proteins in the bacterial periplasm. However, as other 
expression systems are also available, it was decided that labour and time consuming 
optimisation procedures should not be undertaken. Additionally, aglycosylated FcγRI 
expressed in bacteria may not lead to functional binding to IgG. 
IV.3 Expression system N.tabacum 
The successful expression of different complex proteins was published by Fischer et al. in the 
recent years (FISCHER(C) et al. 1999; FISCHER(F) et al. 1999; VAQUERO et al. 1999; 
STOGER et al. 2000; KATHURIA et al. 2002). The use of an SEKDEL sequence is known 
to increase accumulation levels of recombinant protein (WANDELT et al. 1992; 
SCHOUTEN et al. 1996; CONRAD and FIEDLER 1998), whereas it has been shown for 
secreted antibodies that stability can be dramatically reduced in the plant cell culture media 
(SHARP and DORAN 2001; TSOI and DORAN 2002). 
IV.3.1 Anti-HIV antibody 2F5 in BY-2 cells 
Generation and cultivation of BY-2 cells expressing the BY-22F5 was done by Dr. T. 
Rademacher. Previous experiments with different constructs of BY-22F5 showed that the 
SEKDEL tagged BY-22F5 accumulated approximately 10 times higher than the secreted BY-
22F5 (3 – 4 mg/kg). This is consistent with publications describing 10 – 100 times 
enhancement of antibody accumulation (WANDELT et al. 1992; SCHOUTEN et al. 1996). 
Therefore experiments presented here were performed with the SEKDEL-construct and using 
Protein-A affinity chromatography 1.1 mg anti-HIV antibody BY-22F5 were purified from 340 
g fresh weight grown in shake flasks (0.92 mg/L).  
Only trace amounts of antibody were detected in the media supernatant (<1 %), which 
probably was released from damaged, or dead cells. Since the currently achieved 
accumulation levels for BY-22F5 are rather low and as all four chains of the assembled 
antibody exhibit a SEKDEL tag, it is not surprising that no secreted protein was detected.  
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Significantly higher accumulation has been obtained for the human mAb CL4 that is directed 
against HBV surface antigen (YANO et al. 2004). Although the antibody chains were not 
SEKDEL tagged, only between 36 – 63 % of the totally produced antibody was released into 
the culture medium. The maximal yields after Protein-A purification were 16.2 mg/L of 
suspension culture. Compared to the BY-22F5 antibody accumulation of approximately 1 mg/L, 
this represents a 16-fold increase. This may be due to the intrinsic properties of the variable 
domains of the 2F5 IgG1/κ antibody. Agrofiltration experiments of the N.t.2F5 resulted in 
significantly lower accumulation of N.t.2F5 (personal communication M. Sack) compared to 
other antibodies evaluated in our laboratory (up to 40 mg pure protein per kilo fresh leaf 
weight; KATHURIA et al. 2002). 
Different strategies have been described to enhance antibody accumulation levels in plants. 
Addition of various agents to the culture medium, such as inorganic compounds, amino acids, 
dimethylsulfoxide (DMSO), polyethylen glycol (PEG), polyvinylpyrrolidone (PVP), gelatin, 
bovine serum albumin (BSA), gibberellic acid, haemin and Brefeldin A were tested (SHARP 
and DORAN 2001; TSOI and DORAN 2002). Providing amino acids and haemin can 
enhance productivity through faster protein synthesis. The other substances are used for 
stabilisation of the recombinant protein probably by protecting the protein from degradation 
and preventing precipitation or adsorption to available surfaces. Additionally, media 
composition and culture parameters, such as inoculum level, pH, carbon and nitrogen source, 
NH4:NO3-ratio, can be optimised (CHATTOPADHYAY et al. 2002; GORRET et al. 2004). 
Process engineering aspects such as batch, fed-batch, repeated batch, continuous and 
perfusion fermentation, can also enhance accumulation level (KIERAN et al. 1997; 
HELLWIG et al. 2004). 
Even though accumulation of 2F5 in BY2 suspension cells was low, purification by single-
step Protein-A chromatography was very efficient leading to intact and pure antibody. Purity 
of the antibody preparation was enhanced by extensive dialysis as shown by SDS-PAGE and 
Westernblot (III.1.1). More importantly antigen binding activity of BY22F5 and CHO2F5 were 
indistinguishable by ELISA and EMSA (III.1.3). Only a high resolution single binding site 
SPR assay was able to reveal a lower activity of BY22F5 of approximately 9 % compared to 
the CHO2F5. This is probably due to the higher purity of CHO2F5 since minor amounts of 
degradation products of BY22F5 have been observed in over-developed Westernblots (data not 
shown). 
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IV.3.2 rsCD64 in N.tabacum leaves 
RsCD64 was sucessfully expressed in tobacco leaves and could be unambiguously detected 
with anti-his and to less extent with anti-c-myc-antibody. 1µg rsCD64 could be purified per 
gram leave material for both constructs. Expression of rsCD64 was performed using pTRA 
plasmids with and without C-terminal SEKDEL tag but our initial results have not shown any 
differences in the expression level of rsCD64 with and without SEKDEL tag in N.tabacum 
leaves.  
Experiments carried out in parallel in mammalian expression system lead to higher expression 
levels and since glycosylation pattern is closer to human, the validation of the mammalian 
expression was pursued. 
IV.4 Expression system mammalian cells 
Different complex proteins were successfully expressed into the culture supernatant of 
mammalian cells using the pMS-system (STOCKER et al. 2003; BRUELL 2004).  
IV.4.1 Anti-HIV antibody 2F5 
Highest specific productivity of CHO cells producing 2F5 was 22 µg/106cells/day (KUNERT 
et al. 2000) corresponding to 2.2 pg/cell/day. Based on own experiences this correlated to a 
production rate of approximately 1 mg/L (compared with results for rsCD64 III.2.6.2). 
Parallel expression with our established mammalian expression systems was not considered. 
IV.4.2 rsCD64 
Initial expression approaches of rsCD64 in HEK 293T cells succeeded with 1 mg/L of 
purified recombinant protein in a single-step purification out of 20 ml. Thus, the mammalian 
expression system was used to define a process for expression of rsCD64 in larger scale to 
yield sufficient protein (1 mg) for initial characterisation of the protein.  
One interesting aspect concerning FcγRI was the investigation of the glycosylation status. The 
sequence of FcγRI contains 7 potential N-glycosylation sites (ALLEN and SEED 1988), but it 
is not known which sites are naturally glycosylated and how this contributes to the functional 
activity of FcγRI. One study showed that genetic variations between individuals in the extent 
of FcγRIII glycosylation led to differential ligand binding (reviewed in van der POL et al. 
1998). The rsCD64 protein band on SDS-PAGE and Westernblot (III.2.6.2) was broad and 
diffuse probably probably reflecting the occupancy of different glycosylation sites. SPR 
(II.2.7.6) data revealed a molecular mass of 45 kDa (III.2.9.1). In general, glycosylated 
proteins are retarded in polyacrylamide gels, and our results showing a 55-kDa CD64-specific 
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band in the Westernblot confirm this. MS/MS analysis identified tryptic fragments of hFcγRI 
as well as of the human γ-chain (III.2.9.2). Mass spectrometry revealed on tryptic peptide 
containing a N-glycosylation site at position 219 in the third extracellular domain. It can be 
deduced that this site is not or not always used. As no other peptide was identified in the 
experiments, the other potential sites are glycosylated with high probability.  
Initial purification using Ni2+NTA matrix resulted in a co-purification of rsCD64 and a bovine 
antibody present in the fetal calf serum (III.2.6.2). There are no data addressing the binding of 
rsCD64 to bovine antibodies, but our results now suggest that this binding can occur. The use 
of IgG-Sepharose as a purification step failed due to the high leakage of bound human IgG 
from the matrix (III.2.9.1). The strong binding of monomeric antibodies during purification 
indicates a potential problem in recovering pure and active rsCD64, although the binding of 
rsCD64 to IgG-Sepharose did confirm the recombinant protein’s IgG-binding activity. The 
use of serum-free medium could improve the efficiency of purification by avoiding 
immunoglobulin contamination early on, and facilitating a one-step purification using Ni2+-
NTA resin by decreasing the production cost without the expensive FCS. 
Additional evidence for rsCD64 activity was provided by ELISA and SPR analysis (IV.4). 
Initial kinetic analysis determined the dissociation equilibrium constant of rsCD64                
(2 • 109M-1) to be in the same range as the KD value described in the literature (van de 
WINKEL and CAPEL 1996). This clearly demonstrates the functionality and binding activity 
of rsCD64 despite of the aminoacid change in the sequence.  
Data from the SPR (II.2.7.6) analysis revealed a simple stoichiometric interaction between 
rsCD64 and IgG. In theory, since IgG is a dimer, one IgG molecule can bind two Fc-receptor 
molecules, as was described for FcγRII (WOOF and BURTON 2004). In the case of FcγRIII, 
however, the binding of a second FcγRIII receptor molecule is prevented by steric hindrance 
(WOOF and BURTON 2004). This 1:1 stoichiometry was also predicted for FcγRI, since the 
IgG binding site in the hinge region is formed by both IgG heavy-chains (WOOF and 
BURTON 2004). From this work it was deduced that the purified rsCD64 preparation 
contained molecules that were either fully capable or fully incapable of binding to IgG, but 
none with intermediate binding activity. 
Some aspects of the mammalian expression itself have to be optimised in the future. One 
drawback of the system is the random integration of the plasmid DNA into the cell genome. 
Transient expression for research purposes offers fast results as only few days lay between the 
DNA delivery and protein harvest. But protein production under GMP conditions requires 
reproducible and stable expression conditions and can only be achieved with site-specific 
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integration. Enzymes, like P1 Cre recombinase, lambda phage integrase and yeast Flp 
recombinase catalyse the exchange at high frequency if the donor and recipient DNAs are 
flanked by specific attachment regions (WURM 2004). The Flp-InTM System e.g. using the 
Flp recombinase offered by Invitrogen can be combined with HEK 293T cells and is currently 
under investigation in our laboratory. As soon as the system is adapted, stability of clonal cell 
lines will be proved over extended periods of time (several weeks or months).  
Production of recombinant proteins in mammalian cell cultures is performed mainly in two 
formats today: cultures of adherent and suspension cultures. Cultivation of HEK 293T cells in 
CD 293 suspension media (Invitrogen) is currently under investigation. Preliminary 
bioreactor experiments with these cells did fail as cells did not grow as expected (personal 
communication D. Scheffler). Alternative procedures using CytodexTM 1 microcarrier 
(Amersham Biosciences) based on a cross-linked dextran matrix to cultivate adherent HEK 
293T in RPMI media are currently under investigation. 
Like media, host cells can be genetically improved. Proto-oncogenes, cell cycle control genes 
(cyclins), growth factor genes (e.g. insulin-like growth factor) and antiapoptotic genes have 
been inserted into cell lines for the generation of superior production hosts (ARDEN et al. 
2004). The implementation of strategies to control apoptosis and enhance culture 
productivities is also under investigation (ARDEN and BETENBAUGH 2004). Alternatively 
high-producer cell lines offer new perspectives, as the novel mammalian PER-C6 system, 
based on human retinal cells. For PER-C6 cells protein production of > 2 g/L in fed batch 
cultures was reported with corresponding viable cell densities of around 100 x 106 cells/ml 
(COCO-MARTIN 2004). 
Microbial systems are surpassed by mammalian cells cultivated in bioreactors for the 
production of clinical relevant products in number and titre (WURM 2004). Future 
developments will improve the productivity by stable DNA delivery and site-specific 
integration, extended selection and cell line screening, host cell engineering and medium 
optimisation. 
IV.5 Feasibility study: 100-L fermentation and downstream 
processing 
IV.5.1 Large-scale expression in the 100-L bioreactor 
Production of the BY-2 derived antibody 2F5 was scaled up from Erlenmeyer shake flasks to 
initial 7-L bioreactor approaches up to a feasibility study in a 100-L fermenter. The scale-up 
of a bioprocess itself is separated into three stages: (1) laboratory scale, where elementary 
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studies are carried out; (2) pilot scale, where the process optimisations are determined; and (3) 
plant scale of production, where the process is brought to economic results. In this thesis 
laboratory-scale data was determined and initial pilot-scale approaches were performed. 
The following criteria must be considered during scale-up: mass transfer of oxygen, 
mechanical stress on cells, degree of homogeneity and circulation time in the bioreactor 
(STORHAS 2003). Predictable problems occur in larger reactor volumes, such as reduced 
mass transport, enlarged mixing times, less oxygen and heat transfer, higher power input and 
aeration rates. Less predictable are the performance of product quality, foaming and the by-
product formation due to the altered conditions. It is impossible to keep all parameters 
constant during scale-up. The most frequently used criteria are constant specific power input 
(P/V), constant oxygen transfer (kLa), constant tip speed of the agitator and constant dissolved 
oxygen concentration (STORHAS 2003).  
Constant specific power input cannot be realised in general as this would result in highly 
reduced stirrer speed. Constant stirrer speed cannot be realised, as this would require immense 
power input with corresponding high mechanical stress to the cells. Agitation must provide 
good mixing time to minimize the variation of dissolved oxygen, pH and nutrient 
concentration gradients.  
For the scaling-up of an aerobic fermentation, the effect of gas liquid mass transport is the 
most significant factor (HENSIRISAK 1997). Therefore, scale-up in aerobic fermentation is 
often performed on the basis of keeping the value of kLa constant.  
The oxygen transport coefficient (kLa), describes the oxygen transfer from the air bubble into 
the fermentation broth. This can be calculated by the oxygen transfer rate (OTR):  
 
 
 
Fig.IV-1. Formula for determination of the oxygen transfer rate 
 
The driving force for oxygen transfer is given by the concentration difference of actual 
dissolved oxygen in the broth and in the air bubble [(cL* - cL)]. The area available for the 
transport [a] depends on the aeration rate and the size of air bubbles.  
For a given volume of gas, more interfacial area [a] is provided if the gas is dispersed into 
many small bubbles rather than a few large ones. Since the efficiency of oxygen transport is 
approximately proportional to the ratio of the bubble surface area to the bubble volume, the 
OTR = oxygen transfer rate 
kL =  oxygen transfer coefficient [cm·h-1] 
a =  gas – liquid specific area [cm2·cm-3] 
cL* = oxygen concentration inside the air bubble [mg·L-1] 
cL =  actual dissolved oxygen concentration 
         in the broth [mg·L-1]  
OTR = (kL·a) · (cL* - cL) 
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smaller size of micro bubbles increased oxygen transfer rate in the fermenter. In addition, 
smaller bubbles have a longer dwell time in the liquid because of their slower bubble-rise 
velocities allows more time for the oxygen to dissolve.  
Oxygen demand of plant cells with 0.2 - 0.6 mmol•g-1dw•h-1 (1 -3 mmol·L-1·h-1; TATICEK et 
al. 1991) is relatively low compared with 5 – 90 mmol·L-1·h-1 in bacterial cultures (PAIVA 
1999), thus fermentation with aeration below 0.3 vvm and slow stirrer speed is possible 
(HELLWIG 2000). However, with cell growth and increasing viscosity, oxygen transfer is 
becoming more and more inefficient, as a result of poor mixing and failure of air bubbles to 
disengage from the fermentation broth. Addition of antifoam can result in reduction of 
biomass attributed to a lower gas transfer rate, leading to a kLa value of up to 80 % lower with 
antifoam than without (TATICEK et al. 1991).  
Shear stress must also be taken into account in fermentation of plant suspension cells. BY-2 
suspension cells are more susceptible to shear stress than microbial cells because they are 
10 - 100 times larger in size (20 – 40 µm in diameter and 100 – 200 µm in length), and 
especially older cells are almost completely filled with the vacuole. Additionally, plant cells 
contain a cellulose-based cell wall with high tensile strength (TATICEK et al. 1991).  
As soon as elementary studies about the expression of the recombinant protein are finished 
the scale of expression can be enlarged. As the kla value was not determined for the anti-HIV 
antibodies in shake flasks, the first fermentations were performed on the experience of K. 
Schmale (BioVII, RWTH-Aachen and SCHMALE 2002), keeping the concentration of 
dissolved oxygen at 20 % (v/v) by aeration of 0.1 vvm with air. 
The first fermentation studies of an anti-HIV antibody were carried out with the BY-22G12 
construct (III.1.2.1). BY-2 fermentation without antifoam resulted in a maximum 
concentration of 7 mg/kg cells in the first 120 h of fermentation. Intact antibody was detected 
over the whole fermentation process (III.1.2.1). During fermentation without antifoam, 
growth of BY-2 cells on all available surfaces was investigated, as observed before 
(FISCHER(B) et al. 1999; HELLWIG et al. 2004) as well as growth in cell-aggregates. As 
excessive foam formation can lead to blocked filter and probes and pressure builds up in the 
reactor, addition of 0.01 % (v/v) Pluronic®L61 into the sterilised media was performed for 
subsequent fermentations. BY-2 cells grew more homogeneous afterwards, as observed under 
the microscope (data not shown) resulting in the same concentration of intact antibody per 
gram cells and reactor volume. The 7-L bioreactor with 100 rpm and 0.01 vvm aeration 
supplied sufficient oxygen into the media, as levels of dissolved oxygen did not drop below 
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1.5 % (v/v) and cells were not affected by shearing (control of cells under the microscope, 
data not shown). 
Due to these promising results, the BY-22F5 antibody was scaled-up to the 100-L scale. To 
reach sufficient number of cells for inoculation, one 7-L fermentation was carried out. 
However, this seed fermentation showed differences to the 7-L fermentation of the BY-22G12 
before (data not shown). Cell growth stopped after 150 h as the carbon source was depleted 
(in difference to the BY-22G12 fermentation, where cells did grow for 300 h). Perhaps, 
continuous sampling of the fermenter did reduce the overall amount under a critical value. As 
soon as new media was added cell-growth started again and predicted PCV values of 50 % 
(v/v) were reached. The complete 7-L fermenter was used as inoculum for the 100-L 
bioreactor. 
The 140-L pilot bioreactor could not be equally equipped as the 7-L fermenter, because 
marine impeller stirrer and a sinter disc did not exist for this reactor at this time point. 
Therefore, three six-bladed Rushton impeller and a sparger were adjusted into the bioreactor. 
To avoid as much shear stress as possible, baffles were removed and the stirrer was operated 
at 50 rpm. It was taken into account that reduced stirrer speed results in longer circulation 
times and less effective mass and heat transfer. 
Stirrer speed of 50 rpm resulted in bubbles of up to 2 cm in diameter. If the impeller speed is 
to slow, the bubbles will not be broken down and will tend to rise directly to the surface due 
to their buoyancy. The fermentation broth before inoculation showed flooded impeller. Under 
these conditions, the bubbles accumulated and coalesced additionally under the impeller, 
leading to the formation of large bubbles and poor oxygen transfer rate. A similar 
phenomenon can be observed when the aeration rate is too high, but this can never be 
achieved in up scaling (STORHAS 1994). 
The media density increased after inoculation, thus the stirrer speed resulted in better mixing 
of the solution, but a dispersion of the air bubbles could not be achieved. Aeration was set 
from 0.1 to 0.2 vvm, however the metabolic oxygen demand could not be satisfied for more 
than 150 h, when levels of dissolved oxygen dropped below 1 % (v/v). After 180 h of 
fermentation, oxygen limitation started with 0 % (v/v) dissolved oxygen measured in the 
media. Oxygen supply of 0.2 vvm air was maintained for the whole process, but the amount 
of oxygen supplied into the media was immediately used leading to areas in the bioreactor 
with anaerobic conditions.  
In plants, a major route of ATP production under anaerobic conditions is ethanol fermentation 
(TADEGE et al. 1999). Lactic acid and ethanol fermentation was investigated in plant cell 
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fermentation under prolonged periods of anoxia (FARRES and KALLIO 2002). In a twelve-
day fermentation of SR1-derived tobacco suspension culture expressing haemoglobin, ethanol 
level in the extracellular media reached up to 200 mg/L after 8 days, whereas the lactate 
production in the cell cytoplasm was around 1 µg/mg of dry weight. The concentrations of 
ethanol produced by plant cells under anoxia are insufficient to cause toxicity (reviewed in 
SOUSA and SODEK 2002). Lactate on the other hand is frequently associated with 
acidification of the cytosol and acidic pH is known to reduce antigen-binding activity 
(CASTLE et al. 2002) and to cause irreversible precipitation (JISKOOT et al. 1990). This can 
explain the high rate of degraded antibody in the 100-L fermentation. 
If the oxygen level drops below the critical value of 1 – 2 % (v/v; SCHMALE 2002), oxygen 
consumption rate decreases with concomitant decrease in biochemical energy production, and 
as a result the cell growth rate also decreases (STORHAS 1994). For E.coli it is reported that 
limitation of oxygen supply reduced the cell viability since extra energy is required for 
plasmid synthesis and protein synthesis. On the other hand, at higher aeration rates, the 
recombinant strain showed highest growth rate, but low expression of recombinant protein 
(CHAVES et al. 1999). To our surprise, cell growth in the 100-L fermenter was not affected 
by this oxygen limitation.  
IV.5.2 Downstream processing of 100-L fermentation broth 
The downstream processing is the major time and volumetric bottleneck in the 
biopharmaceutical production process (FROST&SULLIVAN(A) 2004). The complete 
downstream processing of therapeutic proteins, including the downstream processing itself 
but also all necessary quality control checks to ensure product quality and prevent 
contamination, can last four to eight weeks (FROST&SULLIVAN(A) 2003). Thus, 
downstream processing is the highest cost in biopharmaceutical production (approximately 
40 %; FROST&SULLIVAN(A) 2004). As the industry is heading to a situation of prolonged 
overcapacity in the manufacturing sector starting 2003, with the highest gap between supplied 
and needed capacity for 2005 and 2006 (FROST&SULLIVAN(B) 2004), fees for contract 
manufacturing are expected to fall at least 25 % over the next three years 
(FROST&SULLIVAN(A) 2003). Thus the production process must be highly standardized. 
To achieve greater volumetric throughput, increasing investment in automated systems must 
be undertaken which additionally reduces human resources, process development costs and 
increases the yield (FROST&SULLIVAN(A) 2004). The purification process of recombinant 
proteins depends on the protein itself and the source of the protein. Some aspects concerning 
purification of recombinant antibodies from plant-extracts were already investigated such as 
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the application of Protein-A, which can be used in a similar manner as in purification from 
ascites or hybridoma supernatants (FISCHER(D) et al. 1999). Based on this, a purification 
protocol for the human anti-HIV antibody BY-22F5 was established in small-scale from 1.2-L 
BY-2 cell suspension culture (III.1.1). Up scaling of the production volume to the fermenter 
scale is possible using special equipment for handling bulk quantities.  
The aim of this downstream processing approach was to evaluate the existing equipment in 
respect to carrying out a process procedure of a 100-L fermentation in two days. 
IV.5.2.1 Strategies to harvest cells from fermentation broth 
Initial recovery of intracellular proteins can be done by separation of the biomass from the 
fermentation broth in centrifugation or filtration steps. Centrifugal separation is performed by 
two different types of centrifuges: disc-stack and tubular bowl centrifuges 
(FROST&SULLIVAN(B) 1999). As a result of different mechanism (rotating bowl versus 
rotating discs) the solids collected from the tubular centrifuge contain less water (LANGER 
2004). Tubular centrifuges are available from Alfa Laval (AS16-VB) and CARR (Powerfuge 
P12). The CARR Powerfuge can be operated with 20,000 g with a maximum flow rate of 500 
litres per hour and solids can be removed in an automated scraping cycle. Disc centrifuges can 
be purchased from Alfa Laval (BTP 205) and Westfalia (CSA 8), with maximum liquid 
capacities of 1,300 and 1,000 litres respectively (LANGER 2004). 
For the filtration of fermentation broth, sufficient surface area must be provided. Thus filter 
membranes are packed in plate and frame stacks or Hollow Fibers. Manufacturers, such as 
Millipore, Pall, Amersham Biosciences and Sartorius offer a wide range of different 
membrane types (FROST&SULLIVAN(A) 1999). Hollow Fiber Systems are offered e.g. by 
Amersham Biosciences (GrandStand pilot) providing 30 litres per minute in cross-flow. A 
tangential flow filtration system e.g. from Millipore (ProFlux M 30 model) is supplied with 
Hollow fiber cartridges or flat membrane modules delivering up to 60 litre per minute. Plate 
and frame systems are provided by Pall (Centrasette 5 model) with 126 litre per hour and 
Sartorius (Sartoflow 20) with 150 litre per minute. Depth filters as single use disposables are 
offered e.g. by Sartorius (Sartoclear P) as capsules and modules in different sizes with 
different retention capacities (TARRACH 2004). The use of disposables has some 
advantages, such as reducing capital budget, less risk of cross-contamination and speeding of 
construction and production time (LANGER 2004). Flexibility is improved and process 
implementation times are shorter. Reduced labour (no cleaning/validation of cleaning and no 
chemicals for cleaning) and smaller space requirements must also be noted. On the other hand 
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time must be invested to test the biological and chemical compatibility of the disposables and 
the material costs per batch are rising.  
IV.5.2.2 Initial cell harvest 
The first step in the purification process is the separation of the biomass from its surrounding 
broth. Since the protein of interest is secreted into the culture supernatant, cell material can be 
discarded. However, more often the protein is expressed within the cell and must be released, 
as it was the case for the BY-22F5 construct. 
As we decided to use the CARR Powerfuge for the separation of the cell debris after cell 
disruption (see Fig.III-9), this centrifuge could not be used for the cell harvesting due to time 
limitations. Initial time calculations for the 100-L purification with the available equipment, 
led to the decision to process the fermentation broth in two batches. It was decided to harvest 
the first batch discontinuously, taken 5-L samples from the 100-L fermenter and separate the 
cells from the fermentation broth by vacuum filtration. Resuspension into appropriate buffer 
was performed with 1 kg biomass samples. 
The sampling in 5-L buckets, the vacuum filtration with Miracloth membrane and the 
homogenisation of the pellet in 5-L buckets was time- and man-power consuming but could 
be finished after almost three hours. For larger volumes, continuous harvesting and cell 
disruption should be the aim. 
In conclusion: The CARR Powerfuge available at the institute can be used for initial harvest 
of BY-2 cells out of the fermentation broth. For taking continuous samples the fermenter must 
be connected to the Powerfuge.  
IV.5.2.3 Strategies for cell disruption 
Cell disruption methods can be divided into mechanical methods, such as sonication, French 
Press, Homogeniser and Ball mills and non-mechanical methods, like chelating or chaotropic 
agents, detergents, alkaline and enzymes (LANGER 2004). Wet (ball) milling is an efficient 
method, but heat is generated and especially in case of plant cells, wet milling can result in 
lysis of subcellular organelles, liberation of noxious chemicals (alkaloids, phenolics) and 
generation of fine cell debris, which are difficult to remove (SCHILLBERG et al. 2003). 
Sonication is the method of choice for small-scale purification, but wet milling and sonication 
are difficult to scale-up (HELLWIG et al. 2004). Ultrasonic industrial devices are offered by 
Hielscher (Teltow, Germany) with up to 16,000 Watts and a frequency of 20 kHz for 
industrial scale cell disruption. In a French Press cells can be opened efficiently, but the 
French Press (Microfluidizer M-110H) available at the institute can be operated for longer 
time periods only with diluted solutions thus enlarging the volume. The M-110H 
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Microfluidizer allows flow rates up to 450 ml/min with up to 1700 bar and contains a product 
heat exchanger, as well as automated CIP (clean in place) and SIP (steam in place) 
equipment in compliance with GMP-regulations. Constant cell disruption by high pressure 
can be achieved additionally e.g. by the B&C Series of Constant Systems Ltd (Low March, 
UK). The GMP model is equipped with drain ports to allow CIP and SIP with flow rates up to 
1.1 L/min at 1000 bar.  
Partial digestion of plant cells was already performed with technical grade pectinase 
(FISCHER(F) et al. 1999). This method can be used for plant-expressed proteins, which are 
retained in the plant cell wall. For ER retarded protein, like the BY-22F5 construct, the cells 
must be disrupted completely. Therefore use of chelating/chaotropic agents and 
alkaline/detergents is not applicable.  
IV.5.2.4 Cell disruption  
For the disruption of BY-2 cells the French Press (Microfluidizer) was used. As investigated 
prior to the large-scale purification, cell disruption at low pressure (150 bar) was sufficient for 
complete release of the recombinant protein (evaluated in the SPR (II.2.7.6), data not shown). 
Higher pressures disrupted the cells into fine cell fragments enhancing the solubilisation of 
fibers and cell wall substances. This increased the viscosity of the homogenate and 
membranes were plugged more easily. Additionally, the solved fibers could not be removed 
with conventional centrifugation steps (data not shown).  
In practise, cell disruption of 40-L in the French Press at low pressures did not work as 
expected since the pressure chamber plugged and had to be manually removed and reversal 
adjusted frequently. Thus the cell pellet was diluted in higher buffer volumes resulting in 
larger volume of homogenate containing more solved fibers than anticipated. 
In conclusion: Different instruments must be tested for their feasibility using plant cells in 
small-scale experiments. Theoretically, the ultrasonic device by Hielscher, the M-110H 
Microfluidizer and the Constant Cell Disruption model by Constant Systems Ltd. seem to be 
applicable. 
IV.5.2.5 Strategies for protein separation and purification 
Separation and purification of the product can be achieved by filtration and chromatography. 
With appropriate membrane devices, the homogenate can be clarified in a tangential flow or 
dead-end filtration (DESAI 2000). For removal of cell debris different companies, like 
Millipore, Pall and Sartorius offer membranes with different pore sizes 
(FROST&SULLIVAN(A) 2004). Disposable single-use capsules by Sartorius can be 
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implemented e.g. for cross-flow filtration (MEYEROLTMANNS 2004), to reduce personal 
costs and enhance the reproducibility.  
Adsorption of the protein to chromatography matrices is performed commonly with three 
types of functional compounds: charged, hydrophobic and affinity. Charged groups are 
divided into two groups: anionic and cationic. Anion exchange (AEX) chromatography can 
be used to capture DNA and impurities (DIERKS 2005). Cation ion exchange (CIEX) 
chromatography, e.g. at pH 5 captures 99 % of different antibodies to the column (DIERKS 
2005). In expanded bed adsorption (EBA), the bed expands through the flow of the feed from 
below, increasing the interstitial spaces among the beads. Thus cruder samples can be applied. 
Genentech has developed an EBA approach, which can purify hybridoma supernatant in a 
single step (LANGER 2004). Resins with the dynamic capacity to allow protein adsorption at 
a high flow rate and short residence time are available from Amersham Pharmacia 
(STREAMLINETM media) and Ciphergen (Hyper Z) with different functional groups serving 
as cation/anion exchanger coupled with Protein-A (LANGER 2004). Clarification, 
concentration and initial purification of proteins from cell extracts or plant cell fermentation 
broth has been performed with the STREAMLINETM by Amersham Biosciences (BAI and 
GLATZ 2003). Initial trials of loading the BY-2 homogenate after the French Press directly to 
the STREAMLINETM-EBA column failed, as the expanded bed was slugged out after a while. 
However, binding of recombinant antibody could be determined by SPR (II.2.7.6, data not 
shown). It can be speculated that different cell disruption methods result in less viscous 
homogenates which can be applied onto the STREAMLINETM.  
In hydrophobic interaction chromatography (HIC) hydrophobic compounds such as methyl, 
ethyl, isopropyl, n-butyl and phenyl are used for capturing of e.g. the hydrophobic Fc part of 
antibodies. This can be implemented as last purification step where the antibody is in the flow 
through but aggregates bind (DIERKS 2005).  
Affinity chromatography uses ligands, which specifically bind the protein of interest. For 
purification of recombinant antibodies Protein-A matrices are applicable, e.g. Mab-Select by 
Amersham Pharmacia (DIERKS 2005), BioSEPRA Protein-A Ceramic HYPERD F by 
Ciphergen, Prosep-A Protein-A by Millipore and Styros-rA by Orachrom.Inc.. New emerging 
alternatives include membrane affinity chromatography by Sepracor Inc. (Trio Bioprocessing 
System), which build a Hollow fiber membrane (FROST&SULLIVAN(A) 2004). Membranes 
are thinner than chromatography column beds, thus the separation can be processed more 
rapidly. Since Protein-A resins are costly and require extensive cleaning and Protein-A cannot 
be used for purification of human IgG3, companies such as BioInvent International AB 
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(Lund, Sweden) and Medimmune (Gaithersburg, MD), have optimised the use of ion 
exchange and hydrophobic chromatography for protein-specific purification (LANGER 
2004).  
IV.5.2.6 Product separation and purification 
The separation of cell debris from the initial 100-L fermentation was performed using the 
CARR Powerfuge in 2 h (with cleaning cycles). Higher rotation speed of the bowl may 
remove even smaller particles, since centrifugation with 10,000 g in the laboratory scale 
centrifuges resulted in a better separation and clearer supernatant (data not shown). For larger 
quantities, equipment for continuous separation can be connected.  
For fine clarification of the supernatant, a Hollow Fiber Unit with a cut-off of 500kDa was 
used. Supernatant was applied with 30 -35 ml/min leading to over-night-recirculation of the 
preparation. The Hollow Fiber unit did no plug, but was unable to separate the remaining 
fibers and cloudy substances from the protein of interest [antibody was detected via SPR 
(II.2.7.6) in the retentate instead of the filtrate (data not shown)]. This can be explained by 
aggregation of antibody or adsorption to fiber particles, resulting in particles with a size larger 
than 500 kDa. Conclusively, increased volumes can be handled with larger Hollow Fiber 
Units but experiments with intact antibody preparations must be repeated before. 
Affinity chromatography of plant extracts on a Protein-A medium was successfully applied 
for removal of contaminants and 100-fold concentration of the protein (FISCHER(F) et al. 
1999). For selective capturing of the human anti-HIV antibody BY-22F5, BioSEPRA Protein-A 
Ceramic HYPERD F matrix was evaluated initially in small-scale experiments (III.1.1). Two-
L clear supernatant were applied onto a XK 26/20 column packed with 10 ml Protein-A with 
10 ml/min. For larger volumes the amount of Protein-A matrix can be increased, allowing 
higher flow rates. 
Protein recovery was 50 % after Protein-A in contrast to the small-scale column, where 84 % 
were eluted from the matrix (III.1.2.3). Since all washing elution were tested (data not shown) 
and the flow-through did not include detectable amounts of antibody, the only explanation is, 
that the antibody still bound to the column or that elution with buffer at pH 2 denatured the 
antibody. The elution and subsequent pH shift to pH 4.5 with 1 M unbuffered sodium acetate 
was optimised in small-scale experiments (data not shown). But Westernblot analysis of the 
fermentation broth revealed only degraded antibody fragments. It can be speculated that these 
fragments were more susceptible to pH-shift and were denatured by elution with pH 2. 
In conclusion: Loading the STREAMLINETM from Amersham Biosciences with crude extract 
or preclarified supernatant is the fastest way of purifying BY-22F5. Depending on the 
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isoelectric point of the protein of interest, cation or anion exchange matrices can be used. 
Alternatively, STREAMLINETM adsorbent coated with Protein-A (STREAMLINETM 
rProteinA) might be an alternative (THOMMES et al. 1996). 
IV.5.2.7 Polishing step 
Subsequent size exclusion chromatography (gel filtration) can be used as polishing step to 
remove antibody dimers and higher aggregates, as successfully performed for a full-size IgG 
by Fischer et al. [(F) 1999].  
In general, viral contamination must be removed in additional steps by inactivation (heat, 
irradiation; DIERKS 2005) or ultrafiltration. One of the advantages in using plant cells is that 
plants do not harbour human pathogens (GIDDINGS et al. 2000). However, plant-derived 
biopharmaceuticals can contain biologically active plant metabolites or alkaloids (e.g. 
nicotine), plant macrometabolites (extraneous proteins, DNA, polysaccharides and lipids) and 
in case of whole plants additionally pesticides and herbicides (MIELE 1997). 
Heat inactivation cannot be performed in most cases due to heat sensitivity of the protein of 
interest. UV-irradiation is a method commonly used in the food processing industry. Three 
different technologies can be used to irradiate food including gamma irradiation, electron 
beam (E-Beam) irradiation and X-ray irradiation. Companies such as Gray*Star, Inc., 
GUARDION and MDS Nordion offer irradiation equipment (FROST&SULLIVAN 2005).  
Sartobind single-use modules (Sartorius; FISCHER-FRÜHHOLZ 2004) were developed for 
the removal of peptides, DNA, endotoxins, viruses and proteins. Sartorius also offers a 
concept for inactivation and removal of viruses and other contaminations by a combination of 
virus retentive membranes, viral inactivation by UV-irradiation and membrane adsorber 
(REIF 2004). 
Final polishing steps will include thermal processing such as drying of the product with 
different dryer types (e.g. vacuum rotary dryer or fluidised bed drying; 
FROST&SULLIVAN(A) 2000) or protein crystallization (Bayer Technology Services; 
FROST&SULLIVAN(A) 2004) to improve stability and purity of the recombinant protein. 
IV.6 Outlook BY-22F5 and large-scale fermentation/purification 
Conclusively, BY-2 suspension cultures can be used to obtain intact and highly active human 
full-size antibody in a few months for detailed studies. The antibody yield in BY-2 cells is 
comparable to the published antibody levels in CHO cells. However, until now, there are no 
FDA-approved plant recombinant antibodies on the market and there might be considerable 
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consumer resistance. The safety of plant derived recombinant proteins, concerning the 
glycosylation pattern must be extensively proven before this antibody can enter clinical trials. 
Initial fermentation of BY-2 cells expressing the BY-22F5 human anti-HIV antibody was 
performed in a 100-L scale. BY-2 cells were successfully grown in the 100-L fermenter but 
the heavy and light chain of the BY-22F5 antibody were degraded during the fermentation 
process. First demand for scale-up into the 100-L bioreactor is the appropriate equipment, as a 
marine impeller stirrer and a sinter disc. This will provide sufficient oxygen transfer at least at 
the fermentation start into the medium and reduces the shear stress onto the cells. Scale-up 
parameters can be calculated since bioreactor design is maintained. 
However, the BY-2F5 antibody yield must be increased dramatically to justify a scale-up into a 
100-L bioreactor. Production of TMV-specific recombinant full-size antibody in plant cells 
yielded 15 mg/kg wet cell weight purified out of 1 kg BY-2 cells (FISCHER(F) et al. 1999). 
Highest yield of BY-22F5 antibody was 3.2 mg/kg in the small-scale purification (III.1.1). 
Additionally, the level of TMV-specific recombinant antibody was transiently increased 
threefold by supplementation of essential and non-essential amino acids (FISCHER(F) et al. 
1999). To investigate the effects of oxygen limitation and amino acid supplementation onto 
BY-2 cells expressing the 2F5 antibody, three additional 5-L fermentations were carried out 
(data no shown). One fermenter was operated with unlimited oxygen and two with forced 
oxygen limitation after 120 h at a PCV of approximately 30 %(v/v). One of the oxygen 
limited fermentations was fed with 2.7 g/L casamino-acids after 120 h. Cell growth measured 
in PCV and FW was faster in the non-limited fermentation, reaching 60 % (v/v) PCV after 
240 h with oxygen in contrast to 40 % (v/v) with limitation. Unlimited oxygen did not result 
in higher antibody yield and the degree of degradation was not tested. The amino acid feed 
seemed to have a stabilizing effect on the intracellular antibody, but these experiments have to 
be repeated. 
Conclusively, the expression level of BY-22F5 antibody in BY-2 cells is not sufficient to repeat 
fermentation studies on a large scale. But the 100-L fermentation trial revealed important 
information to optimise the procedure of BY-2 cultivation in large-scale bioreactors.  
With information from the large-scale purification employing the available equipment and 
taking data from the literature into considerations, suggestions can be made which equipment 
might be suitable to enable a 100-L downstream processing of BY-2 cells harbouring BY-22F5 
antibody in two days. The following schematic overview shows a selection of basic units. 
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DSP step Instrument company flow [ml/min] duration [h]
Cell harvest Powerfuge Carr 300-500 3 ½ - 6 h
Cell disruption Ultrasonication Hielscher ? ?
M-110H Microfluidics 450 4 h
Constant cell disruption Constant Systems Ltd. 1100 1 ½ h
Protein Purification Streamline 200 Amersham Biosciences feed application
1050 - 2100 ¾ - 1½ h
elution sedimented bed
270 - 785 < 1 h   
The eluted volume varies between 4.7 and 9.4 L. As prerequisite, cell disruption must be 
tested and optimised with different equipment to choose a useful device. Downstream 
processing of 100-L might be possible with this equipment in two days in compliance with 
GMP requests. 
IV.7 Outlook rsCD64 
Comparison of three different systems (E.coli, Mammalian HEK 293T cells and N.tabacum 
leaves) for the expression of functional rsCd64 revealed the mammalian expression system as 
the system of choice to produce functional protein at levels of 1 mg/L. 
Successful expression of functional rsCD64 opens many perspectives for biochemical 
characterisation and analytical applications. Physiochemical analysis of the IgG-FcγRI 
interaction will be possible as well as the identification of the binding site of anti-CD64 
antibodies outside the IgG binding site. The property of the unique high-affinity binding to 
monomeric IgG may be revealed and structure determination by crystallization of the soluble 
receptor will be possible.  
A first step towards crystallization is the removal of glycosylation sites through the 
construction of deletion mutants. Expression levels of deletion constructs will provide more 
information about the need of all three domains for the high affinity binding. Rational protein 
design can guide in the construction of rsCD64 with irreducible size and unchanged or even 
enhanced binding affinity. It can be speculated that smaller constructs are expressed at higher 
levels. To further enhance the expression, hydrophobic amino acids will be removed at the C-
terminus. The point mutation at position 83 (leucine to arginine) changes a hydrophobic 
amino acid into a basic one. It can be speculated, that this amino acid change contributes to 
the expression of rsCD64, since nobody has succeeded in the expression of soluble CD64 so 
far. 
Analytical applications can be found primarily in fields where Protein-A/G is currently used.  
Protein-A, G and FcγRI bind to the Fc part of human IgG. Protein-A is a 43kDa protein, 
isolated from Staphylococcus aureaus and Protein-G, a 35kDa protein is isolated from 
Streptococcus sp.. Both react with a large number of IgG isotypes. Protein-A binds human 
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IgG1, 2 and 4 with high affinity, whereas Protein-G strongly binds additionally to human 
IgG3. FcγRI binds to human IgG3, 1 and 4 with high affinity. Binding sites are different, thus 
FcγRI does not compete with Protein-A for binding to IgG1 (WINES et al. 2000).  
Purification of recombinant antibodies is performed in general by Protein-A due to its high 
specificity and strong binding to the Fc part of immunoglobulins (DIERKS 2005). The 
equilibrium constant for Protein-G and Protein-A was determined to 1.13•108 M-1 and 2.9•107 
M-1 respectively (SAHA et al. 2003). The kinetics of association and dissociation of human 
IgG1 to FcγRI on U937 cells was investigated with a 125IgG1 monomer (SHOPES 1995). At 
37 °C, the association constant was determined to 2.7•105 M-1 and the dissociation rate to 
4.5•10-4s-1. The association and dissociation rate of rsCD64 to human IgG1 was determined in 
the SPR (II.2.7.6) analysis to comparable concentrations (kon = 1.5•105 M-1, koff = 3•10-4s-1). 
The resulting equilibrium constant was calculated to be 2•109 M-1. Thus rsCD64 shows 
comparable binding kinetics to human IgG1 as the membrane anchored receptor. Secondly, 
this binding affinity is 10 times stronger than binding to Protein-G and 100 times stronger 
than binding to Protein-A.  
Bulk quantities of rsCD64 might replace Protein-A as the major substance for purification of 
recombinant antibodies. Stronger binding will lead to even more specific separation.  
Other application may benefit from the oriented binding of full-size antibodies. This allows 
direct investigation of the functional activity of different full-size antibodies by binding of the 
target antigen, e.g. in SPR (II.2.7.6) analysis. Interaction properties with the target antigen 
could be investigated in detail. For in-vitro diagnostics, applications like the detection of low 
abundant antigens are imaginable. Interaction properties with the target antigen can be 
investigated in detail. This might also be interesting for in-vivo imaging by directed 
immobilization of disease-related full-length antibodies to rsCD64 conjugated to optically 
detectable labels. 
IV.8 Outlook FcγRI and HIV 
Cells of the monocyte/macrophage lineage exert crucial functions in innate immune response 
as well as in inducing and regulating cognate immunity against infectious agents. 
Macrophages can, however, be infected with any of several pathogens, including parasites, 
bacteria and viruses. In particular, macrophages are one major target of HIV-1. According to 
several studies, macrophages participate in initial transmission of HIV-1, in virus-spreading 
and cell-to-cell transmission within lymphoid tissues (PEREZ-BERCOFF et al. 2003). As 
HIV causes chronic infection of macrophages only with minimal cytopathology, these cells 
Discussion  100  
can provide an important viral reservoir in HIV-infected persons, being even called the 
“Trojan horse” for the dissemination of virions (HOLL et al. 2004). Additionally, 
macrophages are an important reservoir for viral replication in late stages of AIDS, since 
HIV-1 infection of macrophages persists in the tissue for extended periods of time (months) 
with large numbers of virions contained within intracytoplasmic vacuoles (ROSENBERG and 
FAUCI 1991; CROWE 1995).  
Infection of macrophages occurs via a combined role of CD4 and FcγR (JOUAULT et al. 
1991). HIV complexed with human anti-HIV IgG can attach to FcγR of mononuclear 
phagocytes. Connor et al. postulated (1991) two hypotheses for FcγR acting in HIV-infection 
and identified the degree of antibody opsonisation as critical factor. Highly opsonised HIV 
will initiate high-affinity multi-valent interactions with FcγR and mediate endocytosis by 
FcγR and intracellular degradation of antibody-virus complex. Whereas few interactions on 
HIV lead to stabilisation of the virus at the cell-surface and antibody-dependent enhancement 
(ADE) of virus infection can occur subsequently (PORTERFIELD 1986). In particular, IgG 
bound to virus was reported to favour virus persistence when trapped by follicular dendritic 
cells (FDC), a non-leukocyte cell population of unknown origin, mainly concentrated in 
follicles and specialised to capture antigen in form of immune complexes for long time 
periods (JANEWAY et al. 2001; SMITH-FRANKLIN et al. 2002).  
Infected macrophages continuously release cytokines and chronically activate immune cells in 
the near environment. Dysregulation of the cytokine profile in-vivo and in-vitro was 
investigated as e.g. increased IFN-γ secretion and macrophage-colony-stimulating factor (M-
CSF; reviewed in KEDZIERSKA and CROWE 2001). IFN-γ induces de novo expression of 
FcγRI on neutrophils and finally leads to chronically IFN-γ activated macrophages 
(CAPSONI et al. 1992). A significant increase in the expression of FcγRI on alveolar 
macrophages (AM) in the lung of HIV+ subjects in early infections was reported (GILBODY 
et al. 1997), as well as a continuous and significant increase on PMNs, which do not 
constitutively express FcγRI in late stages of HIV-infection (MOALLEM et al. 2000).  
Despite of this, a number of monocyte/macrophage functions are impaired following HIV-1 
infection in vivo and in vitro, including decreased accessory cell function (PETIT et al. 1988), 
chemotaxis (TAS et al. 1988; WAHL et al. 1989), phagocytosis (BIGGS et al. 1995; 
KEDZIERSKA et al. 2000; KEDZIERSKA et al. 2001), intracellular killing (BIGGS et al. 
1995), and cytokine production (reviewed in KEDZIERSKA and CROWE 2001). These 
defects contribute to the pathogenesis of AIDS by allowing reactivation and development of 
opportunistic infections. Reduced phagocytic capacity for certain opportunistic pathogens, 
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including Toxoplasma gondii and Candida albicans, may be responsible for reactivation of 
these pathogens in persons with advanced HIV-infection (reviewed in CROWE 1995). 
Bispecific antibodies targeting HIV-1 and FcγRI reduced the infectivity of HIV towards T 
cells (HOWELL et al. 1994) and mediated ADCC and virus neutralisation (MABONDZO et 
al. 1994). On the other hand, crosslinking of FcγRI and FcγRII activates HIV-1 gene 
expression in infected monocytes by inducing NF-kappa B, which binds to the LTR of HIV-1 
(TSITSIKOV et al. 1995). Chronically infected macrophages have shown impaired 
phagocytosis (BIGGS et al. 1995) and the ability of HIV to persist in latently infected cells is 
the major barrier to eradication or cure of HIV. Thus, macrophages represent a therapeutic 
target which is, unlike to HIV, not highly mutable and directly targets the virus reservoir. One 
drug, WF10, is used as adjunct in highly active antiretroviral therapy (HAART). WF10 
causes changes in macrophages function and activation of gene expression. It appears to down 
regulate inappropriated immunological activation (McGRATH et al. 2002) and increased the 
healthy activity of macrophages without increasing the amount of HIV in the blood. 
FcγRI, the high-affinity receptor for monomeric IgG contributes highly to the degradation of 
pathogens by phagocytosis. In case of HIV-infection, high levels of IFN-γ and M-CSF in the 
sera of HIV-patients enhances the number of FcγRI on constitutive expressing cells further on 
and induces the expression on dendritic cells, neutrophils and mast cells. This leads to an 
overall increasing of FcγRI in immunological cells outnumbering FcγRII and FcγRIII. As 
FcγRI binds monomeric IgG with high-affinity, it can be postulated that HIV-virus opsonised 
with few antibodies is bound to macrophages predominantly by FcγRI. Possibly, FcγRI is the 
main contributor in the mechanism of ADE. Virus persistence by long-time binding of 
opsonised virus particles to FDCs maybe caused also by FcγRI. Perhaps, the interaction of 
FcγRI should be completely avoided in HIV-therapy but it can also be the major factor in 
virus neutralisation with anti-HIV antibodies. 
Conclusively, it is not known whether FcγRI has a positive or negative effect in HIV 
pathogenesis. Binding of soluble FcγRI to human anti-HIV antibodies would specifically 
impair additional binding of the Fc part of these antibodies. How this contributes to virus 
neutralisation can be investigated in future experiments. Combination of rsCD64 and anti-
HIV antibody 2F5 may reveal the underlying mechanism in neutralising action of anti-HIV 
antibodies. 
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V. Summary 
The production of two complex human proteins, the therapeutically relevant anti-HIV full-
size IgG1/κ antibody, BY-22F5, and a soluble form of the high-affinity receptor for human IgG, 
FcγRI (CD64), were successfully established and optimised for heterologous expression in 
plants, bacteria and mammalian. 
Aim of this thesis was the establishment of a protocol for the expression and purification of 
the anti-HIV antibody, 2F5, in plant suspension cultures. Intact and pure antibody could be 
purified at levels of 1 mg/L per suspension culture out of 340 g BY-2 pellet. ELISA proved 
comparable antigen binding capacity of the BY-22F5 antibody, EMSA and SPR to the CHO 
derived control antibody. Neutralisation assays were performed in Vienna with this 
purification showing no influence of plant derived glycosylation.  
Initial fermentation experiments have shown that BY-2 cells can be grown without limitations 
on 100-L scale, but conditions for stable antibody production and downstream processing 
have to be further investigated. For GMP implementation and expression in large-scale 
reactors under defined conditions protocols and procedures must be established first. Based 
on the experience in the 100-L downstream processing, feasible equipment was suggested for 
a purification procedure of 100-L BY-2 culture in approximately two days in compliance with 
GMP regulations. 
The second aim of this thesis was to express FcγRI as soluble recombinant protein in an 
appropriate expression system. The extracellular domain of FcγRI was generated and cloned 
into vectors for the expression in E.coli, mammalian and plant cells. All three systems were 
investigated for their ability to produce functional rsCD64. Highest expression levels were 
reached in the mammalian expression system yielding 1 mg/L. The expression and 
purification protocol was optimised and purity as well as integrity of rsCD64 was confirmed. 
IgG binding activity was confirmed by ELISA and SPR studies.  
Purified rsCD64 was functional as demonstrated by IgG binding, and the binding 
characteristic was comparable to that of the original membrane bound receptor. Functional, 
soluble protein is one of the prerequisites for intensive characterisation of the FcγRI. This 
characterisation, will lead to a better understanding of FcγRI functionality and development of 
new specific FcγRI targeted therapeutics or antibody affinity reagents. 
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Appendices  XVII  
VII. Appendices 
 
VII.1 Abbrevations 
 
α    anti, used in antibody abbrevations 
ADCC    antibody-dependent cell-meditated cytotoxicity  
ADE     antibody-dependent enhancement  
AEX     anion exchange chromatography  
AIDS     acquired immune deficiency syndrome  
AM     alveolar macrophages  
BHK     baby hamster kidney, mammalian cell line 
BGH    bovine growth hormone  
BSA     bovine serum albumin  
BY-2     bright yellow N.tabacum suspension cultures  
CL    constant region of light chain of an an antibody 
CH    constant region of heavy chain of an an antibody 
CaMV    cauliflower mosaic virus  
CDR     complementarity determining region  
CHO     chinese hamster ovary, mammalian cell line  
CIEX    cation ion exchange chromatography 
CIP     clean in place 
CIP     calf intestine phosphatase 
DMSO   dimethylsulfoxide  
dpi     days post infiltration  
EBA     expanded bed adsorption  
eGFP     enhanced green fluorescent protein  
ELISA    enzyme linked immunosorbent assay  
EMEA    European Agency for the evaluation of medicinal products  
ER     endoplasmic reticulum  
Fab-fragments   fragment with antigen binding (antibody fragment) 
Fc fragment    fragment crystallisable (antibody fragment) 
FDA     food and drug administration  
FDC     follicular dendritic cells  
FR    framework region 
FTE     full time employees  
GαH    goat-anti-human antibody 
GαM    goat-anti-mouse antibody 
gp     glycoproteins  
GM-CSF    granulocyte macrophage colony-stimulating factor  
HAART    highly active antiretroviral aherapy  
HBV     hepatitis B virus  
HC     antibody heavy chain  
HEK-293    human embryonic kidney, mammalian cell line  
HIC     hydrophobic interaction chromatography  
HIV     human immunodeficiency virus  
hpi     hours post inoculation  
IDA     iminodiacetic acid  
Appendices  XVIII  
Ig     immunoglobulins  
IMAC     immobilized-metal affinity chromatography  
IRES     internal ribosomal entry site  
ITAM     immunoreceptor tyrosine-based activation motif  
ITIM     immunoreceptor tyrosine-based inhibition motif  
kDa    kilo-Dalton 
kLa     oxygen transfer coefficient 
LC     antibody light chain 
MAbs     monoclonal antibodies  
MCS     multiple cloning site  
MDM     monocyte-derived macrophage 
MHC     major histocompatibility complex  
NBT-BCIP  nitro blue tetrazolium chloride/5-bromo 4-chloroindol-3-yl 
phosphate  
NK     natural killer  
NTA     nitrilotriacetic acid  
o/n     overnight  
OTR    oxygen transfer rate 
PEG     polyethylene glycol  
PCR     polymerase chain reaction  
PVP     polyvinylpyrrolidone  
rpm    rotation per minute 
RT     room temperature  
RU     resonance units  
SAR     scaffold attachment region  
SARS     severe acute respiratory syndrome  
SIP     steam in place 
SIV     simian immunodeficiency virus 
SOE     splice overlap extension  
SOP     standard operation procedure  
SP     signal peptide 
SPR     surface plasmon resonance  
TCR     T cell receptor  
TEV     tobacco etch virus  
TP     transit peptide 
w/v    weight per volume 
VL    variable region of light chain of an antibody 
VH    variable region of heavy chain of an antibody 
v/v    volume per volume 
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